تقرير معدل الإصابة بمرض السرطانªقرير... · 2018-02-18 · Introduction Part I-Materials and Methods Part II-Overview of Cancer Incidence Part III-

Prepared byMrs. Amal Nasser Al.-MadoujMr. Mohammed Saleh HayderMrs. Wafa Abdullah Al-ZahraniMs. Mona Mohammed Al-ShridahMs. Tahani Hussain Al-Shumrani

Reviewed byDr. Ali Saeed Al-ZahraniDr. Hind Mohammed Al-MutlaqDr. Amer Naeem RadwiDr. Shouki Mohammed Bazarbashi

The SCR Scientific Committee MembersDr. Ali Saeed Al-ZahraniDr. Hind Mohammed Al-MutlaqDr. Mushabab Ali AsiriDr. Hassnah Ali Al-GhamdiDr. Amal Mohammed Al-BehaniDr. Abdrrhman Ali Al-ShehriProf. Hassan Yousef Al-IdrisiDr. Mohammed Yahya SaeediDr. Amer Naeem Radwi Dr. Abdulaziz Saleh AbahussiDr. Ali Matar Al-ZahraniDr. Shouki Mohammed BazarbshiDr. Abduziz Abdullah Al-Saif Dr. Abdulrahem Toran Gari

(Chairman) (The Acting Director of SCR)(Regional Director of Central Region)(Regional Director of Western Region)(Regional Director of Madinah and Northern Region)(Regional Director of the Southern Region)(Regional Director of the Eastern Region)(Ministry of Health)(Health Affairs- Ministry of National Guard) (Medical Services- Security Forces)(Medical Services- Military Forces) (KFSH & RC)(Ministry of Education, KSU)(Private Hospital)

3

I am very pleased to present the Annual Cancer Incidence Report for Saudi Cancer Registry (SCR) for the year 2011. It sums up the efforts and full dedication to provide cancer data during a complete year. The Saudi Cancer Incidence reports which have been released since the registry was established in 1994 contributed in supporting the fight against cancer by providing genuine scaling of its epidemiology and by providing those responsible for cancer control and prevention programs with accurate and detailed data which reflect the real situation of cancer in the kingdom and in identifying the most prevalent types of cancer according to gender, age and geographical distribution. These reports are of great value for decision makers in planning to develop new cancer treatment and prevention centers and for scientific research and conferences held in different regions of the country, which goes in line with health strategies and objectives set by the Saudi Health Council.

The Council works continuously to assure effective performance and full administrative and technical support for the registry. It further deploys the published statistics to set national priorities for cancer control and prevention programs in coordination with different health sectors.

In an effort of SCR and through its national committee, one of the Saudi Health Council, approved a new national strategy for cancer prevention and control. It agreed to establish the National Cancer Center (NCC) with the function to set standards and protocols for cancer treatment and prevention to be implemented by different health sectors. The NCC will supervise implementation of the national strategy and setting the medical and research standards with the aim of better health care services provided to cancer patients. It will help in the exchange of expertise between medical centers in different government sectors, raising the level of medical expertise and professional performance and localization of national competencies.

In conclusion, what we see as a significant development in the health field in our beloved country is due to the blessings of the all mighty Allah and the support of our government under the leadership of the Custodian of the Two Holy Mosques and the Crown Prince and the Crown to the Crown Prince –May Allah protect them- who save no effort to offer best service and comfort to the citizens of Saudi Arabia. We like to thank all employees of health sectors, institutions and charities who gave cancer a great care in establishing treatment and awareness programs for cancer in the kingdom.

General Secretary of SHC.

Dr. Yagob Al-Mazrou

Foreword

Introduction

Part I-Materials and Methods

Part II-Overview of Cancer Incidence

Part III- Cancer Incidence for Most Common Sites 2011

This is the fifteenth incidence report published by the Saudi Cancer Registry. Previous publications include the Incidence Reports for the years -1994 2000 -1999 ,1998 - 1997 ,1996 and yearly until 2010.

The structure of this report can be outlined as follows:

Part IV-Cancer Incidence among Non-Saudis

This part presents the incidence of cancer cases among Non-Saudis including the most common types of cancer. The analysis of the Non-Saudis is performed separately due to the nature of the expatriate population in Saudi Arabia in which a large part of the population, particularly among males, falls in the 25 - 44 age groups.

Part V-Incidence Tables

Part V contains the following detailed tables for all newly diagnosed cancer types among Saudis and Non-Saudis for 2011.

• Distribution of cancer cases among Saudis by age group and sex.

• Distribution of cancer cases among Non- Saudis by age group and sex.

• Cancer Incidence (per 100,000 populations) among Saudis by age group and sex.

• Cancer Incidence (per 100,000 populations) among Non-Saudis by age group and sex.

• Age-standardized incidence rate and relative frequencies among Saudis by cancer site, sex and administrative regions.

• Number of In Situ Cases, Myelodysplastic Syndrome and Myeloproliferative Disease among Saudis and Non-Saudis.

Part VI- Arabic Summary

Part VI Contains Arabic Summary of Cancer Statistics in Saudi Arabia for the Year 2011.

This part of the report contains information about the background of the Saudi Cancer Registry and methods used in collecting and analyzing the data. We present the basics of coding and classification of tumor topography, morphology and extent of disease at the time of diagnosis. Also we describe the software programs we have used to analyze the data.

Part II contains figures and tables that show overall cancer incidence in Saudi Arabia for the year 2011. We present these figures and tables mainly by sex and in certain areas we have it analyzed by different age groups. There are bar charts representing the age distribution of cancer incidence for the year 2011 among Saudis by sex and age groups. We present incidence and morphology tables for the most common types of cancers among adults and children. In addition, tables, list the total number of cases, the Age-Standardized Incidence Rate (ASR) per 100,000 population, Crude Incidence Rate (CIR) and Cumulative rates by primary site and sex. Separate bar charts depict the most common types of cancer, by sex, in each of the 13 administrative regions of Saudi Arabia.

In this part the incidence of the most common cancers among Saudi males and females are outlined. A standardized layout presents data for all patients and for both sexes where applicable. For each selected site the number and the percentage of all newly diagnosed cases for the year 2011, the ASR for each sex and the specific cancer rank for both sexes are presented. In addition, ASR for the specified cancer among Saudis is compared with ASR among other populations from selected countries.

5

PART IMATERIALS AND METHODS

Background on Saudi Arabia

Saudi Arabia is a vast country extending over four-fifths of the Arabian Peninsula. It stretches from the Arabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700* square kilometers in area and is divided into 13 administrative regions (Figure 1.1).

The Saudi national population for year 2011 was 19,405,685**. Of these 9,743,626 (50.2%) were males and 49.8% 9,662,059 were females. The Non-Saudi population in 2011 was 8,970,670**; of these 6,297,737 (70.2%) were males and 2,672,933 (29.8%) females. Figures 1.2 and 1.3 show the Saudi and Non- Saudi population pyramids by sex and age group respectively.

Saudi Cancer Registry

The Saudi Cancer Registry (SCR) is a population-based registry established in 1992 under the authority of the Ministry of Health (MOH) by the order of His Excellency the Minister of Health. The SCR was moved to the Saudi Health Council in 1435 (2014). The SCR commenced reporting cancer cases from 01 January 1994.

Objectives

The primary goal of the SCR is to define the population-based incidence of cancer in Saudi Arabia. Another objective is to support the early detection programs and cancer screening programs, as well as cancer research projects through providing accurate cancer data.

Organizational Structure

The representatives from the MOH, King Faisal Specialist Hospital and Research Center (KFSH&RC), and the Medical Services Departments of the Ministry of Defense and Aviation, Ministry of Interior, Ministry of National Guard, King Saud University. The representatives are charged with the responsibility of overseeing the SCR’s establishment, defining demographic and cancer related data to be collected, approving data requests, and reporting findings, as well as disseminating information collected while ensuring the confidentiality of all data reported to the SCR.

02468101214161820 0 2 4 6 8 10 12 14 16 18 20FemaleMale

121,21987,149129,226182,269251,292336,247423,607520,168624,755737,202844,414949,433

1,028,3541,083,508

1,160,6211,264,052

9,743,626 9,662,059

1.2 1.30.91.41.8

2.5

3.34.3

5.36.5

7.8

8.910.010.811.1

11.612.5

0.91.3

1.92.6

3.54.3

5.36.4

7.6

8.79.7

10.611.1

11.913.0

121,00691,562

130758176,791240,525

320,801410,991516,203628,837750,746863,449969,916

1,038,9701,073,603

1,121,5341,206,367

+7570- 7465- 6960 - 6455- 5950 - 5445- 4940- 4435- 3930- 3425- 2920- 2415- 1910- 14

5- 90- 4

+7570- 7465- 6960 - 6455- 5950 - 5445- 4940- 4435- 3930- 3425- 2920- 2415- 1910- 14

5- 90- 4

02468101214161820FemaleMale

0 2 4 6 8 10 12 14 16 18 20

15,38814,38032,62690,461

216,210388,183627,573

883,9481,115,564

1,030,091

521,032224,910212,443280,929315,081

328,918

10,8148,576

13,807

22,588

42,01060,646100,619247,212406,783367,565233,201163,977

180,832241,087282,195291,021

0.2 .40.3

0.5

0.8

1.62.3

3.89.2

15.213.8

8.76.1

6.89.0

10.610.9

0.2

0.51.4

3.46.2

10.0

14.0

17.7

16.48.3

3.63.4

4.55.0

5.2

6,297,737 2,672,933

* Source: ** Source: Central Department of Statistics & Information, Ministry of Economy and Planning

Demographic and Health Indicators for Countries of the East Meditrttanean, WHO, Regional Office for the EM, 1999

10

Figure 1.2 Population Pyramid of Saudis (%) by Sex and Age Group, 2011

Figure 1.1 Administrative Regions of Saudi Arabia

Figure 1.3 Population Pyramid of non-Saudis (%) by Sex and Age Group, 2011

The SCR Main Office, including administrative and technical staff, is located in the Saudi Health Council in Riyadh. Additionally, five regional branches and five hospital-based offices were set up to ensure comprehensive data collection from all over the Kingdom (Figure 1.4).

Regional Offices

1. Central Region: King Fahad Medical City in Riyadh, covering Riyadh, Qassim, and Hail Health Regions.2. Eastern Region: King Fahad Hospital of the University, Al Khobar, covering Dammam, Al Ahsa, and Hafr Al-Batin Health Regions.3. Western Region: King Abdulaziz Hospital and Cancer Center, Jeddah, covering Jeddah, Makkah, Taif and Qunfudah Health Regions.4. Southern Region: Asir Central Hospital, Abha, covering Asir, Baha, Najran, Jazan and Bisha Health Regions.5. Madinah/Northern Region: Maternity and Children Hospital, Madinah, covering Madinah, Tabuk, Jouf and Northern Health Regions.

Offices at the Medical Service Division or Oncology Department of the following establishments

6. King Faisal Specialist Hospital & Research Centre, Riyadh7. Ministry of Defense and Aviation, Armed Forces Hospitals, Riyadh8. Ministry of Interior, Security Forces Hospital, Riyadh9. Ministry of National Guard Hospitals, King Abdulaz iz Medica l City , Pr incess Norah Oncology Center, Jeddah.10.King Khalid University Hospital, Riyadh.

Each of the SCR office operates under the supervision of directors who are responsible for the daily management. Staffing consists of tumor registrars and secretarial staff. The SCR Main Office indirectly supervises the regional offices to ensure accuracy and quality of data collected from all regions. Quality control processes include verification of site, morphology, and staging information as well as case linkage (tumor and patient), and consolidation of data. The Main Office also prepares annual reports for dissemination of information to the medical community, government establishments, international organizations and the media.

Format

The format of the current report is similar to the previous reports.

Figure 1.4 Organizational Chart of the Saudi Cancer Registry of Saudi Arabia

Saudi Cancer RegistryMain Office

Central Region(Riyadh, Qassim & Hail)

Madinah Region(Madinah, Tabuk, Jouf & Northern Region)

Southern Region(Asir, Baha, Jazan & Najran)

Western Region (Jeddah, Makkah, Taif & Qunfudah)

Eastern Region(Dammam, Ahsa & Hafr Al Batin)

Security Forces HospitalRiyadh

King Khalid University HospitalRiyadh

King Faisal Specialist Hospital & RCRiyadh & Jeddah

Armed Forces Hospitals(Riyadh, Western, South & Northern)

National Guard Hospitals (Riyadh, Jeddah, Dammam & Ahsa)

11

Data Management

A ministerial decree has categorized cancer as a mandatory notifiable disease. This ensures the opportunity for comprehensive data collection. The SCR strives for full access to cancer data from all Ministry of Health, governmental and private hospitals, as well as clinics and laboratories throughout the Kingdom. Cancer data are abstracted from patients’ medical records, based on clinical and/or histopathological diagnosis, by SCR-trained cancer registrars. The data abstract includes personal identification (name, ID Number, sex, age), demographic information (address, telephone number, nationality), and tumor details (diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the International Classification of Diseases for Oncology 3rd Edition (ICD-O-3), published by the World Health Organization (WHO), 2000. Effective from year 2001, changes were made in coding of cancer types and behaviors as well as staging according to International guidelines. The new SEER Summary Stage 2000 guidelines should result in increased accuracy and consistency in the coding of stage. There are some differences in the timing rules for determining stage and some sites are coded differently using the new guidelines. However, the new criteria and guidelines should improve the usefulness of staging as a predictor of prognosis and survival as the changes reflect a new understanding of the natural history of cancer. The new guidelines, SEER Summary Stage Manual 2000, are available on the web at: http:/seer.cancer.gov/tools/ ssm/ Cases diagnosed on or after 01 January 2008 are classified according to the updated ICD-O-3. Improvements in the understanding of cancer pathology over the last decade are reflected in the changes to ICD-O-3. While there have not been any changes in the primary site codes, there are significant changes regarding histology (cell types). Leukemias and lymphomas, particularly are affected. Some cases that were previously considered benign are now counted as malignant. Also small number of cancers that were previously coded as borderline tumors are now considered benign. Counts of ovarian cancers, lymphomas and leukemias as well as some hematopoietic diseases will change due to changes in either reportability or definition. However, as with the new staging

guidelines, the ICD-O changes reflect advances in the understanding of the pathology and behavior of cancers. It should be noted that ICD-O-3 codes are converted to ICD-10 for analysis purposes. Since the WHO has not yet converted the ICD-10 hematopoietic disease behavior changes, our software, CanReg 4.33, cannot include these cases for analysis and they have been excluded. Every effort is made to accurately code patient and tumor information, to ensure that all data can be reviewed, linked, and consolidated, as appropriate, so that each malignancy is counted only once for statistical analysis. The computer software programs used for data entry and incidence tables output are CanReg 4.33, developed by the International Agency for Research on Cancer, (IARC) Lyon, France. The second part of the report includes the overall cancer incidence in Saudi Arabia and the relevant epidemiological and clinic pathological details for the 15 most common cancers among Saudi nationals for the year 2011. For each cancer site, the number and the percentage of all newly diagnosed cases for the year 2011, the age-standardized incidence rate (ASR) per 100,000 populations for each sex, and the specific cancer rank in comparison to all cancers for both sexes are presented. Useful international statistics for the specified cancer include the ranking of the cancer worldwide. The source for this information is summarized in page 66. The relevant data incorporate details for all patients presented over the year 2011. For each cancer there are five figures: 1. An arithmetic line graph represents the age-specific incidence rate (AIR) for all age groups at five-year intervals. The graph is plotted by sex, where applicable. 2. A table lists the percentages of the most common histology sub-types for each specific cancer. 3. A pie chart shows the distribution of the clinical stages of each cancer such as localized, regional, distant metastasis and unknown. 4. A bar chart shows regional distribution of ASR for particular cancer across the a d m i n i s t r a t i v e regions by males and females. 5. A bar chart shows comparison of age-standardized incidence rate (ASR) for each cancer type in Saudi Arabia with ASR in selected countries.

12

Notification

The data included in this report were abstracted up to March 2015. The incident cases which were identified after this date (late reporting) will be noted in subsequent incidence reports. It is anticipated that the number of late-reported cases will decrease as case ascertainment processes are improved. Moreover we don’t have up to date statistics because we have to wait until all of the data from the regional cancer branches in Saudi Arabia has been collected before we can publish the annual incidence report. Also, the process of registering a cancer is complicated and there are a number of processes in place to ensure the data is of a high quality. This means there is usually a delay of around 3-2 years before the data is complete enough to be published.

Age-Specific Incidence Rate (AIR)

The number of cancer cases occurring during a specific period in a population of a specific age and sex group, divided by the number of midyear population of that age and sex group.

Age-Standardized Rate (ASR) The Age-standardized rate is a summary measure of a rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age structure. The most frequently used standard population is the World Standard Population (see below). The calculated incidence is known as the World Standardized Incidence Rate. The rate is expressed per 100,000 populations.

Crude Incidence Rate (CIR)

The crude incidence rate for a cancer site is the total number of cases registered as a proportion of the total population. It denotes the approximate number of cases occurring in each 100,000 individuals. All rates are thus, expressed as per 100,000 population.

Cancer rates vary greatly with age and the crude rate is strongly influenced by the demographic structure of the population. Hence, if the population structure changes over time the crude rate over that period may be artificially altered. It is not appropriate to compare crude rates across geographical areas of cancer registries with different population age structures. Therefore, in order to assess time trends in registration data or compare incidence across geographical areas or between registries it is necessary to first standardize the rates with respect to age.

* Doll R. Payne P.Waterhouse J. Cancer Incidence in Five Continents Vol. I. International Union Against Cancer. 1966

Age Class Population

0 - 4

5 - 9

10 - 14

15 - 19

20 - 24

25 - 29

30 - 34

35 - 39

40 - 44

45 - 49

50 - 54

55 - 59

60 - 64

65 - 69

70 - 74

75 +

12,000

10,000

9,000

9,000

8,000

8,000

6,000

6,000

6,000

6,000

5,000

4,000

4,000

3,000

2,000

2,000

Total 100,000

13

Definitions of Statistical Terms

Cumulative Incidence rate

Cumulative incidence rate is the probability or risk of individuals developing the disease during a specified period. For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to develop a particular cancer before the age of 65 (or 70, or 75) if they had the rates of cancers currently observed. Like the age standardized rate, it permits comparison between populations of different age structures. In this report the age ranges 0-64 and 0-74 years are used. The cumulative rate is the summation of the cancer age-specific rates; which are computed for five-year age intervals. The cumulative rate is five times the sum of the age-specific rates calculated over the five-year age groups.

ICD - 10

The World Health Organization’s International Classification of Diseases, tenth edition.

ICD - O - 3

The World Health Organization’s International Classification of Diseases for Oncology, 3rd Edition has been the standard coding system for neoplasms for over 25 years. The coding system includes a four character code for primary site, a four-digit numeric code for cell type, one-digit code for behavior and a one-digit code for tumor aggressiveness (grade).

Incidence rate

An incidence rate is defined as the rate at which a new event occurs in a population. It is calculated as the number of new cases of disease arising in a population over a defined time period, divided by the population at risk of developing that disease. Mean The simple mathematical average of two or more numbers.

Median The midpoint of the range numbers that are arranged in order of value.

Metastasis

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal and or visceral organs.

Range It is the difference between the maximum and minimum values in a set of observations. Rank This measure reflects the importance of a specific cancer site relative to other sites, in terms of the number of registrations. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency. Ratio It is the relation between two quantities. The first quantity as numerator and the second as denominator

Relative Frequency This statistic is defined as the number of specific cancer cases registered relative to the total number of all cancer. It is expressed as a percentage. Summary Stage Staging is the grouping of cancer cases into broad categories based on the extent of disease.

14

PART IIOVERVIEW OF CANCER INCIDENCE

2011

16

Reported Cancer Incidence Cases in Saudi Arabia, 2011

Table 2.1 Distribution of Cancer Cases in Saudi Arabia by Nationality and Sex, 2011

* Unknown nationalities, in situ cases, and ICD-10 conversion failures are excluded from analyses** ICD-10 conversion failure

Saudis Non-Saudis Unknown Nationality All

Male Female Total

Analyzed 4913

4955

113

42

5068

5956

5980

117

24

6097

10869

10935

230

66

11165

1690

1698

51

8

1749

1663

1666

48

3

1714

3353

3364

135

11

3499

0

52

1

0

53

0

59

0

0

59

0

111

1

0

112

14222

14410

366

77

14776

*

Invasive

In Situ

ICD-10 **

Total

Male Female Total Male Female Total Total

As shown on Table 2.1, 14,222 cases wereanalyzed, of which 10,869 (76.4%) were Saudis and 3,353 (23.5%) were Non-Saudis. Among the Saudis 4,913 (45.2%) were male and 5,956 (54.7%) were female. The male to female ratio was 100:87. The crude incidence rate (CIR) of all cancers among Saudi population was 65.0/100,000 (50.5/100,000 among males and 61.7/100,000 among females). The overall age-standardized incidence rate (ASR) for Saudis was 78.8/100,000 in males and 90.1/100,000 in females.

For all sites, the age-specific incidence rate (AIR) increased with age for both males and females. After the age of 64 years, the increase was nearly one and 1.6 fold with male to female ratio 133:100. The median age at diagnosis for men was 59 years; range (0 -120) and 51 years for women; range (0-111).

The geographic regions with the highest ASRamong males were Eastern region at 113.6/100,000, Riyadh region at 105.7/100,000, Tabuk region at 87.2/100,000, Makkah region at 77.4/100,000 and Qassim region at 66.5/100,000, whereas the highest ASR among females were reported from Riyadh region at 115.2/100,000 followed by Eastern region 110.6/100,000, then Makkah region at 93.1/100,000, Tabuk region at 91.5/100,000 and Jouf region at 81.9/100,000.

Between January 01 and December 31, 2011, the total number of cancer incidence cases reported to the Saudi Cancer Registry (SCR) was 14,776. Over all cancer affected 6,870 (46.6%) males and 7,870 (53.4%) females, with a male to female ratio of 100:87. Total of 11,165 cases were reported among Saudi, and 3,499 among Non-Saudis and 112 of unknown nationality.

The total number of cases excluded from analysis include 112 cases of unknown nationalities, other exclusions were 366 in situ cases; the current software program CanReg-4 version 4.33, does not include in situ cases in the statistical analysis. Also, 77 were ICD-O-3 coded cases that failed to convert to ICD-10 codes as described in the Data Management (see page 12 and page 92). This puts the total number of exclusions from the analysis as 554 cases. Table 2.1 illustrates the distribution of the cases by sex, nationality and cancer behavior.

Diagnosis of malignancy was confirmed histologicallyin 88.4% of the cases, and haematological & cytologically in 6.1% of cases. Clinically confirmed cases were 0.2%, radiologically confirmed cases were 2.3%, cases confirmed by death certificate were 2.4% and the method of diagnosis was unknown for 0.6% of the cases.

NHL

17

Perc

enta

ge

Age Group0 - 14

7.5 8.69.5

12.3

21.622.8

31.129.8

22.9

19.0

9.6

5.3

15 - 29 30 - 44 45 - 59 60 - 74 75+

Figure 2.1 Percentage Distribution of Cancer Incidence among Saudis by Sex according to Age Group, 2011

35.2

3.6

3.7

3.7

4.2

6.3

6.7

7.0

7.4

8.8

13.4

26.6

2.2

2.6

2.7

3.3

5.2

5.3

5.6

9.0

10.8

267

Female (5956)Male (4913)

Prostate

Prostate

Hodgkin Disease

Lung

Liver

Leukemia

NHL

Colo-rectal

Skin

Bladder

01020304050 10 20 30 40 50

Other sites

Kidney

All Ages

Corpus Uteri

Ovary

Leukemia

NHL

Colo-rectalThyroid

Breast

Liver

Other sites

Hodgkin Disease

Stomach

6.5

2.8

2.8

3.9

4.2

4.8

5.3

7.0

10.4

13.2

39.0

6.2

1.3

2.3

4.9

6.2

6.5

6.5

6.9

7.5

10.8

40.8


Bone

Connective, Soft Tissue

Adrenal Gland

NHL

Hodgkin Disease

Brain, CNS

Brain, CNS

Leukemia

Eye

Kidney

01020304050 10 20 30 40 50

Other sites

Liver

0 - 14 Years

Hodgkin Disease

NHL

Bone

Eye

Kidney

Brain, CNS

Leukemia

Liver

Connective, Soft Tissue

Other sites

Ovary

Figure 2.2 Percentage Distribution of Most Frequent Types of Cancer by Sex and age-groups among Saudis, 2011

9.52.0

2.73.74.24.46.1

7.610.6

14.314.3

20.6

11.31.82.72.93.34.24.4

8.29.512.4

15.3

24.0


Brain, CNS

TestisBone

NHL

Leukemia

Hodgkin Disease

Skin

Connective, Soft TissueNasopharynx

01020304050 10 20 30 40 50

Other sites

Colo-rectal

15 - 29 Years

Brain, CNS

Ovary

NHL

Leukemia

Breast

Hodgkin Disease

Thyroid

ThyroidConnective, Soft Tissue

Bone

Colo-rectal

Other sites

22.82.73.13.63.83.85.5

5.76.57.4

9.69.8

15.8

9.81.01.11.41.82.52.83.83.83.8

6.719.2

42.2


Hodgkin Disease

TestisNasopharynx

ThyroidLeukemia

Colo-rectalNHL

Connective, Soft TissueStomach

Brain, CNS

Kidney

01020304050 10 20 30 40 50

Other sites

Skin

30 - 44 Years

Ovary

Brain, CNS

LeukemiaNHL

Colo-rectalThyroidBreast

Stomach

Skin

Corpus Uteri

Cervix Uteri

Other sites

Hodgkin Disease

30.7

3.6

3.8

4.2

4.3

4.3

5.6

6.2

6.3

10.5

20.5

19.2

1.9

2.2

2.4

3.0

3.3

3.7

6.1

10.8

11.8

35.7


Bladder

Kidney

Liver

NHL

Lung

Colo-rectal

Stomach

01020304050 10 20 30 40 50

Other sites

Leukemia

45 - 59 Years

Ovary

NHL

Corpus Uteri

Thyroid

Colo-rectal

Breast

Leukemia

Liver

Other sites

Ceruin Uten

Lung

24.6

3.5

3.8

4.1

4.3

5.0

6.9

10.0

10.4

11.2

16.2

26.6

2.6

3.1

3.6

4.2

4.5

5.5

6.7

10.3

11.7

21.1


Bladder

Stomach

NHL

Prostate

Lung

Liver

Colo-rectal

Leukemia

Skin

01020304050 10 20 30 40 50

Other sites

Pancreas

60 - 74 Years

Thyroid

Stomach

Lung

Liver

NHL

Corpus Uteri

Colo-rectal

Breast

Skin

Ovary

Other sites

22.7

3.2

3.4

4.1

5.3

6.5

9.2

10.4

10.5

10.6

14.0

30.2

4.0

4.0

4.3

5.1

5.4

6.0

7.1

8.1

12.7

13.2


Skin

Bladder

Lung

Colo-rectal

Liver

Prostate

Kidney

Stomach

Stomach

01020304050 10 20 30 40 50

Other sites

Pancreas

75+ Years

Liver

Corpus Uteri

NHL

Stomach

Skin

Colo-rectal

Breast

Ovary

Gallbladder, etc.

Lung

Other sites

Cancer among Saudis 2011

As explained earlier the total numbers of cancer cases analyzed among Saudis during the year 2011 were 10,869. Following are figures presenting the percentage distributions of (cancer incidence) and most frequent types of cancers among Saudis by sex and age-group.

18

Table 2.2 Ten Most Common Cancers among Saudis, 2011 (All Ages)

Colo-rectal

NHL

Leukemia

Liver

Lung

Prostate

Hodgkin Disease

Bladder

Skin

Kidney

Figure 2.3 Ten Most Common Cancers among Saudis by Sex, 2011

Male657

432

366

343

330

311

208

184

182

178

13.4%

8.8%

7.4%

7.0%

6.7%

6.3%

4.2%

3.7%

3.7%

3.6%

4913 FemaleBreast

Thyroid

Colo-rectal

Leukemia

Corpus Uteri

NHL

Ovary

Liver

Hodgkin Disease

Stomach

1590

646

537

331

318

312

198

158

157

133

26.7%

10.8%

9.0%

5.6%

5.3%

5.2%

3.3%

2.7%

2.6%

2.0%

5456

Cancer No. %

Breast

Colorectal

Thyroid

NHL

Leukemia

Liver

Lung

Hodgkin Disease

Skin

Corpus Uteri

1606

1194

800

744

697

488

452

341

333

318

14.8

11.0

7.4

6.8

6.4

4.5

4.2

3.1

3.1

2.9

19

Figure 2.4 Age - Specific Incidence Rate (AIR) for All Cancers among Saudis, 2011

Figure 2.5 Age Standardize Rate (ASR*) Regional Distribution (per 100,000) of All Sites of Cancer among Saudis, 2011

*ASR per 100,000

0

100

200

300

400

500

600

700

800

900

0 - 5 - 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

AIR

(per

100

,000

)

Age Groups

Male Female

41.8

41.8

46

57

59.9

60.1

64.3

65.6

66.5

77.4

87.2

105.7

113.6

53.2

65.5

73.2

75.2

81.9

65.3

55.6

56.4

74.7

93.1

91.5

115.2

110.6

0 20 40 60 80 100 120 140

JAZAN

HAIL

BAHA

MADINAH

JOUF

ASIR

NORTHREN

NAJRAN

QASSIM

MAKKAH

TABUK

RIYADH

EASTERN

FEMALE

MALE

20

Table 2.3 Number, Percentage, ASR, CIR and Cumulative Rates (per 100,000) of New Cases by Primary Site and Sex among Saudis, 2010

--------

----

----

----

----

----

----

--------

--------

--------

--------

--------

3.4169Other Other unspecific 2.81.7 2.91.2 3.0178 3.01.8 3.51.6

21

Between January and December 2011, the total number of adult cancer incidence cases reported was 14011. Overall cancer was more in females than in males. Cancer affected 6,459 (46.1%) males and 7,552 (53.9%) female with male to female a ratio of 86:100. Of all cases, there were 10,438 Saudis, 3,463 of Non-Saudis and 110 of unknown nationalities. As shown on table 2.4.1, the total number of analyzed cases were13,505.

Adult Cancers in Saudi Arabia, 2011 (>14 years)

Table 2.4.2 Ten Common Cancer among Saudi Adults, 2011

Table 2.4.1 Distribution of Reported Adult Cancer Cases in Saudi Arabia by Nationality and Sex, 2011

Saudis Non-Saudis Unknown Nationality All

Male Female Total

Analyzed 13505

13683

328

69

14011

0

109

1

0

110

0

58

0

0

58

0

51

1

0

52

3353

3364

99

11

3463

1663

1666

48

3

1714

1690

1698

51

8

1749

10152

10210

228

58

10438

5644

5665

115

21

5780

4508

4545

113

37

4658

*

Invasive

In Situ

ICD-10 **

Total

Male Female Total Male Female Total Total

Figure 2.6 Ten Most Common Cancers among Saudi Adults by sex, 2011

MaleColo-rectal

NHL

Lung

Liver

Prostate

Leukemia

Skin

Bladder

Kidney

Stomach

655

385

342

320

310

227

208

182

163

162

14.4%

8.5%

7.5%

7.0%

6.8%

5.0%

4.6%

4.0%

3.6%

3.6%

4548 FemaleBreast

Thyroid

Colorectal

Corpus Uteri

NHL

Leukemia

Ovary

Liver

Hodgkin Disease

Stomach

1589

642

537

318

292

206

194

151

138

133

28.2%

11.4%

9.5%

5.6%

5.2%

3.6%

3.4%

2.7%

2.4%

2.4%

5644

Cancer No. %

Breast

Colorectal

Thyroid

NHL

Leukemia

Liver

Lung

Skin

Corpus Uteri

Prostate

1589

1192

795

667

433

471

450

332

318

310

14.6

11.0

7.3

6.2

4.0

4.3

4.1

3.1

2.9

2.9

22

Table 2.4.3Number and Percentage of Morphological Types for the Most Common Types of Cancer among Saudi Adult, 2011

Breast

Colorectal

Thyroid

NHL

Leukemia

850085208010800085228523851084809020

81408480826380008261821084908010

82608340834183448343833582908335

9680959195909700969996709690969197029687971496989695

971939729

986198639823983698669835986798379873987598679801

12001000004

5184314141115107

28

7516777934

28

182151916151616131711135875

27

423737287

10696667

70.60.00.05.90.00.00.00.00.0

23.5

78.56.52.12.11.72.31.51.14.2

48.110.34.54.54.55.81.92.6

17.9

47.33.94.94.23.94.24.23.44.42.93.41.32.11.81.37.0

18.516.316.312.33.14.42.64.02.62.62.63.1

1218885653412319131269

42138161012687

23

31211573382813131145

15820151815109

104636213

12

43481320147968753

76.55.53.53.32.61.41.20.80.84.3

77.87.03.01.82.21.11.51.34.3

48.117.711.35.94.32.02.01.76.9

54.16.85.16.25.13.43.13.41.42.11.02.10.70.31.04.1

20.923.36.39.76.83.44.42.93.93.42.41.5

Infiltrating Duct Carcinoma, NOSLobular carcinoma, NOSCarcinoma, NOSNeoplasm, malignantInfiltrating duct and lobular carcinomaInfiltrating duct mixed with other types of carcinomaMedullary carcinoma, NOSMucinous adenocarcinomaPhyllodes tumor, malignantOthers

Adenocarcinoma, NOSMucinous adenocarcinomaAdenocarcinoma in tubulovillous adenomaNeoplasm, malignantAdenocarcinoma in villous adenomaAdenocarcinoma in adenomatous polypSignet ring cell carcinomaCarcinoma, NOSOthers

Papillary adenocarcinoma, NOSPapillary carcinoma, follicular variantPapillary microcarcinomaPapillary carcinoma, columnar cellPapillary carcinoma, encapsulatedFollicular adenocarcinoma, NOSOxyphilic adenocarcinomaFollicular carcinoma, minimally invasiveOthers

Malignant lymphoma, large B-cell, diffuse, NOSMalignant lymphoma, non-Hodgkin, NOSMalignant lymphoma, NOSMycosis fungoidesMarginal zone B-cell lymphoma, NOSMalignant lymphoma, small B lymphocytic, NOSFollicular lymphoma, NOSFollicular lymphoma, grade 2Mature T-cell lymphoma, NOSBurkitt lymphoma, NOSAnaplastic large cell lymphoma, T cell and Null cell typeFollicular lymphoma, grade 3Follicular lymphoma, grade 1NK/T-cell lymphoma, nasal and nasal-typePrecursor T-cell lymphoblastic lymphomaOthers

Acute myeloid leukemia, NOSChronic myeloid leukemia, NOSB-cell chronic lymphocytic leukemia/small lymphocytic lymphomPrecursor B-cell lymphoblastic leukemiaAcute promyelocytic leukemia, t(15;17)(q22;q11-12)Precursor cell lymphoblastic leukemia, NOSAcute monocytic leukemiaPrecursor T-cell lymphoblastic leukemiaAcute myeloid leukemia with maturationChronic myelogenous leukemia, BCR/ABL positiveAcute myelomonocytic leukemiaAcute leukemia, NOS

23

Table 2.4.3 Continued ....

Continued ....Leukemia

Liver

Lung

Skin

Corpus Uteri

Prostate

Leukemia, NOSChronic myelomonocytic leukemia, NOSAcute myeloid leukemia without maturationOthers

Hepatocellular carcinoma, NOSCholangiocarcinomaNeoplasm, malignantAdenocarcinoma, NOSCarcinoma, NOSCombined hepatocellular carcinoma and cholangiocarcinomaOthers

Adenocarcinoma, NOSSquamous cell carcinoma, NOSSmall cell carcinoma, NOSNon-small cell carcinomaNeoplasm, malignantBronchiolo-alveolar adenocarcinoma, NOSCarcinoma, NOSLarge cell carcinoma, NOSSquamous cell carcinoma, keratinizing, NOSCarcinoid tumor, NOSCarcinoma, undifferentiated, NOSOthers

Basal cell carcinoma, NOSSquamous cell carcinoma, NOSBasal cell carcinoma, nodularDermatofibrosarcoma, NOSSquamous cell carcinoma, keratinizing, NOSInfiltrating basal cell carcinoma, NOSBasosquamous carcinomaOthers

Endometrioid adenocarcinoma, NOSAdenocarcinoma, NOSCarcinosarcoma, NOSPapillary serous cystadenocarcinomaClear cell adenocarcinoma, NOSMullerian mixed tumorCarcinoma, NOSSerous cystadenocarcinoma, NOSEndometrial stromal sarcoma, NOSNeoplasm, malignantAdenosquamous carcinomaLeiomyosarcoma, NOSMixed cell adenocarcinomaSerous surface papillary carcinomaOthers

Adenocarcinoma, NOSNeoplasm, malignantAcinar cell carcinomaCarcinoma, NOSTumor cells, malignant

980099459873

817081608000814080108180

81408070804180468000825080108012807182408020

8090807080978832807180928094

83808140898084608310895080108441893080008560889083238461

81408000855080108001

132

20

266201610125

1046234321911148837

40

9551168652

25

−−−−−−−−−−−−−−

2691811111

0.41.30.98.8

83.16.35.03.10.30.61.6

30.418.19.99.45.63.24.12.32.30.92.0

11.7

45.724.57.73.82.92.41.0

12.0

−−−−−−−−−−−−−−

86.85.83.53.5.3

622

13

1121585326

4411676

1071040

12

54269

145547

1904015108766543333

15

−−−−−

2.91.01.06.3

74.29.95.33.32.01.34.0

40.710.25.66.55.69.36.50.90.03.70.0

11.1

43.521.07.3

11.34.04.03.25.6

59.712.64.73.12.52.21.91.91.61.3.9.9.9.9

4.7

−−−−−

24

The total incident cases reported among children (0-14 years) between January and December 2011 were 817. This represents 5.5% of the total number of cancers in Saudi Arabia. The reported incidents show that cancer was more common among boys than girls, 436 (53.4%) cases were reported among boys and 381 (46.6%) among girls, with a male to female ratio of 114:100. Of all the cases reported there were 686 Saudis, 131 non-Saudis and 0 of “unknown nationality”. Based on Table 2.5.1, the total number of cases analyzed was 789 including 675 (46.4%) Saudis and 123 (15.6%) for non-Saudis. Among Saudis, 363 (53.8%) were male and 312 (46.2%) were female. The male to female ratio among Saudis was 116:100. Childhood cancers accounted for 6.2% of all cancer among Saudis. The leading cancer among Saudi children was leukemia, which accounted for 39.1 %, followed by Brain, CNS 10.4% then NHL 9.9 % then Hodgkin Disease 6.5% and Bone 6.1% Table 2.5.2. Figure 2.7 shows the top ten sites by sex and frequency, and Table 2.5.3 shows the number and proportion of the morphological types for the most common types of cancer.

Childhood Cancers in Saudi Arabia, 2011 (≤ 14 years)

* Unknown nationalities, in situ cases and ICD-10 conversion failures are excluded from analysis ** ICD-10 conversion failure

Table 2.5.1 Distribution of Reported Childhood Cancer in Saudi Arabia by Nationality and Sex, 2011

Table 2.5.2 Ten Most Common Cancers among Saudi Arabia Children, 2011

Saudis Non-Saudis All

Male Female Total

Analyzed 789

800

1

11

817

123

124

0

1

131

58

58

0

0

65

65

66

0

1

66

675

685

1

10

686

312

315

1

3

316

363

370

0

7

370

*

Invasive

In Situ

ICD-10 **

Total

Male Female Total Total

Leukemia

Brain, CNS

Hodgkin disease

NHL

Kidney

Bone

Eye

Adrenal gland

Connective, Soft tissue

Liver

264

70

67

44

41

40

35

29

17

12

39.1

10.4

9.9

6.5

6.1

5.9

5.2

4.3

2.5

1.8

Cancer No. %

25

Table 2.5.3 Number and Percentage of Morphological Types for the Most CommonTypes of Cancer among Saudi Children, 2011.

Figure 2.7 Ten Most Common Cancer among Saudi Children by sex, 2011

363 312Boys GirlsLeukemia

NHL

Brain, Nervous system

Hodgkin disease


Bone

Kidney

Eye

Liver

Adrenal gland

Leukemia

Brain, Nervous system

Bone


Kidney

NHL

Hodgkin disease

Eye

Liver

Ovary

139

47

37

25

19

17

15

14

10

10

38.3%

12.9%

10.2%

6.9%

5.2%

4.7%

4.1%

3.9%

2.8%

2.8%

125

33

23

21

20

20

19

15

7

4

40.8%

10.8%

7.5%

6.9%

6.5%

6.5%

6.2%

4.9%

2.3%

1.3%

Leukemia

Brain, CNS

9836

9835

9861

9837

9801

9867

9874

9866

9863

9910

9873

9826

9946

9805

9470

9380

9392

9508

9440

9391

9382

9473

9400

9471

9401

70

26

5

11

6

2

2

4

3

2

1

1

1

0

5

10

7

5

2

0

3

3

2

0

1

1

1

2

50.4

18.7

3.6

7.9

4.3

1.4

1.4

2.9

2.2

1.4

0.7

0.7

0.7

0.0

3.6

27.0

18.9

13.5

5.4

0.0

8.1

8.1

5.4

0.0

2.7

2.7

2.7

5.4

62

25

9

3

1

5

4

2

1

1

2

2

2

2

4

10

5

2

3

4

0

0

1

2

1

0

0

5

49.6

20.0

7.2

2.4

0.8

4.0

3.2

1.6

0.8

0.8

1.6

1.6

1.6

1.6

3.2

30.3

15.2

6.1

9.1

12.1

0.0

0.0

3.0

6.1

3.0

0.0

0.0

15.2

Precursor B-cell lymphoblastic leukemia

Precursor cell lymphoblastic leukemia, NOS

Acute myeloid leukemia, NOS

Precursor T-cell lymphoblastic leukemia

Acute leukemia, NOS

Acute monocytic leukemia

Acute myeloid leukemia with maturation

Acute promyelocytic leukemia, t(15;17)(q22;q11-12)

Chronic myeloid leukemia, NOS

Acute megakaryoblastic leukemia

Acute myeloid leukemia without maturation

Burkitt cell leukemia

Juvenile myelomonocytic leukemia

Acute biphenotypic leukemia

Others

Medulloblastoma, NOS

Glioma, malignant

Ependymoma, anaplastic

Atypical teratoid/rhabdoid tumor

Glioblastoma, NOS

Ependymoma, NOS

Mixed glioma

Primitive neuroectodermal tumor, NOS

Astrocytoma, NOS

Desmoplastic nodular medulloblastoma

Astrocytoma, anaplastic

Choroid plexus carcinoma

Others

26

Table 2.5.3 Continued ....

NHL

Hodgkin Disease

Connective Tissue

Bone

Kidney

Eye

Liver

Adrenal Gland

Burkitt lymphoma, NOS

Malignant lymphoma, NOS

Precursor T-cell Lymphoblastic Lymphoma

Malignant histiocytosis

Malignant Lymphoma, Large B-cell, Diffuse, NOS

Malignant Lymphoma, Non-Hodgkin, NOS

Mycosis fungoides

Precursor cell lymphoblastic lymphoma, NOS

Others

Hodgkin lymphoma, nodular sclerosis, NOS

Hodgkin lymphoma, mixed cellularity, NOS

Hodgkin lymphoma, NOS

Hodgkin lymphoma, nodular lymphocyte predominance

Hodgkin lymphoma, lymphocyte-rich

All

Neuroblastoma, NOS

Embryonal rhabdomyosarcoma, NOS

Alveolar soft part sarcoma

Malignant rhabdoid tumor

Peripheral neuroectodermal tumor

Rhabdomyosarcoma, NOS

Others

Ewing sarcoma

Osteosarcoma, NOS

Chondroblastic osteosarcoma

Peripheral neuroectodermal tumor

Chordoma, NOS

Neoplasm, malignant

Yolk sac tumor

All

Nephroblastoma, NOS

Clear cell sarcoma of kidney

Atypical teratoid/rhabdoid tumor

Malignant rhabdoid tumor

Renal cell carcinoma, NOS

All

Retinoblastoma, NOS

Retinoblastoma, undifferentiated


Hepatoblastoma

Hepatocellular carcinoma, fibrolamellar

Hepatocellular carcinoma, NOS

Malignant myoepithelioma

Neoplasm, malignant

Neuroblastoma, NOS

96879590972997509680959197009727

96639652965096599651

950089109581896393648900

9181937092608000918093649071

89608964950889638312

951095128910

89708171817089828000

9500

2055431234

109231

25

5212105

8640000

18

131010

15

851

71110

10

42.610.610.68.56.42.14.36.48.5

40.036.08.0

12.04.0

100.0

31.312.56.3

12.56.30.0

31.3

44.433.322.20.00.00.00.0100

86.76.70.06.70.0

100.0

57.135.77.1

70.010.010.010.00.0

100.0

1021102103

93601

19

3410123

10532111

23

171101

20

1041

60001

2

50.010.05.05.00.0

10.05.00.0

15.0

47.415.831.60.05.3

100.0

21.428.67.10.07.1

14.321.4

43.521.713.08.74.34.34.3100

85.05.05.00.05.0

100.0

67277

85.70.00.00.0

14.3

100.0

27

The following bar charts list the most common cancer sites in the 13 administrative regions of Saudi Arabia by sex. These sites are listed on the basis of the total number of cases for each site reported by permanent address (region) of the patient at the time of diagnosis. In most regions breast and thyroid cancers were the leading cancer among women, while among men Colorectal and NHL. It is worth noting that the major regions such as Riyadh, Makkah and Eastern Province represent the majority of cases. This can be attributed to the increasing number of people seeking medical attention in these urbanized cities with modern hospital facilities where permanent addresses may not be documented in source record.

Cancer in the 13 Administrative Regions of the Kingdom, 2011

Figure 2.8.1 Riyadh Region, 2011 (Relative Frequency Distribution)

Figure 2.8.2 Makkah Region, 2011 (Relative Frequency Distribution)

24

2.4

2.4

3

3.8

3.8

5

5.4

10.2

14.7

25.3

31.9

3.7

3.7

4.2

4.3

5.7

6.3

8.5

8.7

8.9

14.1

32.0

2.8

3.3

3.3

3.8

6.0

6.8

6.9

9.5

12.0

13.7Colon-rectal

NHL

Leukemia

Liver

Lung

Prostate

Kidney

Hodgkin disease

Skin

Stomach

Other Sites

Breast

Thyroid

Colorectal

Leukemia

NHL

Corpus Uteri

Liver

Ovary

Hodgkin disease

Kidney

Other Sites

Female Breast

Colon-rectal

Thyroid

Leukemia

NHL

Liver

Lung

Kidney

Hodgkin disease

Stomach

Other Sites

0 10Males ( 1391 ) Females ( 1644 ) All ( 3035 )

20 30 40 0 10 20 30 40 0 10 20 30 40

26.2

2.5

2.6

3.6

4

4.7

5.2

6.8

7.9

10

26.5

32.4

3.2

3.2

4.1

4.6

6.7

6.7

7.4

8.5

8.6

14.6

36.4

2.9

3.1

3.7

4.2

5.0

5.4

5.9

6.8

12.1

14.5Colon-rectal

NHL

Lung

Leukemia

Prostate

Liver

Brain, CNS

Bladder

Skin

Stomach

Other Sites

Breast

Colorectal

Thyroid

Corpus Uteri

NHL

Leukemia

Ovary

Corpus Uteri

Skin

Stomach

Other Sites

Female Breast

Colorectal

NHL

Leukemia

Thyroid

Lung

Liver

Corpus Uteri

Prostate

Brain, CNS

Other Sites


20 30 40 0 10 20 30 40 0 10 20 30 40

28

Figure 2.8.3 Eastern Region, 2011 (Relative Frequency Distribution)

Figure 2.8.4 Madinah Region, 2011 (Relative Frequency Distribution)

Figure 2.8.5 Northern Region, 2011 (Relative Frequency Distribution)

23.4

2.0

2.0

2.6

3.1

4.3

5.4

5.8

7.8

8.8

34.8

34.4

3.7

3.8

4.1

4.1

4.7

6.2

7.5

9.3

9.3

12.9

33.2

2.9

3.2

3.5

3.6

5.2

5.8

6.0

6.6

10.6

19.4Colon-rectal

NHL

Lung

Prostate

Leukemia

Hodgkin Disease

Kindey

Liver

Thyroid

Bladder

Other Sites

Breast

Colorectal

Thyroid

Corpus Uteri

Leukemia

NHL

Ovary

Hodgkin Disease


Liver

Other Sites

Female Breast

Colorectal

NHL

Thyroid

Leukemia

Lung

Hodgkin Disease

Prostate

Corpus Uteri

Kindey

Other Sites


20 30 40 0 10 20 30 40 0 10 20 30 40

26.4

3.0

3.0

3.3

3.9

5.1

5.7

6.9

6.9

10.2

25.6

37.2

3.2

3.6

4.0

4.3

4.3

5.5

5.5

9.9

9.9

12.6

37.7

2.7

3.1

3.2

3.2

4.1

6.7

7.2

8.2

9.4

14.5Colon-rectal

Leukemia

NHL

Prostate

Skin

Hodgkin Disease

Pancress

Lung

Liver

Kindey

Other Sites

Breast

Thyroid

Leukemia

Colorectal

Corpus Uteri

NHL

Hodgkin Disease

Ovary

Crvix Uteri

Liver

Other Sites

Female Breast

Colorectal

Leukemia

NHL

Thyroid

Hodgkin Disease

Liver

Corpus Uteri

Other Skin

Pancress

Other Sites


20 30 40 0 10 20 30 40 0 10 20 30 40

21.5

5.9

5.9

5.9

5.9

5.9

5.9

7.8

7.8

7.9

19.6

20.9

4.3

4.3

4.3

4.3

4.3

4.3

4.3

4.3

6.4

6.4

6.4

8.5

8.5

8.5

39.8

3.1

4.1

4.1

5.1

5.1

6.1

7.1

7.1

8.2

10.2Leukemia

Skin

Colon-rectal

Kindey

Testis

Prostate

Hodgkin Disease

Adrenal Gland

Brain, CNS

Bone

Lung

Pancress

Liver

Stomach

Other Sites

Breast

Leukemia

Thyroid

Kindey

NHL

Ovary

Corpus Uteri

Skin

Pancress

Stomach

Other Sites

Female Breast

Leukemia

Skin

Kindey

Colorectal

Stomach

Pancress

Thyroid

NHL

Brain, CNS

Other Sites


20 30 0 10 20 30 40 0 10 20 30 40 50

29

Figure 2.8.7 Jazan Region, 2011 (Relative Frequency Distribution)

Figure 2.8.6 Qassim Region, 2011 (Relative Frequency Distribution)

Figure 2.8.8 Hail Region, 2011 (Relative Frequency Distribution)

24

1.9

2.3

2.3

2.7

3.1

4.2

4.2

8.8

12.7

33.8

27.9

3.7

3.3

4.2

4.2

4.2

4.2

4.7

7.4

8.8

9.3

18.1

31.6

2.7

2.9

3.4

3.4

4.2

5.3

6.5

8.4

13.1

18.5Colon-rectal

NHL

Liver

Lung

Skin

Hodgkin Disease

Prostate

Stomach

Nasopharynx

Kindey

Pancreas

Other Sites

Breast

Thyroid

Colorectal

NHL

Ovary

Leukemia

Hodgkin Disease

Skin

Liver

Oesophagus

Other Sites

Female Breast

Colorectal

Thyroid

NHL

Liver

Lung

Skin

Hodgkin Disease

Leukemia

Stomach

Other Sites


20 30 0 10 20 30 40 0 10 20 30 40

25.9

3.3

3.3

4.3

5.3

5.7

6.2

6.2

7.2

9.6

23

35.6

4.3

4.3

4.9

4.9

5.5

6.1

6.1

8

8

12.3

36.6

3.5

4.0

4.3

4.3

5.9

5.9

6.2

7.5

8.3

13.4NHL

Prostate

Skin

Colon-rectal

Mouth

Leukemia

Stomach

Tongue

Bladder

Liver

Other Sites

Breast

Tongue

Corpus Uteri

Thyroid

Colorectal

Mouth

NHL

Skin

Leukemia

Gallbladder etc.

Other Sites

Female Breast

NHL

Tongue

Colorectal

Skin

Mouth

Thyroid

Leukemia

Corpus Uteri

Prostate

Other Sites


20 30 40 0 10 20 30 40 0 10 20 30 40

25.7

2.1

2.1

2.8

3.5

4.2

4.3

5.7

10.6

18.4

20.6

17.1

3.4

3.4

3.4

4.5

4.5

6.8

6.8

8

8

9.1

10.2

14.8

25.3

2.2

2.6

3.1

3.1

3.5

4.4

4.4

5.2

7.0

12.2

12.7

14.4Colorectal

Liver

NHL

Thyroid

Skin

Brain, CNS

Bladder

Leukemia

Prostate

Kindey

Lung

Nasopharynx

Other Sites

Breast

Thyroid

Colorectal

NHL

Corpus Uteri

Leukemia

Stomach

Bladder

Gallbladder etc.

Liver

Other Sites

Thyroid

Female Breast

Colorectal

NHL

Liver

Leukemia

Bladder

Skin

Stomach

Brain, CNS

Corpus Uteri

Connective , Soft tissue

Other Sites


10 15 20 0 5 10 15 20 25 300 10 20 30 40

30

Figure 2.8.9 Najran Region, 2011 (Relative Frequency Distribution)

Figure 2.8.10 Baha Region, 2011 (Relative Frequency Distribution)

Figure 2.8.11 Asir Region, 2011 (Relative Frequency Distribution)

19.6

2.9

2.9

2.9

2.9

2.9

2.9

2.9

7.2

8.6

8.6

15.7

20

24.8

2.8

3.5

2.8

2.8

4.1

4.8

7.6

7.6

8.3

9.7

10.3

11.0

14.4

2.72.7

2.7

2.72.7

4

4

5.3

6.7

6.7

6.7

6.7

88

16Liver

Leukemia

Colon-rectal

NHL

Prostate

Skin

Stomach

Thyroid

Kindey

Gallbladder etc.

Multiple Myeloma

Hodgkin Disease

Breast

Nasopharynx

Mouth

Other Sites

Breast

Thyroid

NHL

Colorectal

Leukemia

Multiple Myeloma

Hodgkin Disease

Corpus Uteri

Cervix Uteri

Pancreas

Liver

Stomach

Other Sites

Female Breast

Thyroid

Liver

Colorectal

NHL

Leukemia

Stomach

Skin

Prostate

Multiple Myeloma

Kindey

Hodgkin Disease

Other Sites

0 105 25 5 15 25Males ( 75 ) Females ( 70 ) All ( 145 )

20 0 10 20 30 0 10 20 30

17

2.6

2.6

2.6

2.6

2.6

3.5

4.4

6.1

6.1

6.1

7

8.7

28.1

20

2.9

4.3

2.9

2.9

4.3

5.7

7.1

7.1

7.1

10

11.4

14.3

24.5

3.8

3.8

2.7

3.8

4.3

4.3

4.9

5.4

5.4

8.2

10.9

17.9Breast

Colorectal

Thyroid

Leukemia

NHL

Corpus Uteri

Stomach

Ovary

Hodgkin Disease

Brain, CNS

Other Skin

Lung

Liver

Other Sites

Colorectal

Leukemia

Skin

Bladder

Lung

Liver

Prostate

NHL

Larynx

Brain, CNS

Bone

Stomach

Other Sites

Female Breast

Colorectal

Leukemia

Skin

NHL

Thyroid

Lung

Liver

Stomach

Bladder

Corpus Uteri

Brain, CNS

Other Sites

0 10 5 15 25Males ( 70 ) Females ( 114 ) All ( 184 )

20 30 0 10 20 30 40 0 10 20 30

27.6

2.6

2.8

3.1

3.9

5.9

6.2

8

8.8

13

18.1

39.3

4.1

4.3

4.4

4.5

4.7

5.9

8.4

8.6

9.2

9.4

32.5

3.6

3.6

3.9

5.5

6.4

6.6

7.5

8.6

9.1

12.7Colorectal

NHL

Prostate

Bladder

Skin

Liver

Leukemia

Kindey

Thyroid

Brain, CNS

Other Sites

Breast

Thyroid

Corpus Uteri

NHL

Leukemia

Colorectal

Hodgkin Disease

Liver

Ovary

Stomach

Other Sites

Female Breast

Colorectal

NHL

Thyroid

Leukemia

Liver

Corpus Uteri

Bladder

Skin

Prostate

Other Sites

Males ( 362 ) Females ( 386 ) All ( 748 )0 10 20 30 40 0 10 20 30 40 500 10 20 30 40

31

Figure 2.8.12 Tabuk Region, 2011 (Relative Frequency Distribution)

Figure 2.8.13 Jouf Region, 2011 (Relative Frequency Distribution)

18.4

4.0

4.0

4.0

5.0

5.0

5.0

6.0

11.9

11.9

24.8

29.3

3.7

3.7

4.3

4.3

4.3

4.9

5.6

5.6

8.6

9.9

15.4

27.8

4.9

4.9

4.9

4.9

4.9

6.6

6.6

6.6

6.6

6.6

6.6

8.2Lung

Leukemia

Hodgkin Disease

Brain, CNS

Kindey

Skin

Bone

Prostate

Connective, Softtissue

Larynx

Liver

Colorectal

Other Sites

Breast

Thyroid

Leukemia

Colorectal

NHL

Hodgkin Disease

Corpus Uteri

Ovary

Bone

Nasopharynx

Other Sites

Female Breast

Leukemia

Thyroid

Hodgkin Disease

Colorectal

Bone

Lung

Skin

NHL

Nasopharynx

Kindey

Other Sites

Males ( 61 ) Females ( 101 ) All ( 162 )0 10 20 30 40 0 10 20 30 400 10 20 30

14.4

2.9

2.9

2.9

2.9

2.9

2.9

3.5

4.1

5.3

5.9

8.3

11.8

12.4

19.4

32.2

3.0

3.0

4.4

4.4

5.7

7.0

8.7

8.7

11.4

11.4

35.1

3.9

3.9

3.9

3.9

4.7

5.5

5.5

9.3

11

13.3Lung

Leukemia

Colorectal

NHL

Kindey

Bladder

Thyroid

Pancreas

Stomach

Nasopharynx

Other Sites

Breast

Thyroid

Leukemia

Colorectal

NHL

Hodgkin Disease

Ovary

Kindey

Multiple Myeloma

Brain, CNS

Lung

Pancreas

Stomach

Liver

Other Sites

Female Breast

Leukemia

Thyroid

Colorectal

Lung

NHL

Kindey

Hodgkin Disease

Stomach

Pancreas

Other Sites

Males ( 128 ) Females ( 170 ) All ( 298 )0 10 20 30 400 10 20 30 40 0 10 20 30 40

32

* ASR Rer 100.000** Source for this information is summarized on Page 66

Figure 2.9.1Comparison of ASR* for Saudi Males with Selected Countries**

Figure 2.9.2 Comparison of ASR* for Saudi Female with Selected Countries**

Worldwide, GLOBOCAN, 2012 estimated that 14,090,149 people developed cancer in 2012. Of these, 80,142,73 (56.9%) were in developing countries and 60,758,76 (43.1%) in developed countries. In men, ASR is high in Northern America, Europe, and Australia\New Zealand while the lowest ASR is in Western/ Middle Africa and South-Central Asia. As in males, the regions with the highest ASR in females are Northern America, Europe, and Australia\New Zealand whiles the lowest ASR in Middle/Northern/Western Africa and in South-Eastern Asia and South-Central Asia. According to 2012 estimates, the most common cancer site worldwide among men was lung cancer, followed by prostate, colorectal, stomach then liver. However in developed countries prostate was the leading cancer followed by lung, colorectal, then bladder followed by stomach, while in developing countries lung cancer was first followed by liver, stomach, prostate and NHL cancers. In women, the most common cancer site was breast followed by colorectal, lung, cervix uteri cancers and corpus uteri. In developing countries among women, breast cancer was the most common followed by cervix uteri, lung, then colorectal, and stomach. While in the developed countries breast cancer was the leading cancer followed by cancers of the colorectal, corpus uteri then Hodgkin disease.

International Comparison of Age-Standardized Incidence Rates

Ireland

USA, All Races

Canada

UK, Wales

Western Australia

Norway

Korea

Singapore

Bhrain

Argentina

Qatar

Jordan

Kuwait

Tunisia, North

United Arab Emirates

Oman

Saudi Arabia

South Africa, PROMEC

India, Dinigul, Ambillikai

United States of America

United Kingdom

Norway

Western Australia

Korea

Singapore

Uganda, Kyadondo

Qatar

Bhrain

Jordan

Kuwait

Egypt

Tunisia

United Arab Emirates

Saudi Arabia

Oman

422.04

372.1

288

264.3

259.3

205.9

173.5

180.3

155.0

143.1

142.8

138.5

106.0

3.8

90.1

96.8

697.9

502.7

457.6

448.2

365.1

358.4

320

229.6155.0

158.5

155.2

132.8131.1

129.9

77.8106.8

50.5

73.6

54.6

PART IIICANCER INCIDENCE

FOR MOST COMMON SITES 2011

Leukemia

Liver

Lung

Skin

Corpus Uteri

Prostate

35

In this section, the incidence of the most common cancers among Saudi males and females are outlined in accordance to their relative frequencies. The relevant data incorporate details for all patients presented over the period of January through December 2011.

Cancer Incidence for Most Common Sites, 2011

Site

Breast

Colorectal

Thyroid

Non-Hodgkin Lymphoma

Leukemia

Liver

Trachea, Bronchus, Lung

Hodgkin Disease

Other Skin

Corpus Uteri

Prostate

Stomach

Kidney

Brain

Bladder

Other sites

All Sites

Male

16

657

154

432

366

330

343

184

208

0

311

162

178

170

180

1222

4913

Female

1590

537

646

312

331

158

109

157

125

318

0

133

112

99

52

1277

5956

All

1606

1194

800

744

697

488

452

341

333

318

311

295

290

269

232

2499

10869

%

14.8

11.0

7.4

6.8

6.4

4.5

4.2

3.1

3.1

2.9

2.9

2.7

2.7

2.5

2.1

23.0

100.0

Table 3.1 Most Common Cancers among Saudis by Sex, 2011

0

10

20

30

40

50

60

70

80

90

100

0 - 5 - 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

100,

000)

Age Groups

Distant 16%

Localised

31%

Regional 41%

Unknown 12%

36

8500

8520

8010

8000

8522

8523

8510

8480

9020

ICD 3 - 0 Morphology

Infiltrating Duct Carcinoma, NOS

Lobular carcinoma, NOS

Carcinoma, NOS

Neoplasm, malignant

Infiltrating duct and lobular carcinoma

Infiltrating duct mixed with other types of carcinoma

Medullary carcinoma, NOS

Mucinous adenocarcinoma

Phyllodes tumor, malignant

Others

Female

1218

88

56

53

41

23

19

13

12

69

%

76.5

5.5

3.5

3.3

2.6

1.4

1.2

0.8

0.8

4.3

There were 1590 female breast cancer cases for year 2011. Breast cancer ranked first among females accounting for 26.6% of all newly diagnosed female cancers (5,956) in year 2011. The ASR was 23.4/100,000 for female population. The five regions with the highest ASR were Eastern region at 35.8/100,000, Riyadh region at 28.3/100,000, Qassim Region at 23.7/100,000, Makkah Region at 23.6/100,000, Jouf and Baha Region at 20.8/100,000. The median age at diagnosis was 48 years (Range 19-109 years)

Female Breast Cancer (C50)

Figure 3.1.1 Age-Specific Incidence Rate (AIR) for Female Cancer in Saudi Arabia, 2011

Table 3.1.1 Morphological Distribution of Female Breast Cancer in Saudi Arabia, 2011

Figure 3.1.2 Stage Distribution of Female Breast Cancer in Saudi Arabia, 2011

37

Figure 3.1.3 ASR* Regional Distribution of Female Breast Cancer in Saudi Arabia, 2011

Figure 3.1.4 Comparison of ASR* for Female Breast Cancer among Saudi Females with ASR in Selected Countries**

* ASR Per 100,000** Source for this information is summarized on page 66

38


Adenocarcinoma, NOS


Adenocarcinoma in tubulovillous adenoma

Neoplasm, malignant

Adenocarcinoma in villous adenoma

Adenocarcinoma in adenomatous polyp

Signet ring cell carcinoma

Carcinoma, NOS

Mucin-producing adenocarcinoma

Others

Male

520

43

14

14

11

15

10

7

5

18

%

79.1

6.5

2.1

2.1

1.7

2.3

1.5

1.1

0.8

2.7

Female

421

38

16

10

12

6

8

7

5

14

%

78.4

7.1

3.0

1.9

2.2

1.1

1.5

1.3

0.9

2.6

8140

8480

8263

8000

8261

8210

8490

8010

8481

Figure 3.2.1 Age-Specific Incidence Rate (AIR) for Colorectal Cancer in Saudi Arabia, 2011

Table 3.2.1 Morphological Distribution of Colorectal Cancer in Saudi Arabia, 2011

Figure 3.2.2 Stage Distribution of Colorectal Cancer in Saudi Arabia, 2011

There were 1,194 cases of colorectal cancer accounting for 11.0% of all newly diagnosed cases in year 2011. This cancer ranked first among male and third among female. It affected 657 (55.0%) males and 537 (45.0 %) females with a male to female ratio of 122:100. The ASR males was 11.3/100,000 and for females 9.0/100,000. The five regions with the highest ASR for male were in Riyadh and Eastern region at 15.6/100,000 for each, Qassim region at 12.8/100,000, Makkah region at 11.8/100,000, and Tabuk region at 8.7/100,000. In female the highest ASR was in Riyadh region at 13.1/100,000, Eastern region at 11.3/100,000 then Makkah and Tabuk region at 9.8/100,000 for each and Madinah region at 8.5/100,000. The median age at diagnosis was 59 years among males (range 11-96 years) and 56 years among females (range 19-106 years).

Colorectal (C18-C20)

39

*ASR Per 100,000** Source for this information is summarized on page 66

Figure 3.2.3 ASR* Regional Distribution of Colorectal Cancer in Saudi Arabia, 2011

Figure 3.2.4 Comparison of ASR* for Colorectal Cancer among Saudi with ASR in Selected countries**

40


Papillary adenocarcinoma, NOS

Papillary carcinoma, follicular variant

Papillary microcarcinoma

Papillary carcinoma, columnar cell

Papillary carcinoma, encapsulated

Follicular adenocarcinoma, NOS

Oxyphilic adenocarcinoma

Follicular carcinoma, minimally invasive

Medullary carcinoma, NOS

Papillary carcinoma, NOS

Carcinoma, anaplastic, NOS

Others

Male

76

16

8

7

7

9

3

4

5

2

5

12

%

49.4

10.4

5.2

4.5

4.5

5.8

1.9

2.6

3.2

1.3

3.2

7.8

Female

315

115

73

38

28

13

13

11

8

11

7

15

%

48.7

17.8

11.3

5.9

4.3

2.0

2.0

1.7

1.2

1.7

1.1

2.3

8260

8340

8341

8344

8343

8330

8290

8335

8510

8050

8021

There were 800 cases of thyroid cancer accounting for 7.4% of all newly diagnosed cases for the year 2011. This cancer ranked second among female and thirteenth among male population. It affected 154 (19.2%) males and 646 (80.8%) females with a female to male ratio of 419:100. The ASR was 2.2/100,000 for male and 8.1 /100,000 for females. The five regions with the highest ASR for female was in Riyadh region at 13.2/100,000, Hail region at 11.3/100,000, Jouf region at 8.7, Asir and Qassim region at 8.6/100,000 for each. In male the highest ASR was in Eastern region at 3.6/100,000, Hail region at 3.2/100,000, Najran region at 3.1/100,000, Riyadh at 2.7/100,000, Tabuk region at 2.6/100,000 and Asir region at 2.2/100,000. The median age at diagnosis was 46 years among males (range 11-90 years) and 41 years among females (range 11-99 years).

Thyroid (C73)

Figure 3.3.1 Age-Specific Incidence Rate (AIR) for Thyroid Cancer in Saudi Arabia, 2011

Table 3.3.1 Morphological Distribution of Thyroid Cancer in Saudi Arabia, 2011

Figure 3.3.2 Stage Distribution of Thyroid Cancer in Saudi Arabia, 2011

41*ASR Per 100,000** Source for this information is summarized on page 66

Figure 3.3.3 ASR* Regional Distribution of Thyroid Cancer in Saudi Arabia, 2011

Figure 3.3.4 Comparison of ASR* for Thyroid Cancer among Saudi with ASR in Selected countries**

42


Malignant lymphoma, large B-cell, diffuse, NOS

Burkitt lymphoma, NOS

Malignant lymphoma, NOS

Malignant lymphoma, non-Hodgkin, NOS

Mycosis fungoides

Marginal zone B-cell lymphoma, NOS

Malignant lymphoma, small B lymphocytic, NOS

Follicular lymphoma, NOS

Follicular lymphoma, grade 2

Mature T-cell lymphoma, NOS

Others

Male

185

31

24

16

18

15

16

16

14

17

80

%

42.8

7.2

5.6

3.7

4.2

3.5

3.7

3.7

3.2

3.9

18.5

Female

158

16

17

22

19

16

10

9

10

5

30

%

50.6

5.1

5.4

7.1

6.1

5.1

3.2

2.9

3.2

1.6

9.6

9680

9687

9590

9591

9700

9699

9670

9690

9691

9702

There were 744 cases of Non-Hodgkin Lymphoma accounting for 6.8 % of all newly diagnosed cancers in year 2011. This cancer ranked second among male and sixth among female. It affected 432 (58.1%) males and 312 (41.9%) females with a male to female ratio of 138:100. The ASR for males was 6.4/100,000 and 4.8/100,000 for females. The five regions with the highest ASR for male were in Eastern region at 9.0/100,000, Makkah region at 6.1/100,000, Qassim region at 5.9/100,000, Riyadh region at 5.5/100,000 and Asir regions at 5.4/100,000. In female the highest ASR was in Riyadh region at 6.0/100,000, Tabuk region at 5.7/100,000, Baha region at 5.2/100,000, Makkah region at 5.1/100,000 and Asir at 5.0/100,000. The median age at diagnosis was 54 years among males (range 0-110 years) and 52 years among females (range 0-102 years)

Non-Hodgkin Lymphoma (C82-C85: C96)

Figure 3.4.1 Age-Specific Incidence Rate (AIR) for NHL in Saudi Arabia, 2011

Table 3.4.1 Morphological Distribution of NHL in Saudi Arabia, 2011

Figure 3.4.2 Stage Distribution of NHL in Saudi Arabia, 2011

43

Figure 3.4.3 ASR* Regional Distribution of NHL in Saudi Arabia, 2011

Figure 3.4.4 Comparison of ASR* for NHL among Saudi with ASR in Selected Countries**


44

Figure 3.5.1 Age-Specific Incidence Rate (AIR) for Leukemia in Saudi Arabia, 2011

Table 3.5.1 Morphological Distribution of Leukemia in Saudi Arabia, 2011


Precursor B-cell lymphoblastic leukemia

Acute myeloid leukemia, NOS

Chronic myeloid leukemia, NOS

Precursor cell lymphoblastic leukemia, NOS

B-cell chronic lymphocytic leukemia/small lymphocytic lymphom

Precursor T-cell lymphoblastic leukemia

Acute promyelocytic leukemia, t(15;17)(q22;q11-12)

Acute monocytic leukemia

Acute myeloid leukemia with maturation

Acute leukemia, NOS

Chronic myelogenous leukemia, BCR/ABL positive

Acute myelomonocytic leukemia

Leukemia, NOS

Acute myeloid leukemia without maturation

Burkitt cell leukemia

Others

Male

98

47

40

36

37

20

11

8

8

13

6

7

2

3

1

29

%

26.8

12.8

10.9

9.8

10.1

5.5

3.0

2.2

2.2

3.6

1.6

1.9

0.5

0.8

0.3

7.9

Female

82

52

49

32

13

9

16

14

12

4

7

5

7

4

4

21

%

24.8

15.7

14.8

9.7

3.9

2.7

4.8

4.2

3.6

1.2

2.1

1.5

2.1

1.2

1.2

6.3

9836

9861

9863

9835

9823

9837

9866

9891

9874

9801

9875

9867

9800

9873

9826

There were 697 cases of leukemia accounting for 6.4% of all newly diagnosed cancers in year 2011. This cancer ranked third for males and the fourth for females. It affected 366 (52.2%) males and 331 (47.5%) females with a male to female ratio of 110:100. The ASR in males was 4.5/100,000 and 4.0/100,000 for females. The five regions with the highest ASR in male were in Riyadh region at 7.1/100,000, Tabuk region at 6.8/100,000, Najran region at 5.3/100,000, Eastern and Makkah region at 4.6/100,000 for each. In female the highest ASR were in Tabuk region at 9.9/100,000, then Jouf region at 8.0/100,000, Riyadh region at 4.8/100,000, Eastern region at 4.7/100,000 and Najran region at 4.1/100,000. The median age at diagnosis is 23 years among males (range 0-95 years) and 26 years among females (range 0-95 years).

Leukemia (C91 - C95)

45


Figure 3.5.2 ASR* Regional Distribution of Leukemia in Saudi Arabia, 2011

Figure 3.5.3 Comparison of ASR* for Leukeamia among Saudi with ASR in Selected Countries**

46

Figure 3.6.1 Age-Specific Incidence Rate (AIR) for Liver Cancer in Saudi Arabia, 2011

Table 3.6.1 Morphological Distribution of Liver in Saudi Arabia, 2011

Figure 3.6.2 Stage Distribution of Liver Cancer in Saudi Arabia, 2011

There were 488 cases of liver cancer accounting for 4.5% of all newly diagnosed cases in year 2011. This cancer ranked fifth in males and seventh in females. It affected 330 (67.6 %) males and 158 (32.4%) females with a male to female ratio of 208:100. The ASR was 6.1/100,000 for males and 2.9/100,000 for females. The five regions with the highest ASR for male were Najran region at 11.4/100,000, Riyadh region at 10.7/100,000, Qassim region at 6.5/100,000, Makkah region at 5.8/100,000 and Eastern region at 5.6/100,000. In female the highest ASR were in Riyadh region at 5.6/100,000, Jazan region at 4.3/100,000, Tabuk region at 4.0/100,000, Eastern region at 2.9/100,000, Asir and Madinah region at 2.5/100,000 for each. The median age at diagnosis was 68 years in males (range 0-98 years) and 64 years in females (range 0-109 years).

Liver (C22)


Hepatocellular carcinoma, NOS

Cholangiocarcinoma

Neoplasm, malignant

Adenocarcinoma, NOS

Hepatoblastoma

Carcinoma, NOS

Others

Male

267

20

16

10

7

1

9

%

80.9

6.1

4.8

3.0

2.1

0.3

2.7

Female

112

15

9

5

6

3

8

%

70.9

9.5

5.7

3.2

3.8

1.9

5.1

8170

8000

8610

8140

8970

8010

47


Figure 3.6.3 ASR* Regional Distribution of Liver Cancer in Saudi Arabia, 2010

Figure 3.6.4 Comparison of ASR* for Liver among Saudi with ASR in Selected Countries**

48

Figure 3.7.1 Age-Specific Incidence Rate (AIR) for Lung Cancer in Saudi Arabia, 2011

Table 3.7.1 Morphological Distribution of Lung in Saudi Arabia, 2011

Figure 3.7.2 Stage Distribution of Lung Cancer in Saudi Arabia, 2011

There were 452 cases of lung cancer accounting for 4.2% of all diagnosed cases in year 2011. Lung cancer ranked fourth among male and twelfth among female. It affected 343 (75.9%) males and 109 (24.1%) females with a male to female ratio of 314:100. The ASR was 6.4/100,000 for males and 1.9/100,000 for females. The five regions with the highest ASR for male were in Tabuk region at 14.9/100,000, Eastern region at 13.1/100,000, Riyadh region at 8.3/100,000, Makkah region 7.7/100,000 and Qassim 5.8/100,000. In female the highest ASR were in Tabuk region at 2.7/100,000, Riyadh region at 2.6/ 100,000, Eastern region at 2.3/100,000, last Makkah and Baha region 2.0/100,000 for each. The median age at diagnosis was 68 years among males (range 11-104 years) and 60 years among females (range 13-94 years).

Lung (C33 - C34)


Adenocarcinoma, NOS

Squamous cell carcinoma, NOS

Small cell carcinoma, NOS

Non-small cell carcinoma

Neoplasm, malignant

Bronchiolo-alveolar adenocarcinoma, NOS

Carcinoma, NOS

Large cell carcinoma, NOS

Squamous cell carcinoma, keratinizing, NOS

Carcinoid tumor, NOS

Others

Male

104

62

34

32

19

11

14

8

8

3

48

%

30.3

18.1

9.9

9.3

5.5

3.2

4.1

2.3

2.3

0.9

14.0

Female

44

11

6

7

6

10

7

1

0

4

13

%

40.4

10.1

5.5

6.4

5.5

9.2

6.4

0.9

0.0

3.7

11.9

8140

8070

8041

8046

8000

8250

8010

8012

8071

8240

49


Figure 3.7.3 ASR* Regional Distribution of Lung Cancer in Saudi Arabia, 2011

Figure 3.7.4 Comparison of ASR* for Lung Cancer among Saudi with ASR in Selected Countries**

50

Figure 3.8.1 Age-Specific Incidence Rate (AIR) for Hodgkin Disease in Saudi Arabia, 2011

Table 3.8.1 Morphological Distribution of Hodgkin Disease in Saudi Arabia, 2011

Figure 3.8.2 Stage Distribution of Hodgkin Disease in Saudi Arabia, 2011

There were 341 cases of Hodgkin disease accounting for 3.1% of all newly diagnosed cases in year 2011. Hodgkin disease ranked eighth among both males and females. It affected 184 (54.0%) males and 157 (46.0%) females with a male to female ratio of 117:100. The ASR was 1.9/100,000 for males and 1.7/100,000 for females. The five regions with highest ASR in male were Eastern region at 3.2/100,000, Jouf and Riyadh region at 2.6/100,000 for each, Qassim region at 2.0/100,000, and Madinah region at 1.9/100,000. In female the highest ASR were in Tabuk region at 3.9/100,000, Jouf region at 3.3/100,000, Asir region at 2.2/100,000, then Eastern, Madinah and Baha regions at 1.9/100,000 for each. The median age at diagnosis was 25 years (range 0-90 years) in males and 24 year in females (range 0-89).

Hodgkin Disease (C 81)


Hodgkin lymphoma, nodular sclerosis, NOS

Hodgkin lymphoma, NOS

Hodgkin lymphoma, mixed cellularity, NOS

Hodgkin lymphoma, lymphocyte-rich

Hodgkin lymphoma, nodular lymphocyte predominance

Hodgkin lymphoma, lymphocyte depletion, NOS

Hodgkin lymphoma, nodular sclerosis, grade 1

Hodgkin lymphoma, nodular sclerosis, grade 2

Hodgkin lymphoma, nodular sclerosis, cellular phase

Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis

Hodgkin lymphoma, lymphocyte depletion, reticular

Male

92

25

28

10

16

3

4

5

1

0

0

%

50.0

13.6

15.2

5.4

8.7

1.6

2.2

2.7

0.5

0.0

0.0

Female

81

26

20

11

5

4

3

2

3

1

1

%

51.6

16.6

12.7

7.0

3.2

2.5

1.9

1.3

1.9

0.6

0.6

9663

9650

9652

9651

9659

9653

9665

9667

9664

9654

9655

51


Figure 3.8.3 ASR* Regional Distribution of Hodgkin Disease in Saudi Arabia, 2011

Figure 3.8.4 Comparison of ASR* for Hodgkin Disease among Saudi with ASR in Selected Countries**

52

Figure 3.9.1 Age-Specific Incidence Rate (AIR) for Skin Cancer in Saudi Arabia, 2011

Table 3.9.1 Morphological Distribution of Skin Cancer in Saudi Arabia, 2011

Figure 3.9.2 Stage Distribution of Skin Cancer in Saudi Arabia, 2011

There were 333 cases of skin cancer accounting for 3.1% of all newly diagnosed cases in year 2011. This cancer ranked seventh for males tenth females. It affected 208 (62.5%) males and 125 (37.5%) females with a male to female ratio of 166:100. The ASR was 3.6/100,000 for males and 2.2/100,000 for females. The five regions with the highest ASR for male were in Jouf region at 5.5/100,000, Northern and Baha regions at 5.0/100,000 for each, Riyadh region at 4.8/100,000, Asir and Najran regions at 3.9/100,000 for each. In female the highest ASR were in Jouf region at 3.2/100,000, Makkah region at 2.8/100,000, and Eastern region at 2.6/100,000, Jazan region at 2.5/100,000 and Riyadh region at 2.4/100,000. The median age at diagnosis was 70 years among males (range 20-120 years) and 63 years among females (range 10-99years).

Skin (Non-Melanoma) (C 44)


Basal cell carcinoma, NOS


Basal cell carcinoma, nodular

Dermatofibrosarcoma, NOS


Infiltrating basal cell carcinoma, NOS

Basosquamous carcinoma

Multifocal superficial basal cell carcinoma

Sebaceous adenocarcinoma

Adenoid basal carcinoma

Others

Male

95

51

16

8

6

5

2

5

5

1

13

%

45.9

24.6

7.7

3.9

2.9

2.4

1.0

2.4

2.4

0.5

6.3

Female

54

26

9

15

5

5

4

1

1

1

4

%

43.2

20.8

7.2

12.0

4.0

4.0

3.2

0.8

0.8

0.8

3.2

8090

8070

8097

8832

8071

8092

8094

8091

8410

8098

53


Figure 3.9.3 ASR* Regional Distribution of Skin Cancer in Saudi Arabia, 2011

Figure 3.9.4 Comparison of ASR* for Skin Cancer among Saudi with ASR in Selected Countries**

54


Endometrioid adenocarcinoma, NOS

Adenocarcinoma, NOS

Carcinosarcoma, NOS

Papillary serous cystadenocarcinoma

Clear cell adenocarcinoma, NOS

Mullerian mixed tumor

Carcinoma, NOS

Serous cystadenocarcinoma, NOS

Endometrial stromal sarcoma, NOS

Neoplasm, malignant

Others

Female

190

40

15

10

8

7

6

6

5

4

27

%

59.7

12.6

4.7

3.1

2.5

2.2

1.9

1.9

1.6

1.3

8.5

8380

8140

8980

4860

8310

8950

8010

8441

8930

8000

Figure 3.10.1 Age-Specific Incidence Rate (AIR) for Corpus Uteri in Saudi Arabia, 2011

Table 3.10.1 Morphological Distribution of Coups Uteri Cancer in Saudi Arabia, 2011

Figure 3.10.2 Stage Distribution of Corpus Uteri Cancer in Saudi Arabia, 2011

There were 318 cases of corpus uteri cancer among females accounting for 2.9% of all newly diagnosed cases for females (5,956) in year 2011. This cancer ranked fifth among female, with ASR was 5.8/100,000 in females. The five regions with the highest ASR were Eastern region at 8.8/100,000, Makkah region at 7.5/100,000, Asir region at 6.6/100,000, Riyadh region at 5.8/100,000 and Madinah region at 5.2/ 100,000. The median age at diagnosis was 61 years (range 20-98 years).

Corpus Uteri (C 54)

55


Figure 3.10.3 ASR* Regional Distribution of Corpus Uteri Cancer in Saudi Arabia, 2011

Figure 3.10.4 Comparison of ASR* for Corpus Uteri among Saudi with ASR in Selected Countries**

56


Adenocarcinoma, NOS

Neoplasm, malignant

Acinar cell carcinoma

Carcinoma, NOS


Tumor cells, malignant

Male

269

18

11

11

1

1

%

86.5

5.8

3.5

3.5

0.3

0.3

8140

8000

8550

8010

8910

8001

Figure 3.11.1 Age-Specific Incidence Rate (AIR) for Prostate Cancer in Saudi Arabia, 2011

Table 3.11.1 Morphological Distribution of Prostate Cancer in Saudi Arabia, 2011

Figure 3.11.2 Stage Distribution of Prostate Cancer in Saudi Arabia, 2011

There were 311 cases of prostate cancer accounting for 2.9% of all newly diagnosed cases among males in year 2011. This cancer ranked sixth among males. The ASR was 6.0/100,000 among male population. The five regions with the highest ASR were Eastern region at 11.3/100,000, Riyadh region at 8.0/100,000, Makkah region at 5.9/100,000, Northern region at 5.1/100,000 and Asir region at 4.9/100,000. The median age at diagnosis was 72 years (range 6-101 years).

Prostate (C61)

57

Figure 3.11.3 ASR* Regional Distribution of Prostate Cancer in Saudi Arabia, 2011

Figure 3.11.4 Comparison of ASR* for Prostate among Saudi with ASR in Selected Countries**


58

Figure 3.12.1 Age-Specific Incidence Rate (AIR) for Stomach Cancer in Saudi Arabia, 2011

Table 3.12.1 Morphological Distribution of Stomach Cancer in Saudi Arabia, 2011

Figure 3.12.2 Stage Distribution of Stomach Cancer in Saudi Arabia, 2011

There were 295 cases of stomach cancer accounting for 2.7% of all newly diagnosed cases in year 2011. This cancer ranked twelfth among males and ninth among females. It affected 162 (54.9%) males and 133 (45.1%) females with a male to female ratio of 121:100. The ASR for male was 4.3/100,000 and 3.0/100,000 for females. The highest ASR among males was in Najran region at 5.1/100,000, then Riyadh region at 4.3/100,000, Tabuk region at 3.8/100,000, Northern regions at 3.7/100,000, and Qassim region at 3.5/100,000. The highest ASR among females was in Northern region at 4.9/100,000, then Baha region at 3.6/100,000, Riyadh region 3.0/100,000, Jouf and Makkah region 2.6/100,000 and Tabuk 2.5/100,000. The median age at diagnosis was 64 years among males (range 23-107 years) and 63 years among females (range 17-100 years).

Stomach (C16)

ICD O Morphology

Adenocarcinoma, NOS

Signet ring cell carcinoma

Adenocarcinoma, intestinal type

Neoplasm, malignant

Carcinoma, diffuse type

Gastrointestinal stromal sarcoma


Carcinoma, NOS

Neuroendocrine carcinoma, NOS


Others

Male

79

33

19

6

3

4

5

3

4

1

6

%

48.5

20.2

11.7

3.7

1.8

2.5

3.1

1.8

2.5

0.6

3.7

Female

47

31

12

8

8

5

3

4

2

3

10

%

35.3

23.3

9.0

6.0

6.0

3.8

2.3

3.0

1.5

2.3

7.5

8140

8490

8144

8000

8145

8936

8480

8010

8246

8070

59


Figure 3.12.3 ASR* Regional Distribution of Stomach Cancer in Saudi Arabia, 2011

Figure 3.12.4 Comparison of ASR* for Stomach among Saudi with ASR in Selected Countries**

60

Figure 3.13.1 Age-Specific Incidence Rate (AIR) for Kidney Cancer in Saudi Arabia, 2011

Table 3.13.1 Morphological Distribution of Kidney Cancer in Saudi Arabia, 2011

Figure 3.13.2 Stage Distribution of Kidney Cancer in Saudi Arabia, 2011

There were 290 cases of Kidney cancer accounting for 2.7% of all newly diagnosed cases in year 2011. This cancer ranked tenth among male and eleventh among female. It affected 178 (61.3%) males and 112 (38.6%) females with a male to female ratio of 159:100. The ASR was 2.9/100,000 for male and 1.7/100,000 for females. The highest ASR among male was in Tabuk region at 5.0/100,000, Northern region at 4.9/100,000, Riyadh region at 4.6/100,000, Eastern region at 4.2/100,000, and Jouf region at 3.3/100,000. In female the highest ASR was in Northern region at 3.3/100,000, Riyadh region at 2.9/100,000, Tabuk region at 2.7/100,000, Eastern region at 2.4/100,000 and Jouf region at 2.3/100,000. The median age at diagnosis was 57 years among males (range 0-94 years) and 53 years among females (range 0 - 96 Years)

Kidney (C64)

ICD - 3- 0 Morphology

Renal cell carcinoma, NOS

Nephroblastoma, NOS

Clear cell adenocarcinoma, NOS

Renal cell carcinoma, chromophobe type

Papillary adenocarcinoma, NOS

Renal cell carcinoma, sarcomatoid

Neoplasm, malignant

Cyst-associated renal cell carcinoma

Transitional cell carcinoma, NOS

Carcinoma, NOS

Others

Male

93

13

17

15

16

4

3

3

4

2

8

%

52.2

7.3

9.6

8.4

9.0

2.2

1.7

1.7

2.2

1.1

4.5

2420

35

18

26

48

15

11 7

Female

57

18

11

7

5

6

2

1

0

0

5

%

50.9

16.1

9.8

6.3

4.5

5.4

1.8

0.9

0.0

0.0

4.5

8312

8960

8310

8317

8260

8318

8000

8316

8120

8010

61


Figure 3.13.3 ASR* Regional Distribution of Kidney Cancer in Saudi Arabia, 2011

Figure 3.13.4 Comparison of ASR* for Kidney among Saudi with ASR in Selected Countries**

62

Figure 3.14.1 Age-Specific Incidence Rate (AIR) for Brain Cancer in Saudi Arabia, 2011

Table 3.14.1 Morphological Distribution of Brain Cancer in Saudi Arabia, 2011

Figure 3.14.2 Stage Distribution of Brain Cancer in Saudi Arabia, 2011

There were 269 cases of Brain cancer accounting for 2.5% of all newly diagnosed cases in year 2011. This cancer ranked eleventh among male and thirteenth among female. It affected 170 (63.2%) males and 99 (38.8%) females with a male to female ratio of 171:100. The ASR was 2.2/100,000 for male and 1.2/100,000 for females. The highest ASR among male was in Makkah region at 3.1/100,000, Riyadh and Hail region at 2.6/100,000 for both, Eastern region at 2.6/100,000, and Jouf region at 2.0/100,000. In female the highest ASR was in Northern region at 1.8/100,000, Riyadh region at 1.7/100,00, Eastern region at 1.5/100,000, Baha region at 1.3/100,000 and Makah region at 1.1/100,000.The median age at diagnosis was 41 years among males (range 0-97 years) and 24 years among females (range 0-81 years).

Brain (C70-C72)


Glioblastoma, NOS

Medulloblastoma, NOS

Glioma, malignant

Neoplasm, malignant

Astrocytoma, NOS

Mixed glioma

Ependymoma, anaplastic

Oligodendroglioma, NOS

Astrocytoma, anaplastic

Ependymoma, NOS

Other

Male

69

14

10

6

5

10

7

8

6

6

29

%

40.6

8.2

5.9

3.5

2.9

5.9

4.1

4.7

3.5

3.5

17.1

Female

30

15

11

8

6

1

3

2

3

3

17

%

30.3

15.2

11.1

8.1

6.1

1.0

3.0

2.0

3.0

3.0

17.2

9440

9470

9380

8000

9400

9382

93923

9450

9401

9391

63


Figure 3.14.3 ASR* Regional Distribution of Brain Cancer in Saudi Arabia, 2011

Figure 3.14.4 Comparison of ASR* for Brain among Saudi with ASR in Selected Countries**

Makkah

Riyadh

Hail

Eastern

Jouf

Asir

Jazan

Baha

Tabouk

Northern

Madinah

Najran

Qassim

64

Figure 3.14.1 Age-Specific Incidence Rate (AIR) for Bladder Cancer in Saudi Arabia, 2011

Table 3.15.1 Morphological Distribution of Bladder Cancer in Saudi Arabia, 2011

Figure 3.14.2 Stage Distribution of Bladder Cancer in Saudi Arabia, 2011

There were 232 cases of Bladder cancer accounting for 2.1% of all newly diagnosed cases in year 2011. This cancer ranked ninth among male and fourteenth among female. It affected 180 (77.6%) males and 52 (22.4%) females with a male to female ratio of 346:100. The ASR was 3.3/100,000 for male and 1.0/100,000 for females. The highest ASR were among male was in Asir region at 4.8/100,000, Eastern region at 4.76/100,000, Tabuk region at 4.2/100,000, Makkah and Hail region at 3.5/100,000 for each. In female the highest ASR was in Hail region at 2.3/100,000, followed by Makkah, Riyadh and Jouf region at 1.3/100,000 for each, then Baha region at 1.2/100,000. The median age at diagnosis was 65 years among males (range 25-117 years) and 67 years among females (range 1-89 years).

Bladder (C67)


Papillary transitional cell carcinoma

Transitional cell carcinoma, NOS


Neoplasm, malignant

Carcinoma, NOS


Adenocarcinoma, NOS

Others

Male

110

46

5

3

4

4

2

8

%

60.4

25.3

2.7

1.6

2.2

2.2

1.1

4.4

Female

20

16

5

6

2

1

0

2

%

38.5

30.8

9.6

11.5

3.8

1.9

0.0

3.8

8130

8120

8070

8000

8010

8071

8140

65


Figure 3.15.3 ASR* Regional Distribution of Bladder Cancer in Saudi Arabia, 2011

Figure 3.15.4 Comparison of ASR* for Bladder among Saudi with ASR in Selected Countries**

66

1. Canadian Cancer Statistics 2011. Canadian Cancer Society, Statistics Canada, Provincials/Territorial Cancer Registries, Public Health Agency of Canada.

2. Cancer in Ireland 2013: Annual report of the National Cancer Registry. National Cancer Registry Ireland.

3. Cancer Incidence and Mortality in Western Australia, 2010. A Report of the Western Australian Cancer Registry.

4. CDC. Center for Disease Control and Prevention. Department of Health and Human Services. National Program of Cancer Registries (NPCR). 2010 Cancer Types Grouped by Race and Ethnicity. Available from: http://apps.nccd.cdc.gov/uscs/cancersbyraceandethnicity.aspx?printfriendly=1

5. National Cancer Registration and Statistics in Korea. Cancer Incidence in Korea 2010.

6. Cancer in Norway 2011. Cancer incidence, mortality, survival and prevalence in Norway.

7. Singapore Cancer Registry. Interim Annual Registry Report. Trends in Cancer Incidence in Singapore 2006-2010. National Registry of Diseases Office (NRDO). Available from: https://www.nrdo.gov.sg/uploadedFiles/NRDO/Cancer_Trends_Report_06-10_final2.pdf

8. The Hashemite Kingdom of Jordan Ministry of Health. Non-Communicable Diseases Directorate. Jordan Cancer Registry Cancer Incidence in Jordan 2009. Available from:

9. Atlas De Mortalidad Por Cancer. Argentina, 2007-2011.

10. Welsh Cancer Intelligence & Surveillance Unit. Annual Publication No. SA12/01 Cancer Incidence in Wales 2006-2010. Available from: http://www.wales.nhs.uk/sites3/Documents/242/incpub2012.pdf

11. Twelve Years Cancer Incidence among Nationals of the GCC States, 1998-2009.

12. GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide, IARC, Lyon: International Agency for Research on Cancer. Available from: http://www-dep.iarc.fr/globocan/im_sel.HTM

13. Cancer Incidence in Five Continents Vol. X, IARC. Scientific Publication, Lyon, France, 2013. Available from: http://ci5.iarc.fr/CI5-X/ci5-X.htm

http://www.moh.gov.jo/AR/Documents/Annual%20Incidence%20of%20cancer%20in%20Jordan%202010.pdf

69

Between January and December 2011, a total of 3364 cancer cases were reported among Non-Saudi residents. In Situ cases were 99 and 11 cases were ICD-O-3 coded that failed to convert to ICD-10 codes as described in the data management (see page 12 and page 92). This puts the total number of exclusions from the analysis as 110 cases. As a result, the total number of cases analyzed was 3,353. Out of this 1,690 (50.4%) were males and 1,663 (49.6%) were females. The male to female ratio was 102:100. Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly; the pattern of cancer had some significant differences. Those under 15 represented 19.4% of the population, those 60 years and over represented 2.3% and the 15 to 59 age-group represented 78.3% of non-Saudi population. During 2011, approximately 3.7% of all cancers occurred before the age of 15, 21.6 % occurred between the ages 15 to 39 years, 59.9% were between the ages 40-64, and 14.8% occurred after the age of 64. The median age at diagnosis was 52 years in males (range 0-90 years) and 47 years in females (range 0-102 years).

Cancer among Non- Saudi Population 2011

No.

671

377

173

165

160

153

135

122

107

92

1198

%

20.0

11.2

5.2

4.9

4.8

4.6

4.0

3.6

3.2

2.7

35.7

Cancer

Breast

Colorectal

NHL

Skin

Thyroid

Leukaemia

Lung

Prostate

Stomach

Bladder

Other Sites

NationalityYemenEgyptPhilippinesSudanPakistanSyrian Arab RepublicIndiaGaza Strip(Palestine)IndonesiaJordanBangladeshSomaliaBahrainLebanonUnited States of AmericaUnited KingdomEthiopiaEritreaNigeriaChadKuwaitMoroccoMyanmar Sri LankaAfghanistanCanadaTurkeyIraqPalestinian Other Nationalities

No.5884053293082181931531201059183735046464544423430292422221918171616166

%17.512.19.89.26.55.84.63.63.12.72.52.21.51.41.41.31.31.31.00.90.90.70.70.70.60.50.50.50.55.0

No.313233126175115949659135365211933343410161597712894126883

%18.513.87.510.46.85.65.73.50.83.13.81.21.12.02.02.00.60.90.90.50.40.40.70.50.50.20.70.40.54.9

No.275172203133103995761923818523113121134261921221710141014510883

%16.510.312.28.06.26.03.43.75.52.31.13.11.90.80.70.72.01.61.11.31.31.00.60.80.60.80.30.60.55.0

Table 4.1 Ten most common cancers among Non-Saudis, 2011

Table 4.2 Dstribution of cancer cases among different nationalities in order of relative frequency, 2011

All Male Female

70

Figure 4.2 age specific incidence rate for all cancers among non- Saudis in Saudi Arabia, 2011

Figure 4.1 Ten Most common cancers among Non-Saudi by Sex, 2011

Male256

128

122

122

106

93

80

76

57

52

598

15.1%

7.6%

7.2%

7.2%

6.3%

5.5%

4.7%

4.5%

3.4%

3.1%

35.4%

1690 Female 1663Colorectal

NHL

Other Skin

Prostate

Lung

Leukaemia

Bladder

Stomach

Kidney

Brain, CNS

Other Sites

Breast

Colorectal

Thyroid

Cervix Uteri

Corpus Uteri

Ovary

Leukaemia

NHL

Skin

Stomach

Other Sites

659

121

109

71

69

66

60

45

43

31

389

39.6%

7.3%

6.6%

4.3%

4.1%

4.0%

3.6%

2.7%

2.6%

1.90%

23.3%

Incidence Tables

72

Tab

le 5

.1.1

- N

umbe

r of

Can

cer

Cas

es A

mon

g Sa

udi M

ales

by

Pri

mar

y Si

te a

nd A

ge G

roup

s, 2

011

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)8 44 41 14 4 3 12

1 9 3 76 162

35 378

279

11 330

73 128 8 70 343

21 71 16 208

12 19 77 16 0 311

80 6 178 3 5 182 1 20 170

154

13 8 184

432 1 50 202

148

16 169

4913

4705

All

Age

s0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 2

Age

Unk

0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 1 0 0 0 0 0 13 0 0 0 4 0 13 0 0 0 0 13 15 0 10 0 4 15 0 0 46 7 3 5 158

158

0-4

0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 7 0 0 0 0 2 0 0 1 1 1 2 0 0 0 0 0 13 0 0 1 5 18 0 0 45 6 4 1 109

109

5-9

0 0 1 0 0 0 2 0 0 0 0 0 1 1 0 3 0 0 0 0 1 1 10 0 0 0 0 4 0 0 0 1 0 0 0 0 0 0 1 9 1 0 1 16 14 0 0 18 10 0 1 96 96

10-1

40 2 0 0 0 0 3 0 0 0 2 1 0 7 0 0 0 0 0 0 0 0 6 1 4 0 0 4 1 0 0 12 1 0 1 0 0 0 0 12 10 0 0 34 15 0 1 9 9 0 5 14

013

6

20-2

41 0 0 1 0 0 1 0 0 2 2 1 5 6 0 2 0 0 0 0 4 2 8 0 4 0 0 6 0 0 0 24 0 2 0 0 3 0 0 6 6 0 1 21 26 0 0 4 6 0 4 14

814

4

25-2

91 1 0 1 0 0 5 0 0 0 5 1 6 9 1 0 2 0 1 0 0 0 5 0 4 0 0 6 1 0 0 7 0 7 0 0 6 0 0 12 23 0 0 17 19 0 1 3 9 1 3 15

715

3

30-3

40 3 4 1 0 0 8 0 0 5 6 2 20 12 2 2 2 3 0 2 4 5 1 0 5 0 2 8 1 0 1 7 0 6 0 0 3 0 2 7 12 1 0 11 19 0 1 2 12 0 4 18

618

1

35-3

91 4 2 3 0 0 19 1 0 2 5 1 22 23 1 5 2 8 1 4 12 2 2 0 12 0 2 4 0 0 1 8 0 9 0 0 5 0 0 14 21 0 1 10 19 0 5 5 10 1 9 25

624

4

40-4

40 8 2 2 0 0 14 0 0 3 9 5 32 27 0 14 4 10 1 3 14 1 3 2 3 1 1 5 2 0 1 5 1 14 0 0 13 0 0 10 14 1 0 6 34 0 3 5 11 1 10 29

529

2

45-4

91 3 2 0 1 1 16 0 1 4 23 6 58 31 3 18 9 10 1 11 22 2 1 0 13 2 2 5 1 0 15 2 0 24 0 2 15 0 1 13 12 0 1 10 38 0 5 5 8 0 21 41

940

6

50-5

40 2 1 0 1 1 8 0 0 5 15 5 43 31 1 35 7 18 1 8 32 0 1 0 19 1 1 2 0 0 25 1 1 23 0 1 18 0 0 16 11 0 1 3 42 0 4 6 9 0 11 41

039

1

55-5

90 3 3 0 0 0 12 1 1 8 16 1 39 28 1 49 6 16 0 10 46 0 2 3 15 1 4 1 3 0 30 0 1 15 0 1 25 0 0 7 12 0 0 4 29 1 5 12 11 0 13 43

542

0

60-6

41 5 6 1 0 0 8 1 0 4 17 4 59 40 1 41 14 16 1 11 46 0 1 0 25 1 3 2 1 0 57 0 0 21 0 0 16 0 1 8 14 0 0 1 37 0 11 6 10 1 17 50

948

4

65-6

90 9 6 1 1 0 10 2 0 15 25 2 37 26 0 57 7 18 0 11 66 2 1 1 21 2 1 7 3 0 54 0 0 11 0 0 30 1 0 10 10 0 0 4 31 0 3 5 6 2 18 51

649

5

70-7

43 4 14 1 0 1 8 4 0 28 37 6 56 38 1 96 20 29 2 10 95 2 6 9 83 4 3 3 3 0 12

6 1 1 31 2 1 48 0 2 11 7 0 0 9 59 0 11 11 15 2 46 949

866

75+

0.2%

0.9%

0.8%

0.3%

0.1%

0.1%

2.5%

0.2%

0.1%

1.5%

3.3%

0.7%

7.7%

5.7%

0.2%

6.7%

1.5%

2.6%

0.2%

1.4%

7.0%

0.4%

1.4%

0.3%

4.2%

0.2%

0.4%

1.6%

0.3%

0.0%

6.3%

1.6%

0.1%

3.6%

0.1%

0.1%

3.7%

0.0%

0.4%

3.5%

3.1%

0.3%

0.2%

3.7%

8.8%

0.0%

1.0%

4.1%

3.0%

0.3%

3.4%

100.

0%95

.8%

Tota

l (%

)0 0 0 0 1 0 7 0 0 0 0 0 0 0 0 1 0 0 0 0 1 2 17 0 0 0 0 5 0 0 0 7 0 0 0 0 0 0 0 7 1 1 2 29 17 0 0 20 9 1 0 12

812

8

15-1

9Li

pTo

ngue

Mou

thS

aliv

ary

glan

dsTo

nsil

Oth

er O

roph

aryn

xN

asop

hary

nxH

ypop

hary

nxP

hary

nx u

nspe

c.O

esop

hagu

sS

tom

ach

Sm

all i

ntes

tine

Col

onR

ectu

mA

nus

Live

rG

allb

ladd

er e

tc.

Pan

crea

sN

ose,

sin

uses

etc

.La

rynx

Trac

hea,

Bro

nchu

s,Lu

ngO

ther

Tho

raci

c or

gans

Bon

eM

elan

oma

of S

kin

Oth

er S

kin

Mes

othe

liom

aK

apos

i sar

com

aC

onne

ctiv

e,S

oft t

issu

eB

reas

tP

enis

Pro

stat

eTe

stis

Oth

er m

ale

geni

tal

Kid

ney

Ren

al P

elvi

sU

rete

rB

ladd

erO

ther

Urin

ary

orga

nsE

yeB

rain

, Ner

vous

sys

tem

Thyr

oid

Adr

enal

gla

ndO

ther

End

ocrin

eH

odgk

in d

isea

seN

on-H

odgk

in ly

mph

oma

Imm

unop

rolif

erat

ive

dis.

Mul

tiple

Mye

lom

aLy

mph

oid

Leuk

aem

iaM

yelo

id L

euka

emia

Leuk

aem

ia u

nspe

c.O

ther

& u

nspe

cifie

d

All

site

s To

tal

All

site

s bu

t C44

Site

73

Tab

le 5

.1.2

- N

umbe

r of

Can

cer

Cas

es A

mon

g Sa

udi F

emal

es b

y P

rim

ary

Site

and

Age

Gro

ups,

201

1

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)7 52 46 22 1 1 45 16 2 58 13

335 34

219

515 15

890 77 3 6 10

9 7 58 15 125 1 6 72 15

90 7 4 114

318

41 198

12 9 112 2 2 52 0 19 99 646 5 4 157

312 0 47 142

176

13 178

5956

5831

All

Age

s0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

Age

Unk

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 2 3 1 0 0 0 13 1 0 0 0 0 0 0 1 0 15 0 0 1 0 14 13 0 2 0 4 7 0 0 56 12 2 3 157

157

0-4

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 1 0 1 0 0 0 0 0 0 0 2 0 0 0 0 1 13 0 0 0 4 5 0 0 21 7 1 1 61 615-9

0 0 1 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 16 0 1 0 0 7 0 0 0 0 0 0 4 0 0 3 0 0 0 0 0 7 4 0 0 11 8 0 0 15 10 1 2 94 93

10-1

40 1 1 1 0 0 2 1 0 1 2 0 1 2 0 1 1 0 0 0 1 0 7 1 3 0 0 6 11 0 0 0 2 0 7 0 1 5 0 0 1 0 0 10 53 0 2 37 17 0 0 4 11 1 1 19

519

2

20-2

40 1 1 3 0 0 1 0 0 0 7 3 7 4 0 1 0 0 0 0 0 0 4 0 1 0 0 5 56 0 0 1 1 0 10 0 2 3 0 0 0 0 0 7 65 0 0 22 20 0 0 5 10 0 4 24

424

3

25-2

90 0 2 2 0 0 1 0 0 1 4 0 13 4 1 2 0 0 0 0 2 0 2 1 2 0 0 6 11

4 0 1 6 3 1 10 0 0 3 0 0 1 0 0 6 87 1 0 7 11 0 0 4 14 0 7 319

317

30-3

41 1 1 2 0 0 2 2 0 3 6 2 14 10 0 1 0 2 0 0 1 0 1 0 5 0 1 1 17

3 0 0 13 11 1 8 1 1 1 0 0 1 0 0 2 78 0 0 6 22 0 0 3 10 1 5 393

388

35-3

90 5 4 2 0 1 3 1 0 2 8 3 28 15 1 3 4 4 0 0 5 0 5 3 6 0 1 3 24

0 1 0 28 17 2 17 2 2 7 0 0 1 0 0 6 75 0 0 10 15 0 4 3 12 1 12 562

556

40-4

40 6 3 2 1 0 11 2 0 5 5 3 44 28 0 11 14 5 1 0 6 0 2 0 10 0 0 5 25

5 0 0 15 20 8 18 3 3 4 1 0 2 0 0 5 84 0 0 3 22 0 8 4 18 0 13 650

640

45-4

90 8 3 1 0 0 8 1 0 2 10 4 54 27 0 16 7 10 1 0 16 0 2 3 8 0 0 5 23

7 1 0 11 38 5 21 1 0 14 0 0 1 0 0 3 70 0 1 4 23 0 7 0 12 1 15 651

643

50-5

41 6 5 1 0 0 5 4 0 4 12 1 42 18 3 16 9 12 0 2 17 0 1 1 13 0 2 4 15

0 0 2 8 51 3 15 2 0 14 0 1 2 0 1 4 40 0 0 6 21 0 3 4 19 1 27 553

540

55-5

90 7 5 2 0 0 2 1 0 4 16 4 34 28 0 21 10 6 0 1 11 2 1 0 17 0 0 4 11

1 0 0 7 46 7 13 1 0 15 0 0 10 0 1 5 20 0 0 6 25 0 6 6 6 0 12 473

456

60-6

41 1 2 2 0 0 0 2 0 9 10 3 33 16 3 29 12 11 0 1 9 1 1 2 15 0 1 3 96 0 0 11 56 3 20 1 0 11 1 0 10 0 0 3 22 0 1 2 30 0 3 4 6 1 24 47

245

7

65-6

92 7 8 0 0 0 1 0 0 10 22 3 24 20 2 22 11 12 0 1 15 2 0 2 9 1 0 2 72 2 1 4 34 5 27 0 0 6 0 1 11 0 2 5 14 0 0 7 33 0 5 2 4 1 18 43

042

1

70-7

42 9 8 2 0 0 2 2 2 17 30 7 47 23 5 28 22 14 1 1 24 0 2 0 33 0 1 2 73 2 0 10 39 6 22 0 0 7 0 0 11 0 0 3 20 0 0 3 45 0 11 5 10 2 34 58

755

4

75+

0.1%

0.9%

0.8%

0.4%

0.0%

0.0%

0.8%

0.3%

0.0%

1.0%

2.2%

0.6%

5.7%

3.3%

0.3%

2.7%

1.5%

1.3%

0.1%

0.1%

1.8%

0.1%

1.0%

0.3%

2.1%

0.0%

0.1%

1.2%

26.7

%0.

1%0.

1%1.

9%5.

3%0.

7%3.

3%0.

2%0.

2%1.

9%0.

0%0.

0%0.

9%0.

0%0.

3%1.

7%10

.8%

0.1%

0.1%

2.6%

5.2%

0.0%

0.8%

2.4%

3.0%

0.2%

3.0%

100.

0%97

.9%

Tota

l (%

)0 0 2 2 0 0 4 0 0 0 1 2 1 0 0 0 0 1 0 0 1 0 7 1 2 0 0 5 1 0 0 0 0 0 6 0 0 2 0 0 0 0 0 7 14 2 0 25 8 0 0 6 15 0 0 11

511

3

15-1

9Li

pTo

ngue

Mou

thS

aliv

ary

glan

dsTo

nsil

Oth

er O

roph

aryn

xN

asop

hary

nxH

ypop

hary

nxP

hary

nx u

nspe

c.O

esop

hagu

sS

tom

ach

Sm

all i

ntes

tine

Col

onR

ectu

mA

nus

Live

rG

allb

ladd

er e

tc.

Pan

crea

sN

ose,

sin

uses

etc

.La

rynx

Trac

hea,

Bro

nchu

s,Lu

ngO

ther

Tho

raci

c or

gans

Bon

eM

elan

oma

of S

kin

Oth

er S

kin

Mes

othe

liom

aK

apos

i sar

com

aC

onne

ctiv

e,S

oft t

issu

eB

reas

tV

ulva

Vag

ina

Cer

vix

Ute

riC

orpu

s U

teri

Ute

rus

unsp

ec.

Ova

ryO

ther

Fem

ale

Gen

ital

Pla

cent

aK

idne

yR

enal

Pel

vis

Ure

ter

Bla

dder

Oth

er U

rinar

y or

gans

Eye

Bra

in, N

ervo

us s

yste

mTh

yroi

dA

dren

al g

land

Oth

er E

ndoc

rine

Hod

gkin

dis

ease

Non

-Hod

gkin

lym

phom

aIm

mun

opro

lifer

ativ

e di

s.M

ultip

le M

yelo

ma

Lym

phoi

d Le

ukae

mia

Mye

loid

Leu

kaem

iaLe

ukae

mia

uns

pec.

Oth

er &

uns

peci

fied

All

site

s To

tal

All

site

s bu

t C44

Site

74

Tab

le 5

.1.3

- A

ge-S

peci

fic In

cide

nce

Rat

e (A

IR),

Age

-Sta

ndar

dize

d In

cide

nce

Rat

e (A

SR)

Am

ong

Saud

i Mal

es (

per

100,

000)

by

Pri

mar

y Si

te a

nd A

ge G

roup

s, 2

011

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)8 44 41 14 4 3 12

1 9 3 76 162

35 378

279

11 330

73 128 8 70 343

21 71 16 208

12 19 77 16 0 311

80 6 178 3 5 182 1 20 170

154

13 8 184

432 1 50 202

148

16 169

4913

4705

All

Age

s0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 2

Age

Unk

0 0 0 0.2 0 0 0 0 0 0 0 0 0 0 0 0.6 0 0 0 0 0 0.1 0 0 0 0 0 1 0 0 0 0.3 0 1 0 0 0 0 1 1.2 0 0.8 0 0.3

1.2 0 0 3.6

0.6

0.2

0.4

13 130-4

0 0 0 0 0 0 0 0 0.1 0 0 0 0 0 0 0 0 0 0 0 0 0.1

0.6 0 0 0 0 0.2 0 0 0.1

0.1

0.1

0.2 0 0 0 0 0 1.1 0 0 0.1

0.4

1.6 0 0 3.9

0.5

0.3

0.1 9 95-9

0 0 0.1 0 0 0 0.2 0 0 0 0 0 0.1

0.1 0 0.3 0 0 0 0 0.1

0.1

0.9 0 0 0 0 0.4 0 0 0 0.1 0 0 0 0 0 0 0.1

0.8

0.1 0 0.1

1.5

1.3 0 0 1.7

0.9 0 0.1 9 9

10-1

40 0.2 0 0 0 0 0.3 0 0 0 0.2

0.1 0 0.7 0 0 0 0 0 0 0 0 0.6

0.1

0.4 0 0 0.4

0.1 0 0 1.3

0.1 0 0.1 0 0 0 0 1.3

1.1 0 0 3.6

1.6 0 0.1

0.9

0.9 0 0.5

15 14

20-2

40.

1 0 0 0.1 0 0 0.1 0 0 0.2

0.2

0.1

0.6

0.7 0 0.2 0 0 0 0 0.5

0.2

0.9 0 0.5 0 0 0.7 0 0 0 2.8 0 0.2 0 0 0.4 0 0 0.7

0.7 0 0.1

2.5

3.1 0 0 0.5

0.7 0 0.5

18 17

25-2

90.

10.

1 0 0.1 0 0 0.7 0 0 0 0.7

0.1

0.8

1.2

0.1 0 0.3 0 0.1 0 0 0 0.7 0 0.5 0 0 0.8

0.1 0 0 1 0 1 0 0 0.8 0 0 1.6

3.1 0 0 2.3

2.6 0 0.1

0.4

1.2

0.1

0.4

21 21

30-3

40 0.5

0.6

0.2 0 0 1.3 0 0 0.8 1 0.3

3.2

1.9

0.3

0.3

0.3

0.5 0 0.3

0.6

0.8

0.2 0 0.8 0 0.3

1.3

0.2 0 0.2

1.1 0 1 0 0 0.5 0 0.3

1.1

1.9

0.2 0 1.8 3 0 0.2

0.3

1.9 0 0.6

30 29

35-3

90.

20.

80.

40.

6 0 0 3.7

0.2 0 0.4 1 0.2

4.2

4.4

0.2 1 0.4

1.5

0.2

0.8

2.3

0.4

0.4 0 2.3 0 0.4

0.8 0 0 0.2

1.5 0 1.7 0 0 1 0 0 2.7 4 0 0.2

1.9

3.7 0 1 1 1.9

0.2

1.7

49 47

40-4

40 1.9

0.5

0.5 0 0 3.3 0 0 0.7

2.1

1.2

7.6

6.4 0 3.3

0.9

2.4

0.2

0.7

3.3

0.2

0.7

0.5

0.7

0.2

0.2

1.2

0.5 0 0.2

1.2

0.2

3.3 0 0 3.1 0 0 2.4

3.3

0.2 0 1.4 8 0 0.7

1.2

2.6

0.2

2.4

70 69

45-4

90.

30.

90.

6 0 0.3

0.3

4.8 0 0.3

1.2

6.8

1.8

17.3

9.2

0.9

5.4

2.7 3 0.3

3.3

6.5

0.6

0.3 0 3.9

0.6

0.6

1.5

0.3 0 4.5

0.6 0 7.1 0 0.6

4.5 0 0.3

3.9

3.6 0 0.3 3

11.3 0 1.5

1.5

2.4 0 6.2

125

121

50-5

40 0.8

0.4 0 0.4

0.4

3.2 0 0 2 6 2

17.1

12.3

0.4

13.9

2.8

7.2

0.4

3.2

12.7 0 0.4 0 7.6

0.4

0.4

0.8 0 0 10 0.4

0.4

9.2 0 0.4

7.2 0 0 6.4

4.4 0 0.4

1.2

16.7 0 1.6

2.4

3.6 0 4.4

163

156

55-5

90 1.6

1.6 0 0 0 6.6

0.5

0.5

4.4

8.8

0.5

21.4

15.4

0.5

26.9

3.3

8.8 0 5.5

25.3 0 1.1

1.6

8.2

0.5

2.2

0.5

1.6 0

16.5 0 0.5

8.2 0 0.5

13.7 0 0 3.8

6.6 0 0 2.2

15.9

0.5

2.7

6.6 6 0 7.1

239

231

60-6

40.

83.

94.

60.

8 0 0 6.2

0.8 0 3.1

13.2

3.1

45.7

31 0.8

31.7

10.8

12.4

0.8

8.5

35.6 0 0.8 0

19.4

0.8

2.3

1.5

0.8 0

44.1 0 0

16.3 0 0

12.4 0 0.8

6.2

10.8 0 0 0.8

28.7 0 8.5

4.6

7.7

0.8

13.2

394

375

65-6

90

10.3

6.9

1.1

1.1 0

11.5

2.3 0

17.2

28.7

2.3

42.5

29.9 0

65.5 8

20.7 0

12.6

75.8

2.3

1.1

1.1

24.1

2.3

1.1 8 3.4 0 62 0 0

12.6 0 0

34.4

1.1 0

11.5

11.5 0 0 4.6

35.6 0 3.4

5.7

6.9

2.3

20.7

592

568

70-7

42.

53.

311

.60.

8 0 0.8

6.6

3.3 0

23.1

30.5 5

46.2

31.4

0.8

79.2

16.5

23.9

1.7

8.3

78.4

1.7 5 7.4

68.5

3.3

2.5

2.5

2.5 0 104

0.8

0.8

25.6

1.7

0.8

39.6 0 1.7

9.1

5.8 0 0 7.4

48.7 0 9.1

9.1

12.4

1.7

38 783

715

75+

0.1

%0.

5 %

0.4

%0.

1 %

0.0

%0.

0 %

1.2

%0.

1 %

0.0

%0.

8 %

1.7

%0.

4 %

3.9

%2.

9 %

0.1

%3.

4 %

0.7%

1.3%

0.1%

0.7%

3.5%

0.2%

0.7%

0.2%

2.1%

0.1%

0.2%

0.8%

0.2%

0.0%

3.2%

0.8%

0.1%

1.8%

0.0%

0.1%

1.9%

0.0%

0.2%

1.7%

1.6%

0.1%

0.1%

1.9%

4.4%

0.0%

0.5%

2.1%

1.5%

0.2%

1.7%

50.5

%48

.3%

Cru

de R

ate

0.1

0.7

0.7

0.2

0.1 0 1.8

0.2 0 1.3

2.8

0.6

6.6

4.7

0.2

6.1

1.3

2.3

0.1

1.3

6.4

0.3

0.8

0.3

3.6

0.2

0.3

0.9

0.3 0 6 0.8

0.1

2.9 0 0.1

3.3 0 0.2

2.2

2.2

0.1

0.1

1.9

6.4 0 0.9

2.3 2 0.2

2.8

78.8

75.2

ASR

Wor

ld0 0 0 0 0.1 0 0.7 0 0 0 0 0 0 0 0 0.1 0 0 0 0 0.1

0.2

1.7 0 0 0 0 0.5 0 0 0 0.7 0 0 0 0 0 0 0 0.7

0.1

0.1

0.2

2.8

1.7 0 0 1.9

0.9

0.1 0 12 12

15-1

9Li

pTo

ngue

Mou

thS

aliv

ary

glan

dsTo

nsil

Oth

er O

roph

aryn

xN

asop

hary

nxH

ypop

hary

nxP

hary

nx u

nspe

c.O

esop

hagu

sS

tom

ach

Sm

all i

ntes

tine

Col

onR

ectu

mA

nus

Live

rG

allb

ladd

er e

tc.

Pan

crea

sN

ose,

sin

uses

etc

.La

rynx

Trac

hea,

Bro

nchu

s,Lu

ngO

ther

Tho

raci

c or

gans

Bon

eM

elan

oma

of S

kin

Oth

er S

kin

Mes

othe

liom

aK

apos

i sar

com

aC

onne

ctiv

e,S

oft t

issu

eB

reas

tP

enis

Pro

stat

eTe

stis

Oth

er m

ale

geni

tal

Kid

ney

Ren

al P

elvi

sU

rete

rB

ladd

erO

ther

Urin

ary

orga

nsE

yeB

rain

, Ner

vous

sys

tem

Thyr

oid

Adr

enal

gla

ndO

ther

End

ocrin

eH

odgk

in d

isea

seN

on-H

odgk

in ly

mph

oma

Imm

unop

rolif

erat

ive

dis.

Mul

tiple

Mye

lom

aLy

mph

oid

Leuk

aem

iaM

yelo

id L

euka

emia

Leuk

aem

ia u

nspe

c.O

ther

& u

nspe

cifie

d

All

site

s To

tal

All

site

s bu

t C44

Site

75

Tab

le 5

.1.4

- A

ge-S

peci

fic In

cide

nce

Rat

e (A

IR),

Age

-Sta

ndar

dize

d In

cide

nce

Rat

e (A

SR)

Am

ong

Saud

i Fem

ales

(pe

r 10

0,00

0) b

y P

rim

ary

Site

and

Age

Gro

ups,

201

1

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)7 52 46 22 1 1 45 16 2 58 13

335 34

219

515 15

890 77 3 6 10

9 7 58 15 125 1 6 72 15

90 7 4 114

318

41 198

12 9 112 2 2 52 0 19 99 646 5 4 157

312 0 47 142

176

13 178

5956

5831

All

Age

s0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

Age

Unk

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.6 0 0 0 0 0 0.2

0.2

0.1 0 0 0 1.1

0.1 0 0 0 0 0 0 0.1 0 1.2 0 0 0.1 0 1.2

1.1 0 0.2 0 0.3

0.6 0 0 4.6 1 0.2

0.2

13 130-4

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.4 0 0 0 0 0.1 0 0.1 0 0 0 0 0 0 0 0.2 0 0 0 0 0.1

1.2 0 0 0 0.4

0.4 0 0 1.9

0.6

0.1

0.1 5 55-9

0 0 0.1 0 0 0 0.3 0 0 0 0 0 0 0 0 0 0 0 0 0 0.1 0 1.5 0 0.1 0 0 0.7 0 0 0 0 0 0 0.4 0 0 0.3 0 0 0 0 0 0.7

0.4 0 0 1 0.7 0 0 1.4

0.9

0.1

0.2 9 9

10-1

40 0.1

0.1

0.1 0 0 0.2

0.1 0 0.1

0.2 0 0.1

0.2 0 0.1

0.1 0 0 0 0.1 0 0.7

0.1

0.3 0 0 0.6

1.1 0 0 0 0.2 0 0.7 0 0.1

0.5 0 0 0.1 0 0 1 5.5 0 0.2

3.8

1.8 0 0 0.4

1.1

0.1

0.1

20 20

20-2

40 0.1

0.1

0.3 0 0 0.1 0 0 0 0.8

0.3

0.8

0.5 0 0.1 0 0 0 0 0 0 0.5 0 0.1 0 0 0.6

6.5 0 0 0.1

0.1 0 1.2 0 0.2

0.3 0 0 0 0 0 0.8

7.5 0 0 2.5

2.3 0 0 0.6

1.2 0 0.5

28 28

25-2

90 0 0.3

0.3 0 0 0.1 0 0 0.1

0.5 0 1.7

0.5

0.1

0.3 0 0 0 0 0.3 0 0.3

0.1

0.3 0 0 0.8

15.2 0 0.1

0.8

0.4

0.1

1.3 0 0 0.4 0 0 0.1 0 0 0.8

11.6

0.1 0 0.9

1.5 0 0 0.5

1.9 0 0.9

43 42

30-3

40.

20.

20.

20.

3 0 0 0.3

0.3 0 0.5 1 0.3

2.2

1.6 0 0.2 0 0.3 0 0 0.2 0 0.2 0 0.8 0 0.2

0.2

27.5 0 0 2.1

1.8

0.2

1.3

0.2

0.2

0.2 0 0 0.2 0 0 0.3

12.4 0 0 1 3.5 0 0 0.5

1.6

0.2

0.8

63 62

35-3

90 1 0.8

0.4 0 0.2

0.6

0.2 0 0.4

1.6

0.6

5.4

2.9

0.2

0.6

0.8

0.8 0 0 1 0 1 0.6

1.2 0 0.2

0.6

46.5

0.2 0 5.4

3.3

0.4

3.3

0.4

0.4

1.4 0 0 0.2 0 0 1.2

14.5 0 0 1.9

2.9 0 0.8

0.6

2.3

0.2

2.3

109

108

40-4

40 1.5

0.7

0.5

0.2 0 2.7

0.5 0 1.2

1.2

0.7

10.7

6.8 0 2.7

3.4

1.2

0.2 0 1.5 0 0.5 0 2.4 0 0 1.2

62.1 0 0 3.7

4.9

1.9

4.4

0.7

0.7 1 0.2 0 0.5 0 0 1.2

20.5 0 0 0.7

5.4 0 1.9 1 4.4 0 3.2

158

156

45-4

90 2.5

0.9

0.3 0 0 2.5

0.3 0 0.6

3.1

1.2

16.8

8.4 0 5 2.2

3.1

0.3 0 5 0 0.6

0.9

2.5 0 0 1.6

73.9

0.3 0 3.4

11.9

1.6

6.6

0.3 0 4.4 0 0 0.3 0 0 0.9

21.8 0 0.3

1.2

7.2 0 2.2 0 3.7

0.3

4.7

203

201

50-5

40.

42.

52.

10.

4 0 0 2.1

1.7 0 1.7 5 0.4

17.5

7.5

1.2

6.7

3.7 5 0 0.8

7.1 0 0.4

0.4

5.4 0 0.8

1.7

62.4 0 0.8

3.3

21.2

1.2

6.2

0.8 0 5.8 0 0.4

0.8 0 0.4

1.7

16.6 0 0 2.5

8.7 0 1.2

1.7

7.9

0.4

11.2

230

225

55-5

90 4 2.8

1.1 0 0 1.1

0.6 0 2.3

9.1

2.3

19.2

15.8 0

11.9

5.7

3.4 0 0.6

6.2

1.1

0.6 0 9.6 0 0 2.3

62.8 0 0 4 26 4 7.4

0.6 0 8.5 0 0 5.7 0 0.6

2.8

11.3 0 0 3.4

14.2 0 3.4

3.4

3.4 0 6.8

268

258

60-6

40.

80.

81.

51.

5 0 0 0 1.5 0 6.9

7.7

2.3

25.3

12.2

2.3

22.2

9.2

8.4 0 0.8

6.9

0.8

0.8

1.5

11.5 0 0.8

2.3

73.5 0 0 8.4

42.9

2.3

15.3

0.8 0 8.4

0.8 0 7.7 0 0 2.3

16.8 0 0.8

1.5

23 0 2.3

3.1

4.6

0.8

18.4

361

350

65-6

92.

27.

78.

7 0 0 0 1.1 0 0

10.9

24 3.3

26.2

21.9

2.2

24 12 13.1 0 1.1

16.4

2.2 0 2.2

9.8

1.1 0 2.2

78.7

2.2

1.1

4.4

37.2

5.5

29.5 0 0 6.6 0 1.1

12 0 2.2

5.5

15.3 0 0 7.7

36.1 0 5.5

2.2

4.4

1.1

19.7

470

460

70-7

41.

77.

46.

61.

7 0 0 1.7

1.7

1.7

14.1

24.8

5.8

38.9

19 4.1

23.2

18.2

11.6

0.8

0.8

19.8 0 1.7 0

27.3 0 0.8

1.7

60.4

1.7 0 8.3

32.3 5

18.2 0 0 5.8 0 0 9.1 0 0 2.5

16.5 0 0 2.5

37.2 0 9.1

4.1

8.3

1.7

28.1

485

458

75+

0.1

0.5

0.5

0.2 0 0 0.5

0.2 0 0.6

1.4

0.4

3.5 2 0.2

1.6

0.9

0.8 0 0.1

1.1

0.1

0.6

0.2

1.3 0 0.1

0.7

16.5

0.1 0 1.2

3.3

0.4

2.1

0.1

0.1

1.2 0 0 0.5 0 0.2 1 6.7

0.1 0 1.6

3.2 0 0.5

1.5

1.8

0.1

1.8

61.7

60.4

Cru

de R

ate

0.1

0.9

0.8

0.3 0 0 0.6

0.3 0 1 2.3

0.6

5.7

3.3

0.3

2.9

1.6

1.4 0 0.1

1.9

0.1

0.6

0.2

2.2 0 0.1

0.9

23.4

0.1

0.1

1.7

5.8

0.7

3.1

0.2

0.1

1.7 0 0 1 0 0.2

1.2

8.1 0 0.1

1.7

4.8 0 0.8

1.6

2.2

0.2 3

90.1

88

ASR

Wor

ld0 0 0.2

0.2 0 0 0.4 0 0 0 0.1

0.2

0.1 0 0 0 0 0.1 0 0 0.1 0 0.7

0.1

0.2 0 0 0.5

0.1 0 0 0 0 0 0.6 0 0 0.2 0 0 0 0 0 0.7

1.3

0.2 0 2.4

0.8 0 0 0.6

1.4 0 0 11 11

15-1

9Li

pTo

ngue

Mou

thS

aliv

ary

glan

dsTo

nsil

Oth

er O

roph

aryn

xN

asop

hary

nxH

ypop

hary

nxP

hary

nx u

nspe

c.O

esop

hagu

sS

tom

ach

Sm

all i

ntes

tine

Col

onR

ectu

mA

nus

Live

rG

allb

ladd

er e

tc.

Pan

crea

sN

ose,

sin

uses

etc

.La

rynx

Trac

hea,

Bro

nchu

s,Lu

ngO

ther

Tho

raci

c or

gans

Bon

eM

elan

oma

of S

kin

Oth

er S

kin

Mes

othe

liom

aK

apos

i sar

com

aC

onne

ctiv

e,S

oft t

issu

eB

reas

tV

ulva

Vag

ina

Cer

vix

Ute

riC

orpu

s U

teri

Ute

rus

unsp

ec.

Ova

ryO

ther

Fem

ale

Gen

ital

Pla

cent

aK

idne

yR

enal

Pel

vis

Ure

ter

Bla

dder

Oth

er U

rinar

y or

gans

Eye

Bra

in, N

ervo

us s

yste

mTh

yroi

dA

dren

al g

land

Oth

er E

ndoc

rine

Hod

gkin

dis

ease

Non

-Hod

gkin

lym

phom

aIm

mun

opro

lifer

ativ

e di

s.M

ultip

le M

yelo

ma

Lym

phoi

d Le

ukae

mia

Mye

loid

Leu

kaem

iaLe

ukae

mia

uns

pec.

Oth

er &

uns

peci

fied

All

site

s To

tal

All

site

s bu

t C44

Site

76

Tab

le 5

.2.1

- N

umbe

r of

Cas

es, R

elat

ive

Freq

uenc

y, C

rude

Inci

denc

e R

ate

(CIR

) A

ge-S

tand

ardi

zed

Inci

denc

e R

ate

(ASR

)A

mon

g Sa

udi M

ales

(pe

r 10

0,00

0) b

y P

rim

ary

Site

and

Age

Gro

ups

and

Reg

ion,

201

1

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)

2 6 8 1 0 0 6 0 1 7 12 4 36 10 0 23 5 10 1 2 9 3 8 3 24 0 3 7 0 0 31 4 0 14 0 0 27 0 5 13 13 1 0 7 33 0 1 15 4 1 2 362

338

0.60

%1.

70%

2.20

%0.

30%

0.00

%0.

00%

1.70

%0.

00%

0.30

%1.

90%

3.30

%1.

10%

9.90

%2.

80%

0.00

%6.

40%

1.40

%2.

80%

0.30

%0.

60%

2.50

%0.

80%

2.20

%0.

80%

6.60

%0.

00%

0.80

%1.

90%

0.00

%0.

00%

8.60

%1.

10%

0.00

%3.

90%

0.00

%0.

00%

7.50

%0.

00%

1.40

%3.

60%

3.60

%0.

30%

0.00

%1.

90%

9.10

%0.

00%

0.30

%4.

10%

1.10

%0.

30%

0.60

%

100.

00%

93.4

0%

0.2

0.7 1 0.1 0 0 0.7 0 0.1

0.9

1.5

0.5

4.5

1.2 0 2.8

0.6

1.2

0.1

0.2

1.1

0.4 1 0.4 3 0 0.4

0.9 0 0 3.8

0.5 0 1.7 0 0 3.3 0 0.6

1.6

1.6

0.1 0 0.9

4.1 0 0.1

1.9

0.5

0.1

0.2

44.8

41.8

0.3

1.2

1.4

0.2 0 0 1 0 0.1

1.2

2.1

0.6

6.4

1.6 0 4.3

0.9

1.7

0.1

0.4

1.5

0.6 1 0.5

3.9 0 0.6

0.8 0 0 4.9

0.6 0 2.6 0 0 4.8 0 0.6

1.9

2.2

0.1 0 0.9

5.4 0 0.2 2 0.6

0.2

0.4

60.1

56.3

Lip

Tong

ueM

outh

Sal

ivar

y gl

ands

Tons

ilO

ther

Oro

phar

ynx

Nas

opha

rynx

Hyp

opha

rynx

Pha

rynx

uns

pec.

Oes

opha

gus

Sto

mac

hS

mal

l int

estin

eC

olon

Rec

tum

Anu

sLi

ver

Gal

lbla

dder

etc

.P

ancr

eas

Nos

e, s

inus

es e

tc.

Lary

nxTr

ache

a,B

ronc

hus,

Lung

Oth

er T

hora

cic

orga

nsB

one

Mel

anom

a of

Ski

nO

ther

Ski

nM

esot

helio

ma

Kap

osi s

arco

ma

Con

nect

ive,

Sof

t tis

sue

Bre

ast

Pen

isP

rost

ate

Test

isO

ther

mal

e ge

nita

lK

idne

yR

enal

Pel

vis

Ure

ter

Bla

dder

Oth

er U

rinar

y or

gans

Eye

Bra

in, N

ervo

us s

yste

mTh

yroi

dA

dren

al g

land

Oth

er E

ndoc

rine

Hod

gkin

dis

ease

Non

-Hod

gkin

lym

phom

aIm

mun

opro

lifer

ativ

e di

s.M

ultip

le M

yelo

ma

Lym

phoi

d Le

ukae

mia

Mye

loid

Leu

kaem

iaLe

ukae

mia

uns

pec.

Oth

er &

uns

peci

fied

All

site

s To

tal

All

site

s bu

t C44

Site

Asi

r

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld1 0 0 0 0 0 1 0 0 0 2 0 3 7 1 5 1 0 0 3 5 0 2 0 7 0 1 1 1 0 4 0 0 1 0 0 5 0 1 2 1 0 0 1 3 0 0 5 3 0 3 70 63

1.40

%0.

00%

0.00

%0.

00%

0.00

%0.

00%

1.40

%0.

00%

0.00

%0.

00%

2.90

%0.

00%

4.30

%10

.00%

1.40

%7.

10%

1.40

%0.

00%

0.00

%4.

30%

7.10

%0.

00%

2.90

%0.

00%

10.0

0%0.

00%

1.40

%1.

40%

1.40

%0.

00%

5.70

%0.

00%

0.00

%1.

40%

0.00

%0.

00%

7.10

%0.

00%

1.40

%2.

90%

1.40

%0.

00%

0.00

%1.

40%

4.30

%0.

00%

0.00

%7.

10%

4.30

%0.

00%

4.30

%

100.

00%

90.0

0%

0.6 0 0 0 0 0 0.6 0 0 0 1.1 0 1.7 4 0.6

2.9

0.6 0 0 1.7

2.9 0 1.1 0 4 0 0.6

0.6

0.6 0 2.3 0 0 0.6 0 0 2.9 0 0.6

1.1

0.6 0 0 0.6

1.7 0 0 2.9

1.7 0 1.7

40.1

36.1

0.4 0 0 0 0 0 0.6 0 0 0 1.4 0 2.4

4.3

0.7

3.3

0.8 0 0 2.7

3.1 0 1 0 5 0 0.5

0.8

0.8 0 2.3 0 0 0.7 0 0 3.3 0 0.6

1.6

0.5 0 0 0.4 2 0 0 3.3

1.2 0 2.3

46 41

Bah

a

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld1 8 10 0 1 0 3 1 0 2 8 0 9 1 2 7 0 1 1 4 6 2 1 1 13 1 0 4 2 0 13 1 0 2 0 0 7 0 0 6 3 0 0 6 20 0 1 5 3 1 6 16

315

0

0.60

%4.

90%

6.10

%0.

00%

0.60

%0.

00%

1.80

%0.

60%

0.00

%1.

20%

4.90

%0.

00%

5.50

%0.

60%

1.20

%4.

30%

0.00

%0.

60%

0.60

%2.

50%

3.70

%1.

20%

0.60

%0.

60%

8.00

%0.

60%

0.00

%2.

50%

1.20

%0.

00%

8.00

%0.

60%

0.00

%1.

20%

0.00

%0.

00%

4.30

%0.

00%

0.00

%3.

70%

1.80

%0.

00%

0.00

%3.

70%

12.3

0%0.

00%

0.60

%3.

10%

1.80

%0.

60%

3.70

%

100.

00%

92.0

0%

0.2

1.4

1.8 0 0.2 0 0.5

0.2 0 0.4

1.4 0 1.6

0.2

0.4

1.2 0 0.2

0.2

0.7

1.1

0.4

0.2

0.2

2.3

0.2 0 0.7

0.4 0 2.3

0.2 0 0.4 0 0 1.2 0 0 1.1

0.5 0 0 1.1

3.5 0 0.2

0.9

0.5

0.2

1.1

28.8

26.5

0.2 2 2.9 0 0.3 0 0.7

0.3 0 0.6

1.7 0 2.4

0.3

0.4

2.2 0 0.3

0.2

1.2

1.6

0.3

0.2

0.2

3.5

0.4 0 1 0.5 0 3.8

0.2 0 0.6 0 0 2.2 0 0 1.7

0.9 0 0 0.9

4.7 0 0.2

0.8

0.7

0.2

1.6

41.8

38.3

Jaza

n

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld

77

Tab

le 5

.2.2

- N

umbe

r of

Cas

es, R

elat

ive

Freq

uenc

y, C

rude

Inci

denc

e R

ate

(CIR

) A

ge-S

tand

ardi

zed

Inci

denc

e R

ate

(ASR

)A

mon

g Sa

udi M

ales

(pe

r 10

0,00

0) b

y P

rim

ary

Site

and

Age

Gro

ups

and

Reg

ion,

201

1

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)

0 1 2 1 0 0 6 0 0 7 6 4 18 14 1 9 3 11 1 4 10 1 4 3 14 0 0 5 0 0 14 2 0 8 0 1 8 0 2 8 5 2 1 11 25 0 6 17 7 1 10 253

239

0.00

%0.

40%

0.80

%0.

40%

0.00

%0.

00%

2.40

%0.

00%

0.00

%2.

80%

2.40

%1.

60%

7.10

%5.

50%

0.40

%3.

60%

1.20

%4.

30%

0.40

%1.

60%

4.00

%0.

40%

1.60

%1.

20%

5.50

%0.

00%

0.00

%2.

00%

0.00

%0.

00%

5.50

%0.

80%

0.00

%3.

20%

0.00

%0.

40%

3.20

%0.

00%

0.80

%3.

20%

2.00

%0.

80%

0.40

%4.

30%

9.90

%0.

00%

2.40

%6.

70%

2.80

%0.

40%

4.00

%

100.

00%

94.5

0%

0 0.2

0.3

0.2 0 0 0.9 0 0 1.1

0.9

0.6

2.8

2.2

0.2

1.4

0.5

1.7

0.2

0.6

1.5

0.2

0.6

0.5

2.2 0 0 0.8 0 0 2.2

0.3 0 1.2 0 0.2

1.2 0 0.3

1.2

0.8

0.3

0.2

1.7

3.8 0 0.9

2.6

1.1

0.2

1.5

39 36.8

0 0.2

0.4

0.2 0 0 1.4 0 0 2 1.2

0.9

4.9

3.6

0.2

2.3

0.8

2.5

0.1

1.1

2.5

0.2

0.8

0.8

3.3 0 0 1 0 0 3.9

0.4 0 2.2 0 0.2

1.8 0 0.3

1.1

1.4

0.3

0.1

1.9

5.1 0 1.7

2.4

1.5

0.1

1.9

57 53.6

Lip

Tong

ueM

outh

Sal

ivar

y gl

ands

Tons

ilO

ther

Oro

phar

ynx

Nas

opha

rynx

Hyp

opha

rynx

Pha

rynx

uns

pec.

Oes

opha

gus

Sto

mac

hS

mal

l int

estin

eC

olon

Rec

tum

Anu

sLi

ver

Gal

lbla

dder

etc

.P

ancr

eas

Nos

e, s

inus

es e

tc.

Lary

nxTr

ache

a,B

ronc

hus,

Lung

Oth

er T

hora

cic

orga

nsB

one

Mel

anom

a of

Ski

nO

ther

Ski

nM

esot

helio

ma

Kap

osi s

arco

ma

Con

nect

ive,

Sof

t tis

sue

Bre

ast

Pen

isP

rost

ate

Test

isO

ther

mal

e ge

nita

lK

idne

yR

enal

Pel

vis

Ure

ter

Bla

dder

Oth

er U

rinar

y or

gans

Eye

Bra

in, N

ervo

us s

yste

mTh

yroi

dA

dren

al g

land

Oth

er E

ndoc

rine

Hod

gkin

dis

ease

Non

-Hod

gkin

lym

phom

aIm

mun

opro

lifer

ativ

e di

s.M

ultip

le M

yelo

ma

Lym

phoi

d Le

ukae

mia

Mye

loid

Leu

kaem

iaLe

ukae

mia

uns

pec.

Oth

er &

uns

peci

fied

All

site

s To

tal

All

site

s bu

t C44

Site

Mad

inah

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld0 0 0 0 0 0 3 0 0 0 2 1 10 3 0 9 0 2 0 0 3 0 2 0 7 0 0 2 0 0 4 2 0 3 0 0 6 0 0 6 7 0 0 2 8 0 1 3 1 0 1 ----

-88 81

0.00

%0.

00%

0.00

%0.

00%

0.00

%0.

00%

3.40

%0.

00%

0.00

%0.

00%

2.30

%1.

10%

11.4

0%3.

40%

0.00

%10

.20%

0.00

%2.

30%

0.00

%0.

00%

3.40

%0.

00%

2.30

%0.

00%

8.00

%0.

00%

0.00

%2.

30%

0.00

%0.

00%

4.50

%2.

30%

0.00

%3.

40%

0.00

%0.

00%

6.80

%0.

00%

0.00

%6.

80%

8.00

%0.

00%

0.00

%2.

30%

9.10

%0.

00%

1.10

%3.

40%

1.10

%0.

00%

1.10

%--

---

100.

00%

92.0

0%

0 0 0 0 0 0 1.2 0 0 0 0.8

0.4 4 1.2 0 3.6 0 0.8 0 0 1.2 0 0.8 0 2.8 0 0 0.8 0 0 1.6

0.8 0 1.2 0 0 2.4 0 0 2.4

2.8 0 0 0.8

3.2 0 0.4

1.2

0.4 0 0.4

----

-35

.432

.6

0 0 0 0 0 0 1.6 0 0 0 0.8

0.4

5.3

1.6 0 4.3 0 1 0 0 1.4 0 0.8 0 3 0 0 1 0 0 2 0.9 0 1.4 0 0 3.5 0 0 2.6

3.2 0 0 0.7

3.1 0 0.4

1.6

0.6 0 0.5

----

-41

.838

.7

Hai

l

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld1 1 1 0 0 0 9 1 0 5 9 1 20 19 0 19 4 7 0 2 16 2 4 0 10 1 0 2 0 0 9 4 0 8 0 1 4 0 1 1 7 1 1 9 20 0 3 4 1 1 6 ----

-21

520

5

0.50

%0.

50%

0.50

%0.

00%

0.00

%0.

00%

4.20

%0.

50%

0.00

%2.

30%

4.20

%0.

50%

9.30

%8.

80%

0.00

%8.

80%

1.90

%3.

30%

0.00

%0.

90%

7.40

%0.

90%

1.90

%0.

00%

4.70

%0.

50%

0.00

%0.

90%

0.00

%0.

00%

4.20

%1.

90%

0.00

%3.

70%

0.00

%0.

50%

1.90

%0.

00%

0.50

%0.

50%

3.30

%0.

50%

0.50

%4.

20%

9.30

%0.

00%

1.40

%1.

90%

0.50

%0.

50%

2.80

%--

---

100.

00%

95.3

0%

0.2

0.2

0.2 0 0 0 1.9

0.2 0 1 1.9

0.2

4.1

3.9 0 3.9

0.8

1.4 0 0.4

3.3

0.4

0.8 0 2.1

0.2 0 0.4 0 0 1.9

0.8 0 1.7 0 0.2

0.8 0 0.2

0.2

1.4

0.2

0.2

1.9

4.1 0 0.6

0.8

0.2

0.2

1.2

----

-44

.542

.4

0.3

0.3

0.3 0 0 0 2.2

0.3 0 1.7

3.5

0.2

6.8 6 0 6.5

1.3

2.1 0 0.7

5.8

0.5

0.9 0 3.6

0.3 0 0.6 0 0 2.9

0.8 0 2.5 0 0.3

1.4 0 0.5

0.2

1.7

0.2

0.3 2 5.9 0 0.9 1 0.2

0.2

1.7

----

-66

.562

.8

Qas

sim

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld

78

Tab

le 5

.2.3

- N

umbe

r of

Cas

es, R

elat

ive

Freq

uenc

y, C

rude

Inci

denc

e R

ate

(CIR

) A

ge-S

tand

ardi

zed

Inci

denc

e R

ate

(ASR

)A

mon

g Sa

udi M

ales

(pe

r 10

0,00

0) b

y P

rim

ary

Site

and

Age

Gro

ups

and

Reg

ion,

201

1

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)

0 1 2 0 0 0 2 0 0 1 5 0 2 4 0 12 3 1 1 0 0 1 1 0 5 0 0 0 2 0 5 0 0 3 0 0 1 0 0 1 4 0 0 2 5 0 2 2 4 0 3 75 70

0.00

%1.

30%

2.70

%0.

00%

0.00

%0.

00%

2.70

%0.

00%

0.00

%1.

30%

6.70

%0.

00%

2.70

%5.

30%

0.00

%16

.00%

4.00

%1.

30%

1.30

%0.

00%

0.00

%1.

30%

1.30

%0.

00%

6.70

%0.

00%

0.00

%0.

00%

2.70

%0.

00%

6.70

%0.

00%

0.00

%4.

00%

0.00

%0.

00%

1.30

%0.

00%

0.00

%1.

30%

5.30

%0.

00%

0.00

%2.

70%

6.70

%0.

00%

2.70

%2.

70%

5.30

%0.

00%

4.00

%

100.

00%

93.3

0%

0 0.5 1 0 0 0 1 0 0 0.5

2.4 0 1 1.9 0 5.8

1.4

0.5

0.5 0 0 0.5

0.5 0 2.4 0 0 0 1 0 2.4 0 0 1.4 0 0 0.5 0 0 0.5

1.9 0 0 1 2.4 0 1 1 1.9 0 1.4

36.1

33.7

0 1.3

2.4 0 0 0 1.4 0 0 1.1

5.1 0 2 3 0

11.4

2.9

0.8

0.8 0 0 0.4

1.3 0 3.9 0 0 0 2.6 0 4.7 0 0 1.8 0 0 0.7 0 0 0.4

3.1 0 0 0.8

4.2 0 1.6

0.7

4.6 0 2.7

65.6

61.7

Lip

Tong

ueM

outh

Sal

ivar

y gl

ands

Tons

ilO

ther

Oro

phar

ynx

Nas

opha

rynx

Hyp

opha

rynx

Pha

rynx

uns

pec.

Oes

opha

gus

Sto

mac

hS

mal

l int

estin

eC

olon

Rec

tum

Anu

sLi

ver

Gal

lbla

dder

etc

.P

ancr

eas

Nos

e, s

inus

es e

tc.

Lary

nxTr

ache

a,B

ronc

hus,

Lung

Oth

er T

hora

cic

orga

nsB

one

Mel

anom

a of

Ski

nO

ther

Ski

nM

esot

helio

ma

Kap

osi s

arco

ma

Con

nect

ive,

Sof

t tis

sue

Bre

ast

Pen

isP

rost

ate

Test

isO

ther

mal

e ge

nita

lK

idne

yR

enal

Pel

vis

Ure

ter

Bla

dder

Oth

er U

rinar

y or

gans

Eye

Bra

in, N

ervo

us s

yste

mTh

yroi

dA

dren

al g

land

Oth

er E

ndoc

rine

Hod

gkin

dis

ease

Non

-Hod

gkin

lym

phom

aIm

mun

opro

lifer

ativ

e di

s.M

ultip

le M

yelo

ma

Lym

phoi

d Le

ukae

mia

Mye

loid

Leu

kaem

iaLe

ukae

mia

uns

pec.

Oth

er &

uns

peci

fied

All

site

s To

tal

All

site

s bu

t C44

Site

0 0 0 0 0 0 2 0 0 0 1 0 2 1 0 3 0 1 0 3 5 0 4 1 4 0 0 3 0 0 3 1 0 4 0 0 2 0 0 4 2 0 0 4 2 0 0 3 1 0 5 61 57

0.00

%0.

00%

0.00

%0.

00%

0.00

%0.

00%

3.30

%0.

00%

0.00

%0.

00%

1.60

%0.

00%

3.30

%1.

60%

0.00

%4.

90%

0.00

%1.

60%

0.00

%4.

90%

8.20

%0.

00%

6.60

%1.

60%

6.60

%0.

00%

0.00

%4.

90%

0.00

%0.

00%

4.90

%1.

60%

0.00

%6.

60%

0.00

%0.

00%

3.30

%0.

00%

0.00

%6.

60%

3.30

%0.

00%

0.00

%6.

60%

3.30

%0.

00%

0.00

%4.

90%

1.60

%0.

00%

8.20

%

100.

00%

93.4

0%

0 0 0 0 0 0 1.1 0 0 0 0.5 0 1.1

0.5 0 1.6 0 0.5 0 1.6

2.7 0 2.2

0.5

2.2 0 0 1.6 0 0 1.6

0.5 0 2.2 0 0 1.1 0 0 2.2

1.1 0 0 2.2

1.1 0 0 1.6

0.5 0 2.7

33.4

31.2

0 0 0 0 0 0 2.2 0 0 0 1.4 0 2.9

1.3 0 4.3 0 1.3 0 2.9

4.7 0 3.5

1.3

5.5 0 0 1.5 0 0 3.6

0.9 0 3.3 0 0 2.7 0 0 2 1.1 0 0 2.6

2.7 0 0 2.2

0.5 0 5.6

59.9

54.4

0 1 1 0 0 0 5 0 0 4 5 2 9 3 0 3 3 5 0 4 17 1 0 0 4 0 1 2 1 0 3 1 0 7 0 0 6 0 0 4 5 0 0 4 7 0 0 5 7 2 6 128

124

0.00

%0.

80%

0.80

%0.

00%

0.00

%0.

00%

3.90

%0.

00%

0.00

%3.

10%

3.90

%1.

60%

7.00

%2.

30%

0.00

%2.

30%

2.30

%3.

90%

0.00

%3.

10%

13.3

0%0.

80%

0.00

%0.

00%

3.10

%0.

00%

0.80

%1.

60%

0.80

%0.

00%

2.30

%0.

80%

0.00

%5.

50%

0.00

%0.

00%

4.70

%0.

00%

0.00

%3.

10%

3.90

%0.

00%

0.00

%3.

10%

5.50

%0.

00%

0.00

%3.

90%

5.50

%1.

60%

4.70

%

100.

00%

96.9

0%

0 0.3

0.3 0 0 0 1.4 0 0 1.1

1.4

0.6

2.6

0.9 0 0.9

0.9

1.4 0 1.1

4.8

0.3 0 0 1.1 0 0.3

0.6

0.3 0 0.9

0.3 0 2 0 0 1.7 0 0 1.1

1.4 0 0 1.1 2 0 0 1.4 2 0.6

1.7

36.5

35.4

0 0.5 1 0 0 0 3.1 0 0 3 3.8

1.1

6.9

1.8 0 3 1.6

3.9 0 3.3

14.9

0.3 0 0 3.3 0 1 1.2

0.8 0 2.6

0.2 0 5 0 0 4.2 0 0 1.4

2.6 0 0 1.5

4.8 0 0 1.1

4.4

1.3

3.6

87.2

84

0 0 0 0 0 0 1 0 0 0 2 0 3 1 0 2 1 2 0 1 2 0 2 0 4 0 0 1 0 0 3 3 0 3 1 0 1 0 0 2 0 2 1 2 1 0 0 4 0 0 2 47 43

0.00

%0.

00%

0.00

%0.

00%

0.00

%0.

00%

2.10

%0.

00%

0.00

%0.

00%

4.30

%0.

00%

6.40

%2.

10%

0.00

%4.

30%

2.10

%4.

30%

0.00

%2.

10%

4.30

%0.

00%

4.30

%0.

00%

8.50

%0.

00%

0.00

%2.

10%

0.00

%0.

00%

6.40

%6.

40%

0.00

%6.

40%

2.10

%0.

00%

2.10

%0.

00%

0.00

%4.

30%

0.00

%4.

30%

2.10

%4.

30%

2.10

%0.

00%

0.00

%8.

50%

0.00

%0.

00%

4.30

%

100.

00%

91.5

0%

0 0 0 0 0 0 0.7 0 0 0 1.5 0 2.2

0.7 0 1.5

0.7

1.5 0 0.7

1.5 0 1.5 0 2.9 0 0 0.7 0 0 2.2

2.2 0 2.2

0.7 0 0.7 0 0 1.5 0 1.5

0.7

1.5

0.7 0 0 2.9 0 0 1.5

34.1

31.2

0 0 0 0 0 0 0.6 0 0 0 3.7 0 4.4

1.4 0 3.6

1.8

3.7 0 1.9

3.7 0 1.2 0 5 0 0 1.9 0 0 5.1

2.8 0 4.9

1.8 0 1.8 0 0 1.1 0 2 0.7

1.4 2 0 0 4 0 0 3.7

64.3

59.4

Naj

ran

All

Age

sTo

tal (

%)

Crud

e Ra

teAS

R W

orld

Jouf

All

Age

sTo

tal (

%)

Crud

e Ra

teAS

R W

orld

Tabu

k

All

Age

sTo

tal (

%)

Crud

e Ra

teAS

R W

orld

Nor

ther

n R

egio

n

All

Age

sTo

tal (

%)

Crud

e Ra

teAS

R W

orld

79

Tab

le 5

.2.4

- N

umbe

r of

Cas

es, R

elat

ive

Freq

uenc

y, C

rude

Inci

denc

e R

ate

(CIR

) A

ge-S

tand

ardi

zed

Inci

denc

e R

ate

(ASR

)A

mon

g Sa

udi M

ales

(pe

r 10

0,00

0) b

y P

rim

ary

Site

and

Age

Gro

ups

and

Reg

ion,

201

1

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)

2 11 5 4 1 1 33 2 1 20 51 10 111

85 3 118

20 37 2 13 88 2 12 3 51 4 7 22 1 0 79 32 1 60 0 2 35 0 9 44 46 4 3 59 124 0 12 64 55 2 40 13

9113

40

0.10

%0.

80%

0.40

%0.

30%

0.10

%0.

10%

2.40

%0.

10%

0.10

%1.

40%

3.70

%0.

70%

8.00

%6.

10%

0.20

%8.

50%

1.40

%2.

70%

0.10

%0.

90%

6.30

%0.

10%

0.90

%0.

20%

3.70

%0.

30%

0.50

%1.

60%

0.10

%0.

00%

5.70

%2.

30%

0.10

%4.

30%

0.00

%0.

10%

2.50

%0.

00%

0.60

%3.

20%

3.30

%0.

30%

0.20

%4.

20%

8.90

%0.

00%

0.90

%4.

60%

4.00

%0.

10%

2.90

%

100.

00%

96.3

0%

0.1

0.5

0.2

0.2 0 0 1.5

0.1 0 0.9

2.2

0.4

4.9

3.7

0.1

5.2

0.9

1.6

0.1

0.6

3.9

0.1

0.5

0.1

2.2

0.2

0.3 1 0 0 3.5

1.4 0 2.6 0 0.1

1.5 0 0.4

1.9 2 0.2

0.1

2.6

5.5 0 0.5

2.8

2.4

0.1

1.8

61.3

59.1

0.2

0.9

0.4

0.2 0 0.1

2.2

0.2

0.1

1.9

4.3

0.8

8.9

6.7

0.2

10.7

1.9

3.2

0.2 1 8.3

0.1

0.6

0.2

4.8

0.4

0.6

1.2 0 0 8 1.3 0 4.6 0 0.2 3 0 0.4

2.6

2.7

0.2

0.2

2.6

8.7 0 1 3.4

3.5

0.2

3.2

105.

710

0.9

Lip

Tong

ueM

outh

Sal

ivar

y gl

ands

Tons

ilO

ther

Oro

phar

ynx

Nas

opha

rynx

Hyp

opha

rynx

Pha

rynx

uns

pec.

Oes

opha

gus

Sto

mac

hS

mal

l int

estin

eC

olon

Rec

tum

Anu

sLi

ver

Gal

lbla

dder

etc

.P

ancr

eas

Nos

e, s

inus

es e

tc.

Lary

nxTr

ache

a,B

ronc

hus,

Lung

Oth

er T

hora

cic

orga

nsB

one

Mel

anom

a of

Ski

nO

ther

Ski

nM

esot

helio

ma

Kap

osi s

arco

ma

Con

nect

ive,

Sof

t tis

sue

Bre

ast

Pen

isP

rost

ate

Test

isO

ther

mal

e ge

nita

lK

idne

yR

enal

Pel

vis

Ure

ter

Bla

dder

Oth

er U

rinar

y or

gans

Eye

Bra

in, N

ervo

us s

yste

mTh

yroi

dA

dren

al g

land

Oth

er E

ndoc

rine

Hod

gkin

dis

ease

Non

-Hod

gkin

lym

phom

aIm

mun

opro

lifer

ativ

e di

s.M

ultip

le M

yelo

ma

Lym

phoi

d Le

ukae

mia

Mye

loid

Leu

kaem

iaLe

ukae

mia

uns

pec.

Oth

er &

uns

peci

fied

All

site

s To

tal

All

site

s bu

t C44

Site

Riy

adh

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld1 7 7 4 1 0 29 2 1 20 38 8 93 81 2 80 19 25 1 18 10

1 7 22 4 38 5 2 14 2 0 80 16 2 30 1 0 49 0 2 55 29 2 1 37 104 1 15 45 37 6 48 11

9211

54

0.10

%0.

60%

0.60

%0.

30%

0.10

%0.

00%

2.40

%0.

20%

0.10

%1.

70%

3.20

%0.

70%

7.80

%6.

80%

0.20

%6.

70%

1.60

%2.

10%

0.10

%1.

50%

8.50

%0.

60%

1.80

%0.

30%

3.20

%0.

40%

0.20

%1.

20%

0.20

%0.

00%

6.70

%1.

30%

0.20

%2.

50%

0.10

%0.

00%

4.10

%0.

00%

0.20

%4.

60%

2.40

%0.

20%

0.10

%3.

10%

8.70

%0.

10%

1.30

%3.

80%

3.10

%0.

50%

4.00

%

100.

00%

96.8

0%

0 0.3

0.3

0.2 0 0 1.4

0.1 0 0.9

1.8

0.4

4.4

3.8

0.1

3.8

0.9

1.2 0 0.8

4.7

0.3 1 0.2

1.8

0.2

0.1

0.7

0.1 0 3.8

0.8

0.1

1.4 0 0 2.3 0 0.1

2.6

1.4

0.1 0 1.7

4.9 0 0.7

2.1

1.7

0.3

2.3

55.9

54.1

0.1

0.4

0.5

0.2

0.1 0 1.8

0.1

0.1

1.3

2.7

0.5

6.4

5.4

0.1

5.8

1.2

1.9

0.1

1.4

7.7

0.3 1 0.3

2.5

0.4

0.1

0.7

0.1 0 5.9

0.7

0.1 2 0.1 0 3.5 0 0.1

3.1

1.7

0.1 0 1.7

6.1

0.1

1.2

2.3 2 0.3

3.2

77.4

74.9

Mak

kah

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld0 8 5 4 1 2 21 3 0 10 21 5 60 49 2 35 13 26 1 15 79 2 9 1 27 1 5 14 7 0 63 14 3 35 0 1 31 1 0 24 32 1 1 40 79 0 8 27 24 2 33 84

581

8

0.00

%0.

90%

0.60

%0.

50%

0.10

%0.

20%

2.50

%0.

40%

0.00

%1.

20%

2.50

%0.

60%

7.10

%5.

80%

0.20

%4.

10%

1.50

%3.

10%

0.10

%1.

80%

9.30

%0.

20%

1.10

%0.

10%

3.20

%0.

10%

0.60

%1.

70%

0.80

%0.

00%

7.50

%1.

70%

0.40

%4.

10%

0.00

%0.

10%

3.70

%0.

10%

0.00

%2.

80%

3.80

%0.

10%

0.10

%4.

70%

9.30

%0.

00%

0.90

%3.

20%

2.80

%0.

20%

3.90

%

100.

00%

96.8

0%

0 0.5

0.3

0.3

0.1

0.1

1.4

0.2 0 0.7

1.4

0.3

3.9

3.2

0.1

2.3

0.9

1.7

0.1 1 5.2

0.1

0.6

0.1

1.8

0.1

0.3

0.9

0.5 0 4.1

0.9

0.2

2.3 0 0.1 2 0.1 0 1.6

2.1

0.1

0.1

2.6

5.2 0 0.5

1.8

1.6

0.1

2.2

55.4

53.6

0 1.4

0.5

0.4

0.1

0.3

2.8

0.6 0 1.2

3.3

0.7 9 6.6

0.3

5.6

2.1

4.4

0.1

2.3

13.1

0.1

0.6

0.2

3.7

0.2

0.7

1.1

1.1 0

11.3 1 0.3

4.2 0 0.1

4.7

0.2 0 2.5

3.6

0.1

0.1

3.2 9 0 1.3

2.1

2.2

0.3

5.1

113.

610

9.8

East

ern

Prov

ince

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld

80

Tab

le 5

.3.1

- N

umbe

r of

Cas

es, R

elat

ive

Freq

uenc

y, C

rude

Inci

denc

e R

ate

(CIR

) A

ge-S

tand

ardi

zed

Inci

denc

e R

ate

(ASR

)

Am

ong

Saud

i Fem

ales

(pe

r 10

0,00

0) b

y P

rim

ary

Site

and

Age

Gro

ups

and

Reg

ion,

201

1

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)

2 5 6 1 0 0 5 3 0 6 10 3 11 12 0 12 6 3 0 0 8 1 4 2 8 0 0 4 70 0 0 5 34 1 11 0 1 5 0 0 6 0 0 8 50 0 0 15 31 0 3 10 14 0 10 386

378

0.50

%1.

30%

1.60

%0.

30%

0.00

%0.

00%

1.30

%0.

80%

0.00

%1.

60%

2.60

%0.

80%

2.80

%3.

10%

0.00

%3.

10%

1.60

%0.

80%

0.00

%0.

00%

2.10

%0.

30%

1.00

%0.

50%

2.10

%0.

00%

0.00

%1.

00%

18.1

0%0.

00%

0.00

%1.

30%

8.80

%0.

30%

2.80

%0.

00%

0.30

%1.

30%

0.00

%0.

00%

1.60

%0.

00%

0.00

%2.

10%

13.0

0%0.

00%

0.00

%3.

90%

8.00

%0.

00%

0.80

%2.

60%

3.60

%0.

00%

2.60

%

100.

00%

97.9

0%

0.2

0.6

0.7

0.1 0 0 0.6

0.4 0 0.7

1.2

0.4

1.3

1.4 0 1.4

0.7

0.4 0 0 1 0.1

0.5

0.2 1 0 0 0.5

8.3 0 0 0.6 4 0.1

1.3 0 0.1

0.6 0 0 0.7 0 0 1 5.9 0 0 1.8

3.7 0 0.4

1.2

1.7 0 1.2

45.9

45

0.4 1 1 0.2 0 0 0.7

0.6 0 1 1.6

0.7

2.1 2 0 2.5

1.2

0.5 0 0 1.3

0.2

0.4

0.3

1.3 0 0 0.7

11.6 0 0 0.8

6.6

0.2

1.6 0 0.2

0.8 0 0 1.1 0 0 1.1

8.6 0 0 2.2 5 0 0.5

1.2

2.1 0 1.9

65.3

64

Lip

Tong

ueM

outh

Sal

ivar

y gl

ands

Tons

ilO

ther

Oro

phar

ynx

Nas

opha

rynx

Hyp

opha

rynx

Pha

rynx

uns

pec.

Oes

opha

gus

Sto

mac

hS

mal

l int

estin

eC

olon

Rec

tum

Anu

sLi

ver

Gal

lbla

dder

etc

.P

ancr

eas

Nos

e, s

inus

es e

tc.

Lary

nxTr

ache

a,B

ronc

hus,

Lung

Oth

er T

hora

cic

orga

nsB

one

Mel

anom

a of

Ski

nO

ther

Ski

nM

esot

helio

ma

Kap

osi s

arco

ma

Con

nect

ive,

Sof

t tis

sue

Bre

ast

Vul

vaV

agin

aC

ervi

x U

teri

Cor

pus

Ute

riU

teru

s un

spec

.O

vary

Oth

er F

emal

e G

enita

lP

lace

nta

Kid

ney

Ren

al P

elvi

sU

rete

rB

ladd

erO

ther

Urin

ary

orga

nsE

yeB

rain

, Ner

vous

sys

tem

Thyr

oid

Adr

enal

gla

ndO

ther

End

ocrin

eH

odgk

in d

isea

seN

on-H

odgk

in ly

mph

oma

Imm

unop

rolif

erat

ive

dis.

Mul

tiple

Mye

lom

aLy

mph

oid

Leuk

aem

iaM

yelo

id L

euka

emia

Leuk

aem

ia u

nspe

c.O

ther

& u

nspe

cifie

d

All

site

s To

tal

All

site

s bu

t C44

Site

Asi

r

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld0 1 0 0 0 0 0 0 0 0 5 0 7 3 0 3 2 0 0 1 3 0 0 0 3 0 0 2 32 0 0 1 7 1 4 0 1 1 0 0 2 0 0 3 8 0 0 3 7 0 0 3 4 0 7 11

411

1

0.00

%0.

90%

0.00

%0.

00%

0.00

%0.

00%

0.00

%0.

00%

0.00

%0.

00%

4.40

%0.

00%

6.10

%2.

60%

0.00

%2.

60%

1.80

%0.

00%

0.00

%0.

90%

2.60

%0.

00%

0.00

%0.

00%

2.60

%0.

00%

0.00

%1.

80%

28.1

0%0.

00%

0.00

%0.

90%

6.10

%0.

90%

3.50

%0.

00%

0.90

%0.

90%

0.00

%0.

00%

1.80

%0.

00%

0.00

%2.

60%

7.00

%0.

00%

0.00

%2.

60%

6.10

%0.

00%

0.00

%2.

60%

3.50

%0.

00%

6.10

%

100.

00%

97.4

0%

0 0.5 0 0 0 0 0 0 0 0 2.7 0 3.7

1.6 0 1.6

1.1 0 0 0.5

1.6 0 0 0 1.6 0 0 1.1

17.1 0 0 0.5

3.7

0.5

2.1 0 0.5

0.5 0 0 1.1 0 0 1.6

4.3 0 0 1.6

3.7 0 0 1.6

2.1 0 3.7

61 59.4

0 0.6 0 0 0 0 0 0 0 0 3.6 0 4.8

2.3 0 2.3

1.5 0 0 0.8 2 0 0 0 1.4 0 0 1.3

20.8 0 0 0.6 4 0.9

2.4 0 0.8

0.8 0 0 1.2 0 0 1.3

4.8 0 0 1.9

5.2 0 0 1.5

2.3 0 4.2

73.2

71.8

Bah

a

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld1 20 12 1 0 1 0 3 2 4 1 0 9 4 0 3 7 1 0 1 3 0 5 0 9 0 0 1 48 0 0 3 15 4 5 0 0 2 1 0 1 0 1 3 13 0 0 6 11 0 0 3 4 0 1 20

920

0

0.50

%9.

60%

5.70

%0.

50%

0.00

%0.

50%

0.00

%1.

40%

1.00

%1.

90%

0.50

%0.

00%

4.30

%1.

90%

0.00

%1.

40%

3.30

%0.

50%

0.00

%0.

50%

1.40

%0.

00%

2.40

%0.

00%

4.30

%0.

00%

0.00

%0.

50%

23.0

0%0.

00%

0.00

%1.

40%

7.20

%1.

90%

2.40

%0.

00%

0.00

%1.

00%

0.50

%0.

00%

0.50

%0.

00%

0.50

%1.

40%

6.20

%0.

00%

0.00

%2.

90%

5.30

%0.

00%

0.00

%1.

40%

1.90

%0.

00%

0.50

%

100.

00%

95.7

0%

0.2

3.5

2.1

0.2 0 0.2 0 0.5

0.3

0.7

0.2 0 1.6

0.7 0 0.5

1.2

0.2 0 0.2

0.5 0 0.9 0 1.6 0 0 0.2

8.3 0 0 0.5

2.6

0.7

0.9 0 0 0.3

0.2 0 0.2 0 0.2

0.5

2.2 0 0 1 1.9 0 0 0.5

0.7 0 0.2

36.1

34.5

0.4

5.8

3.5

0.2 0 0.2 0 0.7

0.4

1.1

0.1 0 2.4 1 0 0.8

1.7

0.3 0 0.4

0.7 0 0.8 0 2.5 0 0 0.1

12.3 0 0 0.7

4.1

1.2

1.4 0 0 0.4

0.3 0 0.4 0 0.4

0.5

2.9 0 0 1 2.4 0 0 0.5

1.2 0 0.1

53.2

50.7

Jaza

n

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld

81

Tab

le 5

.3.2

- N

umbe

r of

Cas

es, R

elat

ive

Freq

uenc

y, C

rude

Inci

denc

e R

ate

(CIR

) A

ge-S

tand

ardi

zed

Inci

denc

e R

ate

(ASR

) A

mon

g Sa

udi F

emal

es (

per

100,

000)

by

Pri

mar

y Si

te a

nd A

ge G

roup

s an

d R

egio

n, 2

011

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)

0 2 2 0 0 0 5 1 0 5 7 1 14 9 0 10 3 5 0 1 6 0 4 1 4 1 0 2 85 1 0 10 19 3 11 0 1 5 1 0 1 0 4 6 34 0 1 13 17 0 3 11 10 2 11 332

328

0.00

%0.

60%

0.60

%0.

00%

0.00

%0.

00%

1.50

%0.

30%

0.00

%1.

50%

2.10

%0.

30%

4.20

%2.

70%

0.00

%3.

00%

0.90

%1.

50%

0.00

%0.

30%

1.80

%0.

00%

1.20

%0.

30%

1.20

%0.

30%

0.00

%0.

60%

25.6

0%0.

30%

0.00

%3.

00%

5.70

%0.

90%

3.30

%0.

00%

0.30

%1.

50%

0.30

%0.

00%

0.30

%0.

00%

1.20

%1.

80%

10.2

0%0.

00%

0.30

%3.

90%

5.10

%0.

00%

0.90

%3.

30%

3.00

%0.

60%

3.30

%

100.

00%

98.8

0%

0 0.3

0.3 0 0 0 0.8

0.2 0 0.8

1.1

0.2

2.1

1.4 0 1.5

0.5

0.8 0 0.2

0.9 0 0.6

0.2

0.6

0.2 0 0.3

12.9

0.2 0 1.5

2.9

0.5

1.7 0 0.2

0.8

0.2 0 0.2 0 0.6

0.9

5.2 0 0.2 2 2.6 0 0.5

1.7

1.5

0.3

1.7

50.4

49.7

0 0.5

0.5 0 0 0 1.4

0.2 0 1.4

1.6

0.1

3.6

2.4 0 2.5

0.9

1.5 0 0.3

1.5 0 0.5

0.2

1.1

0.3 0 0.3

19.1

0.2 0 2.3

5.2

0.7

3.2 0 0.1

0.9

0.2 0 0.3 0 0.7 1 6.7 0 0.2

1.9

3.8 0 0.8

1.6

1.8

0.6

2.7

75.2

74.1

Lip

Tong

ueM

outh

Sal

ivar

y gl

ands

Tons

ilO

ther

Oro

phar

ynx

Nas

opha

rynx

Hyp

opha

rynx

Pha

rynx

uns

pec.

Oes

opha

gus

Sto

mac

hS

mal

l int

estin

eC

olon

Rec

tum

Anu

sLi

ver

Gal

lbla

dder

etc

.P

ancr

eas

Nos

e, s

inus

es e

tc.

Lary

nxTr

ache

a,B

ronc

hus,

Lung

Oth

er T

hora

cic

orga

nsB

one

Mel

anom

a of

Ski

nO

ther

Ski

nM

esot

helio

ma

Kap

osi s

arco

ma

Con

nect

ive,

Sof

t tis

sue

Bre

ast

Vul

vaV

agin

aC

ervi

x U

teri

Cor

pus

Ute

riU

teru

s un

spec

.O

vary

Oth

er F

emal

e G

enita

lP

lace

nta

Kid

ney

Ren

al P

elvi

sU

rete

rB

ladd

erO

ther

Urin

ary

orga

nsE

yeB

rain

, Ner

vous

sys

tem

Thyr

oid

Adr

enal

gla

ndO

ther

End

ocrin

eH

odgk

in d

isea

seN

on-H

odgk

in ly

mph

oma

Imm

unop

rolif

erat

ive

dis.

Mul

tiple

Mye

lom

aLy

mph

oid

Leuk

aem

iaM

yelo

id L

euka

emia

Leuk

aem

ia u

nspe

c.O

ther

& u

nspe

cifie

d

All

site

s To

tal

All

site

s bu

t C44

Site

Mad

inah

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld0 0 1 1 0 0 0 1 0 2 5 0 10 5 0 3 3 1 0 0 1 0 1 0 1 0 0 3 29 2 0 1 6 1 3 0 0 1 0 0 4 0 1 1 26 0 0 1 8 0 3 2 4 0 10 14

114

0

0.00

%0.

00%

0.70

%0.

70%

0.00

%0.

00%

0.00

%0.

70%

0.00

%1.

40%

3.50

%0.

00%

7.10

%3.

50%

0.00

%2.

10%

2.10

%0.

70%

0.00

%0.

00%

0.70

%0.

00%

0.70

%0.

00%

0.70

%0.

00%

0.00

%2.

10%

20.6

0%1.

40%

0.00

%0.

70%

4.30

%0.

70%

2.10

%0.

00%

0.00

%0.

70%

0.00

%0.

00%

2.80

%0.

00%

0.70

%0.

70%

18.4

0%0.

00%

0.00

%0.

70%

5.70

%0.

00%

2.10

%1.

40%

2.80

%0.

00%

7.10

%

100.

00%

99.3

0%

0 0 0.4

0.4 0 0 0 0.4 0 0.8 2 0 3.9 2 0 1.2

1.2

0.4 0 0 0.4 0 0.4 0 0.4 0 0 1.2

11.3

0.8 0 0.4

2.3

0.4

1.2 0 0 0.4 0 0 1.6 0 0.4

0.4

10.1 0 0 0.4

3.1 0 1.2

0.8

1.6 0 3.9

55 54.6

0 0 0.4

0.6 0 0 0 0.4 0 0.7

2.3 0 4.9

2.3 0 1.5

1.4

0.5 0 0 0.5 0 0.3 0 0.5 0 0 1.3

14.5

0.8 0 0.5

2.9

0.5

1.4 0 0 0.5 0 0 2.3 0 0.4

0.3

11.3 0 0 0.4

3.3 0 1.5

0.8

1.7 0 4.7

65.5

65

Hai

l

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld0 0 2 0 0 0 3 1 0 5 4 3 11 12 1 6 3 3 0 0 4 1 3 1 6 0 0 4 88 0 1 2 4 3 11 0 0 3 0 0 2 0 1 2 33 0 0 7 11 0 2 3 4 1 9 26

025

4

0.00

%0.

00%

0.80

%0.

00%

0.00

%0.

00%

1.20

%0.

40%

0.00

%1.

90%

1.50

%1.

20%

4.20

%4.

60%

0.40

%2.

30%

1.20

%1.

20%

0.00

%0.

00%

1.50

%0.

40%

1.20

%0.

40%

2.30

%0.

00%

0.00

%1.

50%

33.8

0%0.

00%

0.40

%0.

80%

1.50

%1.

20%

4.20

%0.

00%

0.00

%1.

20%

0.00

%0.

00%

0.80

%0.

00%

0.40

%0.

80%

12.7

0%0.

00%

0.00

%2.

70%

4.20

%0.

00%

0.80

%1.

20%

1.50

%0.

40%

3.50

%

100.

00%

97.7

0%

0 0 0.4 0 0 0 0.6

0.2 0 1 0.8

0.6

2.3

2.5

0.2

1.3

0.6

0.6 0 0 0.8

0.2

0.6

0.2

1.3 0 0 0.8

18.4 0 0.2

0.4

0.8

0.6

2.3 0 0 0.6 0 0 0.4 0 0.2

0.4

6.9 0 0 1.5

2.3 0 0.4

0.6

0.8

0.2

1.9

54.3

53.1

0 0 0.7 0 0 0 0.8

0.4 0 1.9

1.5 1 3.9

4.1

0.4

2.2

1.1 1 0 0 1.2

0.4

0.8

0.2

1.9 0 0 1

23.7 0 0.2

0.6

1.2

0.9

3.5 0 0 0.8 0 0 0.9 0 0.2

0.3

8.6 0 0 1.2 3 0 0.6

0.6

0.8

0.2

3.1

74.7

72.8

Qas

sim

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld

82

Tab

le 5

.3.3

- N

umbe

r of

Cas

es, R

elat

ive

Freq

uenc

y, C

rude

Inci

denc

e R

ate

(CIR

) A

ge-S

tand

ardi

zed

Inci

denc

e R

ate

(ASR

)A

mon

g Sa

udi F

emal

es (

per

100,

000)

by

Pri

mar

y Si

te a

nd A

ge G

roup

s an

d R

egio

n, 2

011

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)

0 0 1 0 0 0 0 0 0 1 2 0 3 3 0 2 0 2 0 0 0 1 0 1 1 0 0 0 14 0 1 2 2 0 1 1 0 1 0 0 0 0 0 0 11 0 0 2 6 0 2 3 2 0 5 70 69

0.00

%0.

00%

1.40

%0.

00%

0.00

%0.

00%

0.00

%0.

00%

0.00

%1.

40%

2.90

%0.

00%

4.30

%4.

30%

0.00

%2.

90%

0.00

%2.

90%

0.00

%0.

00%

0.00

%1.

40%

0.00

%1.

40%

1.40

%0.

00%

0.00

%0.

00%

20.0

0%0.

00%

1.40

%2.

90%

2.90

%0.

00%

1.40

%1.

40%

0.00

%1.

40%

0.00

%0.

00%

0.00

%0.

00%

0.00

%0.

00%

15.7

0%0.

00%

0.00

%2.

90%

8.60

%0.

00%

2.90

%4.

30%

2.90

%0.

00%

7.10

%

100.

00%

98.6

0%

0 0 0.5 0 0 0 0 0 0 0.5 1 0 1.4

1.4 0 1 0 1 0 0 0 0.5 0 0.5

0.5 0 0 0 6.7 0 0.5 1 1 0 0.5

0.5 0 0.5 0 0 0 0 0 0 5.3 0 0 1 2.9 0 1 1.4 1 0 2.4

33.5

33

0 0 1.2 0 0 0 0 0 0 0.8

1.8 0 2.5

2.2 0 1.9 0 1.9 0 0 0 1.1 0 1.1 1 0 0 0

10.2 0 1.1

1.6

1.5 0 0.8

0.7 0 1.1 0 0 0 0 0 0 7.3 0 0 0.8

4.4 0 2.3

2.7

1.4 0 5.1

56.4

55.4

Lip

Tong

ueM

outh

Sal

ivar

y gl

ands

Tons

ilO

ther

Oro

phar

ynx

Nas

opha

rynx

Hyp

opha

rynx

Pha

rynx

uns

pec.

Oes

opha

gus

Sto

mac

hS

mal

l int

estin

eC

olon

Rec

tum

Anu

sLi

ver

Gal

lbla

dder

etc

.P

ancr

eas

Nos

e, s

inus

es e

tc.

Lary

nxTr

ache

a,B

ronc

hus,

Lung

Oth

er T

hora

cic

orga

nsB

one

Mel

anom

a of

Ski

nO

ther

Ski

nM

esot

helio

ma

Kap

osi s

arco

ma

Con

nect

ive,

Sof

t tis

sue

Bre

ast

Vul

vaV

agin

aC

ervi

x U

teri

Cor

pus

Ute

riU

teru

s un

spec

.O

vary

Oth

er F

emal

e G

enita

lP

lace

nta

Kid

ney

Ren

al P

elvi

sU

rete

rB

ladd

erO

ther

Urin

ary

orga

nsE

yeB

rain

, Ner

vous

sys

tem

Thyr

oid

Adr

enal

gla

ndO

ther

End

ocrin

eH

odgk

in d

isea

seN

on-H

odgk

in ly

mph

oma

Imm

unop

rolif

erat

ive

dis.

Mul

tiple

Mye

lom

aLy

mph

oid

Leuk

aem

iaM

yelo

id L

euka

emia

Leuk

aem

ia u

nspe

c.O

ther

& u

nspe

cifie

d

All

site

s To

tal

All

site

s bu

t C44

Site

0 0 1 0 0 0 4 0 0 0 2 0 2 4 0 0 0 1 0 0 2 0 4 1 3 0 0 0 25 0 0 3 5 1 4 0 0 2 0 0 1 0 0 1 12 0 0 5 5 0 0 4 7 1 1 101

98

0.00

%0.

00%

1.00

%0.

00%

0.00

%0.

00%

4.00

%0.

00%

0.00

%0.

00%

2.00

%0.

00%

2.00

%4.

00%

0.00

%0.

00%

0.00

%1.

00%

0.00

%0.

00%

2.00

%0.

00%

4.00

%1.

00%

3.00

%0.

00%

0.00

%0.

00%

24.8

0%0.

00%

0.00

%3.

00%

5.00

%1.

00%

4.00

%0.

00%

0.00

%2.

00%

0.00

%0.

00%

1.00

%0.

00%

0.00

%1.

00%

11.9

0%0.

00%

0.00

%5.

00%

5.00

%0.

00%

0.00

%4.

00%

6.90

%1.

00%

1.00

%

100.

00%

97.0

0%

0 0 0.6 0 0 0 2.2 0 0 0 1.1 0 1.1

2.2 0 0 0 0.6 0 0 1.1 0 2.2

0.6

1.7 0 0 0

13.9 0 0 1.7

2.8

0.6

2.2 0 0 1.1 0 0 0.6 0 0 0.6

6.7 0 0 2.8

2.8 0 0 2.2

3.9

0.6

0.6

56.4

54.7

0 0 0.7 0 0 0 3.6 0 0 0 2.6 0 1.3

4.6 0 0 0 0.9 0 0 1.6 0 2 1 3.2 0 0 0

20.8 0 0 2.6

4.2

1.3 2 0 0 2.3 0 0 1.3 0 0 0.5

8.7 0 0 3.3 4 0 0 2.9

4.1 1 1.3

81.9

78.7

0 0 1 1 0 0 0 1 0 1 4 2 11 3 0 5 2 4 0 0 4 1 3 0 2 0 0 2 33 0 0 1 3 0 7 0 3 6 0 0 0 0 1 4 21 0 0 9 10 0 4 9 8 3 1 170

168

0.00

%0.

00%

0.60

%0.

60%

0.00

%0.

00%

0.00

%0.

60%

0.00

%0.

60%

2.40

%1.

20%

6.50

%1.

80%

0.00

%2.

90%

1.20

%2.

40%

0.00

%0.

00%

2.40

%0.

60%

1.80

%0.

00%

1.20

%0.

00%

0.00

%1.

20%

19.4

0%0.

00%

0.00

%0.

60%

1.80

%0.

00%

4.10

%0.

00%

1.80

%3.

50%

0.00

%0.

00%

0.00

%0.

00%

0.60

%2.

40%

12.4

0%0.

00%

0.00

%5.

30%

5.90

%0.

00%

2.40

%5.

30%

4.70

%1.

80%

0.60

%

100.

00%

98.8

0%

0 0 0.3

0.3 0 0 0 0.3 0 0.3

1.2

0.6

3.3

0.9 0 1.5

0.6

1.2 0 0 1.2

0.3

0.9 0 0.6 0 0 0.6

9.9 0 0 0.3

0.9 0 2.1 0 0.9

1.8 0 0 0 0 0.3

1.2

6.3 0 0 2.7 3 0 1.2

2.7

2.4

0.9

0.3

50.8

50.2

0 0 0.7

0.9 0 0 0 0.4 0 0.7

2.5

0.7

8.2

1.6 0 4 1.3

3.1 0 0 2.7

0.2

0.7 0 1.7 0 0 0.5

20 0 0 0.4

1.7 0 5.2 0 0.8

2.7 0 0 0 0 0.2

0.9

6.8 0 0 3.9

5.7 0 2.5

3.8

4.9

1.2

0.7

91.5

89.8

1 0 0 0 0 0 0 0 0 0 3 0 1 1 0 0 0 3 0 0 1 0 0 0 3 0 0 2 10 0 1 2 3 0 3 0 0 4 0 0 0 0 0 1 4 0 0 0 3 0 0 1 3 0 1 51 48

2.00

%0.

00%

0.00

%0.

00%

0.00

%0.

00%

0.00

%0.

00%

0.00

%0.

00%

5.90

%0.

00%

2.00

%2.

00%

0.00

%0.

00%

0.00

%5.

90%

0.00

%0.

00%

2.00

%0.

00%

0.00

%0.

00%

5.90

%0.

00%

0.00

%3.

90%

19.6

0%0.

00%

2.00

%3.

90%

5.90

%0.

00%

5.90

%0.

00%

0.00

%7.

80%

0.00

%0.

00%

0.00

%0.

00%

0.00

%2.

00%

7.80

%0.

00%

0.00

%0.

00%

5.90

%0.

00%

0.00

%2.

00%

5.90

%0.

00%

2.00

%

100.

00%

94.1

0%

0.7 0 0 0 0 0 0 0 0 0 2.1 0 0.7

0.7 0 0 0 2.1 0 0 0.7 0 0 0 2.1 0 0 1.4

7.1 0 0.7

1.4

2.1 0 2.1 0 0 2.9 0 0 0 0 0 0.7

2.9 0 0 0 2.1 0 0 0.7

2.1 0 0.7

36.4

34.2

1.4 0 0 0 0 0 0 0 0 0 4.9 0 1.5

1.7 0 0 0 4 0 0 1.7 0 0 0 2.5 0 0 1.1

10.4 0 1.2

2.2

4.4 0 4 0 0 3.3 0 0 0 0 0 1.8

2.5 0 0 0 3.7 0 0 0.6

1.8 0 1.2

55.6

53.2

Naj

ran

All

Age

sTo

tal (

%)

Crud

e Ra

teAS

R W

orld

Jouf

All

Age

sTo

tal (

%)

Crud

e Ra

teAS

R W

orld

Tabu

k

All

Age

sTo

tal (

%)

Crud

e Ra

teAS

R W

orld

Nor

ther

n R

egio

n

All

Age

sTo

tal (

%)

Crud

e Ra

teAS

R W

orld

83

Tab

le 5

.3.4

- N

umbe

r of

Cas

es, R

elat

ive

Freq

uenc

y, C

rude

Inci

denc

e R

ate

(CIR

) A

ge-S

tand

ardi

zed

Inci

denc

e R

ate

(ASR

)A

mon

g Sa

udi F

emal

es (

per

100,

000)

by

Pri

mar

y Si

te a

nd A

ge G

roup

s an

d R

egio

n, 2

011

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)

3 7 10 8 1 0 16 2 0 12 35 10 117

51 3 63 30 18 0 1 28 0 20 5 29 0 0 17 416 2 0 17 63 7 49 4 0 39 0 2 13 0 8 29 241 1 0 40 82 0 15 38 49 2 41 16

4416

15

0.20

%0.

40%

0.60

%0.

50%

0.10

%0.

00%

1.00

%0.

10%

0.00

%0.

70%

2.10

%0.

60%

7.10

%3.

10%

0.20

%3.

80%

1.80

%1.

10%

0.00

%0.

10%

1.70

%0.

00%

1.20

%0.

30%

1.80

%0.

00%

0.00

%1.

00%

25.3

0%0.

10%

0.00

%1.

00%

3.80

%0.

40%

3.00

%0.

20%

0.00

%2.

40%

0.00

%0.

10%

0.80

%0.

00%

0.50

%1.

80%

14.7

0%0.

10%

0.00

%2.

40%

5.00

%0.

00%

0.90

%2.

30%

3.00

%0.

10%

2.50

%

100.

00%

98.2

0%

0.1

0.3

0.5

0.4 0 0 0.7

0.1 0 0.5

1.6

0.5

5.4

2.3

0.1

2.9

1.4

0.8 0 0 1.3 0 0.9

0.2

1.3 0 0 0.8

19 0.1 0 0.8

2.9

0.3

2.2

0.2 0 1.8 0 0.1

0.6 0 0.4

1.3

11 0 0 1.8

3.8 0 0.7

1.7

2.2

0.1

1.9

75.2

73.9

0.2

0.6

0.6

0.5

0.1 0 0.8

0.1 0 1.2 3 0.7

8.8

4.3

0.2

5.6

2.7

1.5 0 0.1

2.6 0 1 0.4

2.4 0 0 0.8

28.3

0.1 0 1 5.8

0.6

3.5

0.3 0 2.9 0 0.2

1.3 0 0.4

1.7

13.2 0 0 1.8 6 0 1.3

1.8

2.9

0.1

3.4

115.

211

2.8

Lip

Tong

ueM

outh

Sal

ivar

y gl

ands

Tons

ilO

ther

Oro

phar

ynx

Nas

opha

rynx

Hyp

opha

rynx

Pha

rynx

uns

pec.

Oes

opha

gus

Sto

mac

hS

mal

l int

estin

eC

olon

Rec

tum

Anu

sLi

ver

Gal

lbla

dder

etc

.P

ancr

eas

Nos

e, s

inus

es e

tc.

Lary

nxTr

ache

a,B

ronc

hus,

Lung

Oth

er T

hora

cic

orga

nsB

one

Mel

anom

a of

Ski

nO

ther

Ski

nM

esot

helio

ma

Kap

osi s

arco

ma

Con

nect

ive,

Sof

t tis

sue

Bre

ast

Vul

vaV

agin

aC

ervi

x U

teri

Cor

pus

Ute

riU

teru

s un

spec

.O

vary

Oth

er F

emal

e G

enita

lP

lace

nta

Kid

ney

Ren

al P

elvi

sU

rete

rB

ladd

erO

ther

Urin

ary

orga

nsE

yeB

rain

, Ner

vous

sys

tem

Thyr

oid

Adr

enal

gla

ndO

ther

End

ocrin

eH

odgk

in d

isea

seN

on-H

odgk

in ly

mph

oma

Imm

unop

rolif

erat

ive

dis.

Mul

tiple

Mye

lom

aLy

mph

oid

Leuk

aem

iaM

yelo

id L

euka

emia

Leuk

aem

ia u

nspe

c.O

ther

& u

nspe

cifie

d

All

site

s To

tal

All

site

s bu

t C44

Site

Riy

adh

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld0 10 5 5 0 0 9 1 0 16 36 12 91 52 7 30 20 20 1 2 29 2 8 4 37 0 4 14 37

9 2 1 51 97 17 57 5 2 22 0 0 16 0 2 21 113 0 2 27 74 0 7 35 32 1 53 14

3113

94

0.00

%0.

70%

0.30

%0.

30%

0.00

%0.

00%

0.60

%0.

10%

0.00

%1.

10%

2.50

%0.

80%

6.40

%3.

60%

0.50

%2.

10%

1.40

%1.

40%

0.10

%0.

10%

2.00

%0.

10%

0.60

%0.

30%

2.60

%0.

00%

0.30

%1.

00%

26.5

0%0.

10%

0.10

%3.

60%

6.80

%1.

20%

4.00

%0.

30%

0.10

%1.

50%

0.00

%0.

00%

1.10

%0.

00%

0.10

%1.

50%

7.90

%0.

00%

0.10

%1.

90%

5.20

%0.

00%

0.50

%2.

40%

2.20

%0.

10%

3.70

%

100.

00%

97.4

0%

0 0.5

0.2

0.2 0 0 0.4 0 0 0.7

1.7

0.6

4.3

2.4

0.3

1.4

0.9

0.9 0 0.1

1.4

0.1

0.4

0.2

1.7 0 0.2

0.7

17.8

0.1 0 2.4

4.5

0.8

2.7

0.2

0.1 1 0 0 0.7 0 0.1 1 5.3 0 0.1

1.3

3.5 0 0.3

1.6

1.5 0 2.5

67.1

65.3

0 0.6

0.3

0.3 0 0 0.5

0.1 0 1.2

2.6

0.9

6.2

3.6

0.5

2.3

1.5

1.5

0.1

0.2 2 0.1

0.4

0.2

2.8 0 0.2

0.9

23.6

0.2

0.1

3.1

7.5

1.3

3.9

0.3

0.1

1.4 0 0 1.3 0 0.1

1.1

5.9 0 0.1

1.4

5.1 0 0.5

1.7

1.7 0 3.7

93.1

90.3

Mak

kah

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld0 7 5 5 0 0 3 3 0 6 18 4 55 35 4 21 14 16 2 0 18 1 5 0 19 0 2 21 35

7 0 0 16 60 3 32 2 1 19 0 0 6 0 1 20 80 3 1 27 44 0 8 20 33 3 27 1027

1008

0.00

%0.

70%

0.50

%0.

50%

0.00

%0.

00%

0.30

%0.

30%

0.00

%0.

60%

1.80

%0.

40%

5.40

%3.

40%

0.40

%2.

00%

1.40

%1.

60%

0.20

%0.

00%

1.80

%0.

10%

0.50

%0.

00%

1.90

%0.

00%

0.20

%2.

00%

34.8

0%0.

00%

0.00

%1.

60%

5.80

%0.

30%

3.10

%0.

20%

0.10

%1.

90%

0.00

%0.

00%

0.60

%0.

00%

0.10

%1.

90%

7.80

%0.

30%

0.10

%2.

60%

4.30

%0.

00%

0.80

%1.

90%

3.20

%0.

30%

2.60

%

100.

00%

98.1

0%

0 0.5

0.3

0.3 0 0 0.2

0.2 0 0.4

1.2

0.3

3.7

2.4

0.3

1.4 1 1.1

0.1 0 1.2

0.1

0.3 0 1.3 0 0.1

1.4

24.3 0 0 1.1

4.1

0.2

2.2

0.1

0.1

1.3 0 0 0.4 0 0.1

1.4

5.4

0.2

0.1

1.8 3 0 0.5

1.4

2.2

0.2

1.8

69.8

68.5

0 0.7

0.7

0.4 0 0 0.3

0.4 0 0.8

2.2

0.4

6.9

4.4

0.6

2.9

1.9

2.3

0.2 0 2.3

0.2

0.3 0 2.6 0 0.3

1.7

35.8 0 0 2.1

8.8

0.4

3.4

0.2

0.1

2.4 0 0 0.8 0 0.1

1.5

6.9

0.2

0.1

1.9

4.7 0 1 1.7

2.8

0.2

3.2

----

-11

0.6

108

East

ern

Prov

ince

All

Age

sTo

tal (

%)

Cru

de R

ate

ASR

Wor

ld

84

Tab

le 5

.4.1

- N

umbe

r of

Can

cer

Cas

es A

mon

g N

on-S

audi

Mal

es b

y P

rim

ary

Site

and

Age

Gro

ups,

201

1

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)4 21 17 9 0 1 49 2 0 25 76 13 16

690 7 48 21 23 2 25 10

6 9 16 10 122 3 3 26 12 1 122

17 2 57 1 2 80 1 5 52 51 0 1 53 128 0 24 43 44 6 94 16

9015

68

All

Age

s0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

Age

Unk

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 4 0 0 0 2 0 3 0 0 0 0 1 3 0 0 0 0 2 0 0 6 3 0 1 28 270-4

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 7 0 0 1 1 2 0 0 8 2 0 1 23 235-9

0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 1 0 0 2 2 0 0 14 14

10-1

40 0 0 0 0 0 3 0 0 0 1 0 1 0 0 1 0 0 0 0 1 0 1 0 0 0 0 2 0 0 0 1 0 2 0 0 1 0 0 0 2 0 0 8 7 0 0 3 1 0 1 36 36

20-2

40 1 0 1 0 0 2 0 0 0 2 0 5 6 0 0 1 0 0 0 0 0 2 1 3 0 0 2 1 0 0 6 0 1 0 0 0 0 1 2 1 0 0 9 10 0 1 0 4 0 1 63 60

25-2

90 1 0 1 0 0 1 0 0 2 5 1 7 5 1 1 1 0 0 0 2 0 0 0 3 0 1 3 0 0 0 1 0 0 0 0 0 0 0 6 6 0 0 6 11 0 1 4 2 2 8 82 79

30-3

40 3 3 2 0 0 5 0 0 0 4 2 6 4 1 0 2 0 0 0 4 0 1 1 9 0 0 0 0 0 0 1 2 5 0 1 1 0 1 5 11 0 0 8 9 0 1 1 5 0 4 10

293

35-3

90 5 5 2 0 1 7 0 0 2 5 2 18 9 1 2 2 0 0 2 12 3 0 1 14 0 0 2 1 0 2 3 0 8 0 1 8 0 0 3 4 0 0 5 8 0 2 1 6 1 8 15

614

2

40-4

44 1 1 0 0 0 7 1 0 2 9 4 22 10 1 9 0 5 0 3 8 2 1 1 9 1 0 2 1 0 6 0 0 7 0 0 9 0 0 4 7 0 0 5 12 0 1 3 6 0 8 17

216

3

45-4

90 1 1 1 0 0 10 0 0 4 15 4 29 19 1 10 4 0 0 5 18 1 4 1 24 0 2 3 1 0 15 1 0 12 1 0 10 0 0 7 9 0 0 1 26 0 5 2 6 0 19 27

224

8

50-5

40 3 3 0 0 0 4 0 0 6 15 0 35 18 1 4 4 6 1 2 21 1 3 2 32 2 0 4 3 0 25 0 0 6 0 0 19 0 1 2 5 0 0 1 16 0 6 2 2 2 17 27

424

2

55-5

90 3 0 2 0 0 2 1 0 4 6 0 12 6 0 8 2 4 0 2 13 2 0 2 17 0 0 1 3 0 23 1 0 6 0 0 12 0 0 2 1 0 0 1 10 0 2 2 2 1 10 163

146

60-6

40 0 1 0 0 0 1 0 0 3 5 0 17 5 1 4 3 5 0 2 14 0 0 0 3 0 0 0 1 0 23 0 0 3 0 0 6 0 0 3 4 0 0 2 6 0 2 3 1 0 2 12

011

7

65-6

90 0 2 0 0 0 1 0 0 1 6 0 7 3 0 5 1 3 0 5 9 0 0 0 5 0 0 2 0 0 16 0 0 4 0 0 9 0 0 2 1 0 0 0 2 0 1 2 0 0 9 96 91

70-7

40 3 1 0 0 0 1 0 0 1 3 0 7 5 0 3 1 0 1 3 2 0 0 1 2 0 0 0 1 1 12 0 0 0 0 0 5 1 0 1 0 0 0 1 2 0 2 1 2 0 5 68 6675+

0.20

%1.

20%

1.00

%0.

50%

0.00

%0.

10%

2.90

%0.

10%

0.00

%1.

50%

4.50

%0.

80%

9.80

%5.

30%

0.40

%2.

80%

1.20

%1.

40%

0.10

%1.

50%

6.30

%0.

50%

0.90

%0.

60%

7.20

%0.

20%

0.20

%1.

50%

0.70

%0.

10%

7.20

%1.

00%

0.10

%3.

40%

0.10

%0.

10%

4.70

%0.

10%

0.30

%3.

10%

3.00

%0.

00%

0.10

%3.

10%

7.60

%0.

00%

1.40

%2.

50%

2.60

%0.

40%

5.60

%

100.

00%

92.8

0%

Tota

l (%

)0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 3 0 0 0 5 4 0 0 3 0 0 0 21 21

15-1

9Li

pTo

ngue

Mou

thS

aliv

ary

glan

dsTo

nsil

Oth

er O

roph

aryn

xN

asop

hary

nxH

ypop

hary

nxP

hary

nx u

nspe

c.O

esop

hagu

sS

tom

ach

Sm

all i

ntes

tine

Col

onR

ectu

mA

nus

Live

rG

allb

ladd

er e

tc.

Pan

crea

sN

ose,

sin

uses

etc

.La

rynx

Trac

hea,

Bro

nchu

s,Lu

ngO

ther

Tho

raci

c or

gans

Bon

eM

elan

oma

of S

kin

Oth

er S

kin

Mes

othe

liom

aK

apos

i sar

com

aC

onne

ctiv

e,S

oft t

issu

eB

reas

tP

enis

Pro

stat

eTe

stis

Oth

er m

ale

geni

tal

Kid

ney

Ren

al P

elvi

sU

rete

rB

ladd

erO

ther

Urin

ary

orga

nsE

yeB

rain

, Ner

vous

sys

tem

Thyr

oid

Adr

enal

gla

ndO

ther

End

ocrin

eH

odgk

in d

isea

seN

on-H

odgk

in ly

mph

oma

Imm

unop

rolif

erat

ive

dis.

Mul

tiple

Mye

lom

aLy

mph

oid

Leuk

aem

iaM

yelo

id L

euka

emia

Leuk

aem

ia u

nspe

c.O

ther

& u

nspe

cifie

d

All

site

s To

tal

All

site

s bu

t C44

Site

85

Tab

le 5

.4.2

- N

umbe

r of

Can

cer

Cas

es A

mon

g N

on-S

audi

Fem

ales

by

Pri

mar

y Si

te a

nd A

ge G

roup

s, 2

011

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)2 11 9 6 1 0 9 3 1 7 31 4 80 41 6 17 15 14 6 1 29 2 13 5 43 3 1 22 65

9 2 2 71 69 14 66 4 1 29 0 0 12 1 6 25 109 0 0 27 45 0 13 24 28 8 66 16

6316

20

All

Age

s0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

Age

Unk

0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 5 0 0 0 0 1 1 0 0 0 0 0 0 0 10 3 0 0 24 240-4

0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 6 1 1 0 12 125-9

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 1 0 0 4 1 0 1 3 1 1 2 22 22

10-1

40 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 3 0 0 0 1 1 4 0 0 0 1 0 3 0 0 0 0 0 0 0 0 0 8 0 0 7 2 0 0 3 3 1 0 39 39

20-2

40 0 0 1 0 0 1 1 0 0 0 0 3 0 0 0 0 0 0 0 1 2 1 0 3 0 0 2 24 0 0 2 0 0 0 1 0 1 0 0 0 0 2 0 12 0 0 3 0 0 0 0 4 0 3 67 64

25-2

90 1 0 0 0 0 1 0 0 0 0 0 2 3 0 1 0 0 2 0 0 0 1 0 3 0 0 2 58 0 0 3 0 2 4 0 0 0 0 0 0 0 1 0 22 0 0 3 5 0 0 0 3 1 3 12

111

8

30-3

40 3 0 0 0 0 2 0 0 0 4 0 9 5 0 1 0 0 0 0 0 0 0 2 4 1 0 0 76 0 1 9 4 1 6 0 0 3 0 0 2 0 1 3 15 0 0 0 3 0 0 0 3 0 7 16

516

1

35-3

90 0 3 1 0 0 2 0 0 0 0 0 9 2 3 0 3 0 1 0 1 0 0 1 3 0 0 5 11

7 1 0 13 9 0 5 0 0 4 0 0 0 0 0 2 16 0 0 0 3 0 0 0 2 0 4 210

207

40-4

40 0 0 2 0 0 0 1 0 0 5 3 13 7 0 1 2 1 0 1 2 0 2 0 4 1 0 2 11

2 0 1 10 8 1 9 2 1 5 0 0 3 0 0 2 10 0 0 1 5 0 0 0 1 0 11 229

225

45-4

90 3 0 0 0 0 0 0 1 2 6 0 4 7 0 1 4 4 1 0 2 0 0 0 5 1 0 2 10

5 0 0 13 10 4 8 0 0 5 0 0 2 0 0 3 5 0 0 0 7 0 2 0 2 3 6 218

213

50-5

40 1 1 0 0 0 2 0 0 1 1 0 9 4 1 1 3 5 1 0 6 0 0 2 7 0 0 1 67 1 0 7 17 1 11 1 0 0 0 0 1 0 0 0 7 0 0 1 7 0 3 1 1 0 7 17

917

2

55-5

92 2 3 0 1 0 0 0 0 1 6 0 10 4 2 2 1 2 0 0 8 0 1 0 4 0 0 0 42 0 0 5 10 2 4 0 0 1 0 0 1 0 0 1 4 0 0 0 4 0 3 0 0 0 11 13

713

3

60-6

40 0 1 1 0 0 0 0 0 1 5 0 6 3 0 3 0 1 0 0 3 0 0 0 2 0 0 1 25 0 0 3 8 3 10 0 0 1 0 0 0 0 0 3 1 0 0 1 3 0 1 0 0 0 4 90 88

65-6

90 0 0 0 0 0 0 0 0 1 2 0 4 2 0 1 0 1 0 0 1 0 0 0 4 0 0 1 18 0 0 0 1 0 1 0 0 1 0 0 1 1 1 1 4 0 0 1 1 0 0 0 3 0 5 56 52

70-7

40 1 1 0 0 0 0 0 0 1 1 0 11 3 0 4 1 0 0 0 4 0 0 0 4 0 0 1 10 0 0 6 1 0 4 0 0 1 0 0 2 0 0 0 1 0 0 1 2 0 3 0 0 1 3 67 6375+

0.10

%0.

70%

0.50

%0.

40%

0.10

%0.

00%

0.50

%0.

20%

0.10

%0.

40%

1.90

%0.

20%

4.80

%2.

50%

0.40

%1.

00%

0.90

%0.

80%

0.40

%0.

10%

1.70

%0.

10%

0.80

%0.

30%

2.60

%0.

20%

0.10

%1.

30%

39.6

0%0.

10%

0.10

%4.

30%

4.10

%0.

80%

4.00

%0.

20%

0.10

%1.

70%

0.00

%0.

00%

0.70

%0.

10%

0.40

%1.

50%

6.60

%0.

00%

0.00

%1.

60%

2.70

%0.

00%

0.80

%1.

40%

1.70

%0.

50%

4.00

%

100.

00%

97.4

0%

Tota

l (%

)0 0 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 4 0 0 0 0 2 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0 2 3 0 0 5 2 0 0 1 1 0 0 27 27

15-1

9Li

pTo

ngue

Mou

thS

aliv

ary

glan

dsTo

nsil

Oth

er O

roph

aryn

xN

asop

hary

nxH

ypop

hary

nxP

hary

nx u

nspe

c.O

esop

hagu

sS

tom

ach

Sm

all i

ntes

tine

Col

onR

ectu

mA

nus

Live

rG

allb

ladd

er e

tc.

Pan

crea

sN

ose,

sin

uses

etc

.La

rynx

Trac

hea,

Bro

nchu

s,Lu

ngO

ther

Tho

raci

c or

gans

Bon

eM

elan

oma

of S

kin

Oth

er S

kin

Mes

othe

liom

aK

apos

i sar

com

aC

onne

ctiv

e,S

oft t

issu

eB

reas

tV

ulva

Vag

ina

Cer

vix

Ute

riC

orpu

s U

teri

Ute

rus

unsp

ec.

Ova

ryO

ther

Fem

ale

Gen

ital

Pla

cent

aK

idne

yR

enal

Pel

vis

Ure

ter

Bla

dder

Oth

er U

rinar

y or

gans

Eye

Bra

in, N

ervo

us s

yste

mTh

yroi

dA

dren

al g

land

Oth

er E

ndoc

rine

Hod

gkin

dis

ease

Non

-Hod

gkin

lym

phom

aIm

mun

opro

lifer

ativ

e di

s.M

ultip

le M

yelo

ma

Lym

phoi

d Le

ukae

mia

Mye

loid

Leu

kaem

iaLe

ukae

mia

uns

pec.

Oth

er &

uns

peci

fied

All

site

s To

tal

All

site

s bu

t C44

Site

86

Tab

le 5

.4.3

- A

ge-S

peci

fic R

ate

(AIR

), A

ge-S

tand

ardi

zed

Inci

denc

e R

ate

(ASR

) A

mon

g N

on-S

audi

Mal

es (

per

100,

000)

by

Pri

mar

y Si

te a

nd A

ge G

roup

s, 2

011

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)4 21 17 9 0 1 49 2 0 25 76 13 16

690 7 48 21 23 2 25 10

6 9 16 10 122 3 3 26 12 1 122

17 2 57 1 2 80 1 5 52 51 0 1 53 128 0 24 43 44 6 94 16

9015

68

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.3 0 0 0 0 0 0 0.3 0 0.3 0 0 1.2 0 0 0 0.6 0 0.9 0 0 0 0 0.3

0.9 0 0 0 0 0.6 0 0 1.8

0.9 0 0.3 9 8

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.3

2.2 0 0 0.3

0.3

0.6 0 0 2.5

0.6 0 0.3 7 7

0 0 0 0 0 0 1.4 0 0 0 0 0 0 0 0 0 0 0 0 0 0.4 0 0.7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.7 0 0 0 0 0.4 0 0 0.7

0.7 0 0 5 5

0 0 0 0 0 0 1.3 0 0 0 0.4 0 0.4 0 0 0.4 0 0 0 0 0.4 0 0.4 0 0 0 0 0.9 0 0 0 0.4 0 0.9 0 0 0.4 0 0 0 0.9 0 0 3.6

3.1 0 0 1.3

0.4 0 0.4

16 16

0 0.2 0 0.2 0 0 0.4 0 0 0 0.4 0 1 1.2 0 0 0.2 0 0 0 0 0 0.4

0.2

0.6 0 0 0.4

0.2 0 0 1.2 0 0.2 0 0 0 0 0.2

0.4

0.2 0 0 1.7

1.9 0 0.2 0 0.8 0 0.2

12 12

0 0.1 0 0.1 0 0 0.1 0 0 0.2

0.5

0.1

0.7

0.5

0.1

0.1

0.1 0 0 0 0.2 0 0 0 0.3 0 0.1

0.3 0 0 0 0.1 0 0 0 0 0 0 0 0.6

0.6 0 0 0.6

1.1 0 0.1

0.4

0.2

0.2

0.8 8 8

0 0.3

0.3

0.2 0 0 0.4 0 0 0 0.4

0.2

0.5

0.4

0.1 0 0.2 0 0 0 0.4 0 0.1

0.1

0.8 0 0 0 0 0 0 0.1

0.2

0.4 0 0.1

0.1 0 0.1

0.4 1 0 0 0.7

0.8 0 0.1

0.1

0.4 0 0.4 9 8

0 0.6

0.6

0.2 0 0.1

0.8 0 0 0.2

0.6

0.2 2 1 0.1

0.2

0.2 0 0 0.2

1.4

0.3 0 0.1

1.6 0 0 0.2

0.1 0 0.2

0.3 0 0.9 0 0.1

0.9 0 0 0.3

0.5 0 0 0.6

0.9 0 0.2

0.1

0.7

0.1

0.9

18 16

0.6

0.2

0.2 0 0 0 1.1

0.2 0 0.3

1.4

0.6

3.5

1.6

0.2

1.4 0 0.8 0 0.5

1.3

0.3

0.2

0.2

1.4

0.2 0 0.3

0.2 0 1 0 0 1.1 0 0 1.4 0 0 0.6

1.1 0 0 0.8

1.9 0 0.2

0.5 1 0 1.3

27 26

0 0.3

0.3

0.3 0 0 2.6 0 0 1 3.9 1 7.5

4.9

0.3

2.6 1 0 0 1.3

4.6

0.3 1 0.3

6.2 0 0.5

0.8

0.3 0 3.9

0.3 0 3.1

0.3 0 2.6 0 0 1.8

2.3 0 0 0.3

6.7 0 1.3

0.5

1.5 0 4.9

70 64

0 1.4

1.4 0 0 0 1.9 0 0 2.8

6.9 0

16.2

8.3

0.5

1.9

1.9

2.8

0.5

0.9

9.7

0.5

1.4

0.9

14.8

0.9 0 1.9

1.4 0

11.6 0 0 2.8 0 0 8.8 0 0.5

0.9

2.3 0 0 0.5

7.4 0 2.8

0.9

0.9

0.9

7.9

127

112

0 3.3 0 2.2 0 0 2.2

1.1 0 4.4

6.6 0

13.3

6.6 0 8.8

2.2

4.4 0 2.2

14.4

2.2 0 2.2

18.8 0 0 1.1

3.3 0

25.4

1.1 0 6.6 0 0

13.3 0 0 2.2

1.1 0 0 1.1

11.1 0 2.2

2.2

2.2

1.1

11.1

180

162

0 0 3.1 0 0 0 3.1 0 0 9.2

15.3 0

52.1

15.3

3.1

12.3

9.2

15.3 0 6.1

42.9 0 0 0 9.2 0 0 0 3.1 0

70.5 0 0 9.2 0 0

18.4 0 0 9.2

12.3 0 0 6.1

18.4 0 6.1

9.2

3.1 0 6.1

368

359

0 013

.9 0 0 0 7 0 0 741

.8 048

.720

.9 034

.8 720

.9 034

.862

.6 0 0 034

.8 0 013

.9 0 011

1.3

0 027

.8 0 062

.6 0 013

.9 7 0 0 013

.9 0 713

.9 0 062

.6

668

633

019

.56.

5 0 0 0 6.5 0 0 6.5

19.5 0

45.5

32.5 0

19.5

6.5 0 6.5

19.5

13 0 0 6.5

13 0 0 0 6.5

6.5

78 0 0 0 0 032

.56.

5 0 6.5 0 0 0 6.5

13 0 13 6.5

13 032

.5

442

429

0.1

0.3

0.3

0.1 0 0 0.8 0 0 0.4

1.2

0.2

2.6

1.4

0.1

0.8

0.3

0.4 0 0.4

1.7

0.1

0.3

0.2

1.9 0 0 0.4

0.2 0 1.9

0.3 0 0.9 0 0 1.3 0 0.1

0.8

0.8 0 0 0.8 2 0 0.4

0.7

0.7

0.1

1.5

26.9

24.9

0 0.7

0.6

0.1 0 0 1.1

0.1 0 0.9

2.7

0.1

5.5

2.7

0.2

2.2

0.8

1.2

0.1

1.5

4.3

0.2

0.3

0.3

3.2 0 0 0.8

0.5

0.1

7.6

0.3 0 1.7 0 0 3.6

0.1

0.1

1.6 1 0 0 1.2

3.2 0 0.9

1.7 1 0.1

3.4

----

-58

.154

.9

0 0 0 0 0 0 0.5 0 0 0 0 0 0 0 0 0 0 0 0 0.5

0.5 0 0.5 0 0 0 0 0.5 0 0 0 0.5 0 0 0 0 0 0 0 1.4 0 0 0 2.4

1.9 0 0 1.4 0 0 0 10 10

Lip

Tong

ueM

outh

Sal

ivar

y gl

ands

Tons

ilO

ther

Oro

phar

ynx

Nas

opha

rynx

Hyp

opha

rynx

Pha

rynx

uns

pec.

Oes

opha

gus

Sto

mac

hS

mal

l int

estin

eC

olon

Rec

tum

Anu

sLi

ver

Gal

lbla

dder

etc

.P

ancr

eas

Nos

e, s

inus

es e

tc.

Lary

nxTr

ache

a,B

ronc

hus,

Lung

Oth

er T

hora

cic

orga

nsB

one

Mel

anom

a of

Ski

nO

ther

Ski

nM

esot

helio

ma

Kap

osi s

arco

ma

Con

nect

ive,

Sof

t tis

sue

Bre

ast

Pen

isP

rost

ate

Test

isO

ther

mal

e ge

nita

lK

idne

yR

enal

Pel

vis

Ure

ter

Bla

dder

Oth

er U

rinar

y or

gans

Eye

Bra

in, N

ervo

us s

yste

mTh

yroi

dA

dren

al g

land

Oth

er E

ndoc

rine

Hod

gkin

dis

ease

Non

-Hod

gkin

lym

phom

aIm

mun

opro

lifer

ativ

e di

s.M

ultip

le M

yelo

ma

Lym

phoi

d Le

ukae

mia

Mye

loid

Leu

kaem

iaLe

ukae

mia

uns

pec.

Oth

er &

uns

peci

fied

All

site

s To

tal

All

site

s bu

t C44

Site

All

Age

sA

ge U

nk0-

45-

910

-14

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

+C

rude

Rat

eA

SR W

orld

15-1

9

87

Tab

le 5

.4.4

- A

ge-S

peci

fic In

cide

nce

Rat

e (A

IR),

Age

-Sta

ndar

dize

d In

cide

nce

Rat

e (A

SR)

Am

ong

Non

-Sau

di F

emal

es (

per

100,

000)

by

Pri

mar

y Si

te a

nd A

ge G

roup

s, 2

011

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)2 11 9 6 1 0 9 3 1 7 31 4 80 41 6 17 15 14 6 1 29 2 13 5 43 3 1 22 65

9 2 2 71 69 14 66 4 1 29 0 0 12 1 6 25 109 0 0 27 45 0 13 24 28 8 66 16

6316

20

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0 0 0 0 0 0.3 0 0.3 0 0 0.3 0 0 0 0 0 0 0 0 0.3 0 0 0 0 0 0 0 0 0 1.7 0 0 0 0 0.3

0.3 0 0 0 0 0 0 0 3.4 1 0 0 8 8

0 0 0 0.4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.4 0 0 0 0 0 0 0 0 0 0.4 0 0 0 0 0 0.4 0 0 0 0 0 0 0 2.1

0.4

0.4 0 4 4

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.4 0 0 0 0 0 0 0.4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2.5

0.4 0 0 1.7

0.4 0 0.4

1.2

0.4

0.4

0.8 9 9

0 0 0 0 0 0 0 0 0 0 0.6 0 0 0 0 0 0.6 0 0 0 0 0 1.8 0 0 0 0.6

0.6

2.4 0 0 0 0.6 0 1.8 0 0 0 0 0 0 0 0 0 4.9 0 0 4.3

1.2 0 0 1.8

1.8

0.6 0 24 24

0 0 0 0.4 0 0 0.4

0.4 0 0 0 0 1.3 0 0 0 0 0 0 0 0.4

0.9

0.4 0 1.3 0 0 0.9

10.3 0 0 0.9 0 0 0 0.4 0 0.4 0 0 0 0 0.9 0 5.1 0 0 1.3 0 0 0 0 1.7 0 1.3

29 27

0 0.3 0 0 0 0 0.3 0 0 0 0 0 0.5

0.8 0 0.3 0 0 0.5 0 0 0 0.3 0 0.8 0 0 0.5

15.8 0 0 0.8 0 0.5

1.1 0 0 0 0 0 0 0 0.3 0 6 0 0 0.8

1.4 0 0 0 0.8

0.3

0.8

33 32

0 0.7 0 0 0 0 0.5 0 0 0 1 0 2.2

1.2 0 0.2 0 0 0 0 0 0 0 0.5 1 0.2 0 0

18.7 0 0.2

2.2 1 0.2

1.5 0 0 0.7 0 0 0.5 0 0.2

0.7

3.7 0 0 0 0.7 0 0 0 0.7 0 1.7

41 40

0 0 1.2

0.4 0 0 0.8 0 0 0 0 0 3.6

0.8

1.2 0 1.2 0 0.4 0 0.4 0 0 0.4

1.2 0 0 2

47.4

0.4 0 5.3

3.6 0 2 0 0 1.6 0 0 0 0 0 0.8

6.5 0 0 0 1.2 0 0 0 0.8 0 1.6

85 84

0 0 0 2 0 0 0 1 0 0 5 312

.9 7 0 1 2 1 0 1 2 0 2 0 4 1 0 211

1.4

0 1 9.9 8 1 9 2 1 5 0 0 3 0 0 2 9.9 0 0 1 5 0 0 0 1 0

10.9

228

224

0 5 0 0 0 0 0 0 1.7

3.3

9.9 0 6.6

11.6 0 1.7

6.6

6.6

1.7 0 3.3 0 0 0 8.3

1.7 0 3.3

173.

30 0

21.5

16.5

6.6

13.2 0 0 8.3 0 0 3.3 0 0 5 8.3 0 0 0

11.6 0 3.3 0 3.3 5 9.9

360

351

0 2.4

2.4 0 0 0 4.8 0 0 2.4

2.4 0

21.4

9.5

2.4

2.4

7.1

11.9

2.4 0

14.3 0 0 4.8

16.7 0 0 2.4

159.

62.

4 016

.740

.52.

426

.22.

4 0 0 0 0 2.4 0 0 0

16.7 0 0 2.4

16.7 0 7.1

2.4

2.4 0

16.7

426

410

8.9

8.9

13.3 0 4.4 0 0 0 0 4.4

26.6 0

44.3

17.7

8.9

8.9

4.4

8.9 0 0

35.4 0 4.4 0

17.7 0 0 0

186.

10 0

22.2

44.3

8.9

17.7 0 0 4.4 0 0 4.4 0 0 4.4

17.7 0 0 0

17.7 0

13.3 0 0 0

48.7

607

589

0 0 7.2

7.2 0 0 0 0 0 7.2

36.2 0

43.5

21.7 0

21.7 0 7.2 0 0

21.7 0 0 0

14.5 0 0 7.2

181.

20 0

21.7

58 21.7

72.5 0 0 7.2 0 0 0 0 0

21.7

7.2 0 0 7.2

21.7 0 7.2 0 0 0 29 652

638

0 0 0 0 0 0 0 0 011

.723

.3 046

.723

.3 011

.7 011

.7 0 011

.7 0 0 046

.7 0 011

.721

0 0 0 011

.7 011

.7 0 011

.7 0 011

.711

.711

.711

.746

.7 0 011

.711

.7 0 0 0 35 058

.3

653

607

0 9.3

9.3 0 0 0 0 0 0 9.3

9.3 0

101.

827

.8 0 37 9.3 0 0 0 37 0 0 0 37 0 0 9.3

92.5 0 0

55.5

9.3 0 37 0 0 9.3 0 0

18.5 0 0 0 9.3 0 0 9.3

18.5 0

27.8 0 0 9.3

27.8

620

583

0.1

0.4

0.3

0.2 0 0 0.3

0.1 0 0.3

1.2

0.1 3 1.5

0.2

0.6

0.6

0.5

0.2 0 1.1

0.1

0.5

0.2

1.6

0.1 0 0.8

24.7

0.1

0.1

2.7

2.6

0.5

2.5

0.1 0 1.1 0 0 0.4 0 0.2

0.9

4.1 0 0 1 1.7 0 0.5

0.9 1 0.3

2.5

62.3

60.6

0.4

0.9

1.1

0.4

0.2 0 0.4

0.1

0.1

1.1

3.8

0.2

8.5 4 0.5

2.3

1.2

1.7

0.3

0.1 4 0.1

0.7

0.2

4.4

0.2 0 1.5

46.6

0.1

0.1

5.6

7.2

1.5

6.6

0.2

0.1 2 0 0 1.2

0.2

0.4

1.9

5.7 0 0 1.7

3.9 0 1.8 1 1.7

0.6

6.8

135.

313

0.9

0 0 0 0 0 0 0.6

0.6 0 0 0 0.6 0 0 0 0 0 0 0 0 0.6 0 2.2 0 0 0 0 1.1

0.6 0 0 0 0 0 0.6 0 0 0.6 0 0 0 0 0 1.1

1.7 0 0 2.8

1.1 0 0 0.6

0.6 0 0 15 15

Lip

Tong

ueM

outh

Sal

ivar

y gl

ands

Tons

ilO

ther

Oro

phar

ynx

Nas

opha

rynx

Hyp

opha

rynx

Pha

rynx

uns

pec.

Oes

opha

gus

Sto

mac

hS

mal

l int

estin

eC

olon

Rec

tum

Anu

sLi

ver

Gal

lbla

dder

etc

.P

ancr

eas

Nos

e, s

inus

es e

tc.

Lary

nxTr

ache

a,B

ronc

hus,

Lung

Oth

er T

hora

cic

orga

nsB

one

Mel

anom

a of

Ski

nO

ther

Ski

nM

esot

helio

ma

Kap

osi s

arco

ma

Con

nect

ive,

Sof

t tis

sue

Bre

ast

Vul

vaV

agin

aC

ervi

x U

teri

Cor

pus

Ute

riU

teru

s un

spec

.O

vary

Oth

er F

emal

e G

enita

lP

lace

nta

Kid

ney

Ren

al P

elvi

sU

rete

rB

ladd

erO

ther

Urin

ary

orga

nsE

yeB

rain

, Ner

vous

sys

tem

Thyr

oid

Adr

enal

gla

ndO

ther

End

ocrin

eH

odgk

in d

isea

seN

on-H

odgk

in ly

mph

oma

Imm

unop

rolif

erat

ive

dis.

Mul

tiple

Mye

lom

aLy

mph

oid

Leuk

aem

iaM

yelo

id L

euka

emia

Leuk

aem

ia u

nspe

c.O

ther

& u

nspe

cifie

d

All

site

s To

tal

All

site

s bu

t C44

Site

All

Age

sA

ge U

nk0-

45-

910

-14

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

+C

rude

Rat

eA

SR W

orld

15-1

9

88

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)7 32 24 4 4 2 78 10 0 77 13

010 61 83 10 29

924 50 5 49 18

8 7 47 21 104 5 15 85 11 3 150

32 1 69 5 1 165 1 21 131

73 8 2 104

272 0 59 151

94 10 147

2941

2837

2 15 23 10 9 3 59 10 2 71 129 8 87 66 9 298

32 49 6 48 183

11 50 8 117 4 10 68 15 4 148

21 2 78 5 3 154 1 12 99 61 9 3 105

214 0 41 118

90 5 122

2697

2580

5 21 30 6 2 3 86 18 0 68 133

11 72 66 7 276

25 53 10 43 184

12 34 8 112 5 14 51 6 1 154

25 0 56 0 1 127 1 18 126

58 8 5 105

231 0 30 146

84 5 98 2640

2528

5 24 25 11 4 1 99 7 0 60 108

11 85 66 8 268

22 44 4 40 162

13 46 8 107 5 14 60 12 8 123

29 3 63 0 0 126 0 34 122

73 8 1 97 226 1 36 139

103 5 131

2647

2540

4 13 24 7 6 1 109 6 1 81 122

15 104

64 6 326

28 60 10 46 223 8 51 6 97 7 12 50 19 0 159

38 1 71 10 3 152 1 16 101

84 4 2 133

283 0 48 150

94 8 140

3004

2907

2 25 27 12 2 3 96 6 1 53 103

13 101

89 5 296

25 58 13 43 203

17 53 7 120 2 11 67 12 1 150

31 2 81 2 0 152 1 24 120

84 9 2 118

268 1 37 137

109 6 138

2938

2818

6 29 24 8 1 0 88 5 0 67 124

15 115

82 10 290

27 68 5 44 197 7 51 11 112 7 19 55 15 1 184

35 3 73 6 4 155 0 26 139

77 10 1 125

265 0 46 152

90 14 126

3014

2902

1 14 27 16 4 3 121 8 2 62 126

13 120

108

12 274

39 53 9 53 189 7 67 9 154 5 19 48 12 1 170

35 3 87 2 1 143 0 22 120

74 7 4 136

246 0 36 158

129

13 133

3095

2941

5 23 26 14 5 3 84 6 2 70 146

17 152

123

14 292

41 75 14 32 194 5 51 12 149 3 21 63 16 3 194

45 3 91 1 0 160 1 24 120

91 6 1 122

272 0 30 146

115

12 153

3248

3099

5 29 26 10 5 0 88 7 4 68 182

15 177

143

11 283

39 85 10 60 201

12 44 10 166 6 26 69 16 1 192

38 4 84 7 6 176 1 21 148

87 15 5 145

329 1 39 165

90 14 140

3505

3339

8 33 38 14 2 2 101 7 4 54 150

22 202

173

17 277

26 82 10 55 253

12 66 13 140 6 26 59 13 3 247

46 3 124 8 3 175 1 21 155

95 6 3 176

351 2 46 155

119

13 149

3766

3626

6 38 29 15 3 3 114

10 4 57 160

23 260

192

16 289

37 97 14 51 280

22 56 14 156 9 22 75 15 5 272

44 2 104 4 3 170 1 17 141

93 10 6 167

351 0 60 166

109

15 179

3986

3830

6 38 29 17 0 0 97 9 3 58 169

22 231

181 8 319

48 101 9 64 237

15 65 12 189 8 22 64 17 1 236

40 4 120 5 1 174 0 28 155

121

21 5 178

363 0 53 163

130

26 181

4043

3854

12 40 39 20 4 2 93 14 3 70 169

28 270

203

12 333

54 128

10 55 325

19 69 17 168

12 18 72 20 0 259

63 0 146 4 2 173 1 23 139

122

16 4 179

425 0 46 195

119

27 169

4391

4223

9 32 39 17 2 2 121 5 3 52 165

31 292

195

12 338

54 102

14 61 294

11 78 13 161

18 17 72 18 3 279

74 0 158 5 3 178 1 27 162

136

16 9 187

381 0 40 167

144

37 155

4390

4229

5 42 42 19 0 1 93 6 2 69 205

30 344

274

22 328

58 130 5 58 287

17 65 13 184 5 33 72 24 2 305

78 2 185 5 1 208 1 29 156

150

20 6 199

436 1 62 194

147

16 162

4798

4614

8 53 45 11 2 2 131 9 3 73 165

27 303

238

18 329

51 114 9 48 292

25 74 12 168 9 21 69 24 1 280

78 2 167 5 1 193 3 22 148

149

29 0 194

407 0 61 187

156

16 161

4593

4425

8 44 41 14 4 3 121 9 3 76 162

35 378

279

11 330

73 128 8 70 343

21 71 16 208

12 19 77 16 0 311

80 6 178 3 5 182 1 20 170

154

13 8 184

432 1 50 202

148

16 169

4913

4705

Tab

le 5

.5.1

Num

ber

Of N

ew C

ases

by

Pri

mar

y Si

te a

nd Y

ears

am

ong

Saud

i Mal

es,1

994-

2011

Lip

Tong

ueM

outh

Sal

ivar

y G

land

sTo

nsil

Oth

er O

roph

aryn

xN

asop

hary

nxH

ypop

hary

nxP

hary

nx U

nspe

cifie

dO

esop

hagu

sS

tom

ach

Sm

all I

ntes

tine

Col

onR

ectu

mA

nus

Live

rG

allb

ladd

er e

tc.

Pan

crea

sN

ose,

Sin

uses

etc

.La

rynx

Trac

hea,

Bro

nchu

s, L

ung

Oth

er T

hora

cic

Org

ans

Bon

eM

elan

oma

of S

kin

Oth

er S

kin

Mes

othe

liom

aK

apos

i Sar

com

aC

onne

ctiv

e,S

oft T

issu

eB

reas

tP

enis

Pro

stat

eTe

stis

Oth

er M

ale

Gen

ital

Kid

ney

Ren

al P

elvi

sU

rete

rB

ladd

erO

ther

Urin

ary

Org

ans

Eye

Bra

in, N

ervo

us s

yste

mTh

yroi

dA

dren

al G

land

Oth

er E

ndoc

rine

Hod

gkin

Dis

ease

Non

-Hod

gkin

Lym

phom

aIm

mun

opro

lifer

ativ

e D

isea

seM

ultip

le M

yelo

ma

Lym

phoi

d Le

ukem

iaM

yelo

id L

euke

mia

Leuk

emia

Uns

peci

fied

Oth

er &

Uns

peci

fied

All

site

s To

tal

All

site

s bu

t C44

Site

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

89

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)3 21 23 8 0 0 38 19 2 75 67 9 65 44 6 11

051 28 6 10 51 7 26 11 78 1 0 42 42

9 8 5 78 57 3 96 1 17 60 0 0 28 0 15 80 207

10 2 59 143 0 20 76 77 6 103

2381

2303

3 20 38 7 3 1 27 10 3 54 71 11 80 49 3 88 37 30 9 2 55 6 38 7 55 0 3 55 434 6 6 73 47 2 100 1 10 37 1 1 39 0 16 73 218 6 1 69 149 0 33 89 78 6 95 23

5523

00

4 28 37 6 3 0 39 14 1 68 64 9 85 52 1 101

25 24 5 7 48 5 38 7 87 1 0 42 463 7 2 83 39 9 96 0 13 49 0 1 23 0 18 76 198

10 2 59 142 0 20 80 75 1 93 23

6022

73

2 28 22 3 3 0 31 15 1 52 58 10 78 59 3 86 31 25 4 10 53 6 25 2 57 1 8 46 464 3 4 75 48 10 114 2 7 57 2 0 29 0 13 94 210

11 1 57 146 1 13 82 90 5 95 23

5222

95

1 29 32 11 1 1 37 19 1 44 66 16 72 57 5 123

50 50 9 8 50 5 44 8 83 0 7 61 516 3 2 94 60 16 107 2 10 52 3 1 39 0 12 85 264 9 2 74 186 0 24 73 83 6 137

2750

2667

5 31 39 8 1 0 36 16 1 46 71 8 105

86 2 93 59 41 8 10 47 5 37 8 77 4 8 50 514 3 3 79 58 12 101 4 13 64 3 1 37 1 24 78 282

10 3 76 176 1 27 95 89 11 127

2794

2717

4 23 25 14 3 0 23 10 2 55 62 10 108

72 4 121

46 35 6 9 52 8 38 6 80 1 4 48 602 8 1 81 92 5 104 3 8 49 2 0 39 1 24 84 259

14 1 87 186 1 25 112

93 9 122

2881

2801

3 19 27 8 1 0 41 12 0 37 72 14 143

87 2 101

55 35 5 2 57 5 43 8 102 1 5 43 565 7 5 84 78 13 111 5 15 70 1 1 51 0 17 84 258 8 0 78 202 1 19 86 102 4 116

2909

2807

6 30 29 6 5 2 41 12 3 58 77 8 134

104 5 116

41 54 8 7 52 3 35 7 95 3 3 39 672 5 5 85 88 14 108 4 16 69 1 1 41 0 20 85 279

10 0 76 203 0 19 101

100 5 117

3107

3012

5 30 30 10 4 0 39 2 1 50 75 11 147

106 9 129

60 41 2 4 64 10 39 9 124 7 6 54 713 6 1 91 111

15 123 5 5 68 2 1 42 0 16 95 368

14 1 114

238 1 16 93 103

11 161

3482

3358

8 29 21 12 1 2 45 16 3 51 76 13 179

118 7 120

53 35 6 6 69 9 40 12 131 5 5 75 815

11 5 89 125

13 119

10 8 84 2 2 43 1 18 108

346

17 2 105

244 0 26 85 125

11 175

3736

3605

6 23 43 13 1 2 35 16 0 65 74 13 197

144 8 114

68 52 10 6 87 11 41 9 131 6 8 52 952 1 7 98 149

18 147 6 14 65 4 4 39 1 20 103

391 9 5 104

259 0 26 86 100

17 147

4007

3876

4 25 36 14 1 0 44 10 1 62 115

13 222

142 8 137

72 78 12 9 81 11 40 15 134 4 15 41 988 3 1 74 151

24 139 9 22 79 4 2 42 0 19 108

432

10 5 119

246 0 33 92 122 9 170

4249

4115

5 38 51 18 3 1 56 9 3 55 126

14 246

149

12 130

85 53 13 10 91 7 30 18 119 3 6 65 11

73 4 4 102

185

29 147 8 12 84 1 0 36 0 20 117

459 9 4 135

285 0 49 117

108

19 152

4675

4556

6 30 46 17 3 0 50 17 1 56 103

14 277

163 7 126

83 70 7 5 84 12 49 11 126 2 5 55 12

15 5 0 95 194

22 172 6 13 98 1 0 40 1 17 95 496

13 2 136

313 0 29 118

110

30 166

4812

4686

8 39 37 21 3 0 42 12 3 47 116

25 308

197

16 150

90 87 7 18 106

10 46 8 144

10 4 66 1353 6 3 101

257

31 179 7 12 124 3 1 40 0 24 115

576

11 2 154

287 1 39 137

127

23 164

5397

5253

5 43 48 15 0 1 40 17 2 50 126

13 306

186 9 154

89 81 4 5 105

11 44 12 151 4 6 76 14

73 9 2 82 220

29 175 6 5 117 5 4 50 2 24 105

548

14 1 142

296 0 42 113

128

16 167

5378

5227

7 52 46 22 1 1 45 16 2 58 133

35 342

195

15 158

90 77 3 6 109 7 58 15 125 1 6 72 15

90 7 4 114

318

41 198

12 9 112 2 2 52 0 19 99 646 5 4 157

312 0 47 142

176

13 178

5956

5831

Tab

le 5

.5.2

Num

ber

Of N

ew C

ases

by

Pri

mar

y Si

te a

nd Y

ears

am

ong

Saud

i Fem

ales

,199

4-20

11

Lip

Tong

ueM

outh

Sal

ivar

y G

land

sTo

nsil

Oth

er O

roph

aryn

xN

asop

hary

nxH

ypop

hary

nxP

hary

nx U

nspe

cifie

dO

esop

hagu

sS

tom

ach

Sm

all I

ntes

tine

Col

onR

ectu

mA

nus

Live

rG

allb

ladd

er e

tc.

Pan

crea

sN

ose,

Sin

uses

etc

.La

rynx

Trac

hea,

Bro

nchu

s, L

ung

Oth

er T

hora

cic

Org

ans

Bon

eM

elan

oma

of S

kin

Oth

er S

kin

Mes

othe

liom

aK

apos

i Sar

com

aC

onne

ctiv

e,S

oft T

issu

eB

reas

tV

ulva

Vag

ina

Cer

vix

Ute

riC

orpu

s U

teri

Ute

rus

Uns

peci

fied

Ova

ryO

ther

Fem

ale

Gen

ital

Pla

cent

aK

idne

yR

enal

Pel

vis

Ure

ter

Bla

dder

Oth

er U

rinar

y O

rgan

sE

yeB

rain

, Ner

vous

Sys

tem

Thyr

oid

Adr

enal

Gla

ndO

ther

End

ocrin

eH

odgk

in D

isea

seN

on-H

odgk

in L

ymph

oma

Imm

unop

rolif

erat

ive

Dis

ease

Mul

tiple

Mye

lom

aLy

mph

oid

Leuk

emia

Mye

loid

Leu

kem

iaLe

ukem

ia U

nspe

cifie

dO

ther

& U

nspe

cifie

d

All

site

s To

tal

All

site

s bu

t C44

Site

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

90

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)0.

20.

90.

70.

10.

10.

12.

10.

3 0 2.2

3.7

0.3

1.8

2.4

0.3

8.7

0.7

1.4

0.1

1.5

5.6

0.2

0.7

0.6

2.7

0.1

0.5

1.8

0.3

0.1 4 0.7 0 1.8

0.1 0 4.6 0 0.5

2.9 2 0.1

0.1

2.1

6.6 0 1.8

2.2

1.9

0.2 4

75.9

73.1

0.1

0.5

0.7

0.3

0.2

0.1

1.5

0.2 0 1.9

3.6

0.2

2.4

1.9

0.2

8.6

0.9

1.3

0.2

1.4

5.3

0.2

0.7

0.2 3 0.1

0.3

1.4

0.4

0.1

3.9

0.4 0 2 0.1

0.1

4.3 0 0.2

1.8

1.5

0.1

0.1

1.9 5 0 1.1

1.8

1.7

0.1

3.1

67.1

64.1

0.1

0.6

0.9

0.2

0.1

0.1

2.3

0.4 0 1.7

3.5

0.3

1.9

1.6

0.2

7.5

0.7

1.5

0.3

1.2

4.9

0.2

0.5

0.2

2.8

0.2

0.3 1 0.1 0 3.8

0.5 0 1.4 0 0 3.4 0 0.3

2.4

1.5

0.2

0.1

1.7

5.5 0 0.8

2.1

1.7

0.1

2.6

63.1

60.3

0.1

0.6

0.6

0.3

0.1 0 2.5

0.2 0 1.5

2.7

0.3

2.1

1.7

0.2

7.1

0.6

1.2

0.1 1 4.4

0.2

0.7

0.2

2.8

0.1

0.3

1.2

0.3

0.2

2.9

0.5

0.1

1.5 0 0 3.2 0 0.5

2.2

1.8

0.1 0 1.5 5 0 1 2.1 2 0.1

3.3

61 58.3

0.1

0.3

0.6

0.1

0.1 0 2.6

0.2 0 2 3 0.4

2.5

1.6

0.2

8.4

0.7

1.5

0.2

1.2

5.8

0.2

0.7

0.2

2.4

0.2

0.3

0.8

0.5 0 3.9

0.7 0 1.7

0.3

0.1

3.8 0 0.2

1.6

1.9 0 0 2.2

6.2 0 1.3

2.3 2 0.2

3.4

68.7

66.4

0 0.6

0.6

0.2

0.1

0.1

2.2

0.1 0 1.2

2.4

0.3

2.5

2.3

0.1

7.5

0.6

1.4

0.3

1.1

5.2

0.3

0.7

0.2

2.7

0.1

0.2

1.2

0.3 0 3.5

0.6 0 1.7

0.1 0 3.7 0 0.4

2.1

1.7

0.1 0 1.9

6.1 0 1 2 1.9

0.1

3.4

65 62.3

0.1

0.8

0.5

0.2 0 0 2 0.1 0 1.5 3 0.4

2.9 2 0.3

7.3

0.7

1.6

0.1

1.1 5 0.1

0.7

0.3

2.5

0.2

0.4

0.9

0.4 0 4 0.6

0.1

1.7

0.1

0.1

3.9 0 0.3

2.3

1.6

0.2 0 1.8

5.4 0 1.1

2.1

1.7

0.3

2.8

65.1

62.7

0 0.3

0.7

0.3

0.1

0.1

2.5

0.2 0 1.6

2.9

0.3

2.9

2.4

0.3

7.3

1.1

1.3

0.3

1.5

4.8

0.1

0.8

0.2

3.5

0.1

0.5

0.9

0.3 0 4.4

0.5

0.1

1.9 0 0 3.4 0 0.5

2.1

1.6

0.1 0 2.1 5 0 0.9

2.4

2.1

0.3

3.4

67.9

64.4

0.1

0.5

0.6

0.3

0.1

0.1

1.8

0.1 0 1.6

3.2

0.4

3.4

2.6

0.3

7.1

0.9

1.7

0.3

0.8 5 0.1

0.6

0.3

3.2

0.1

0.5

1.1

0.4

0.1

4.3

0.7

0.1

1.8 0 0 3.5 0 0.4

1.9

1.9

0.1 0 1.9

5.2 0 0.6

2.1 2 0.2

3.5

67.4

64.2

0.1

0.6

0.6

0.2

0.1 0 1.7

0.1

0.1

1.6

4.2

0.3 4 3.3

0.3

7.1 1 2 0.2

1.5

5.1

0.3

0.6

0.2

3.7

0.1

0.6

1.2

0.4 0 4.5

0.5

0.1

1.8

0.2

0.2

4.1 0 0.3

2.5

1.7

0.2

0.1 2 6.4 0 0.9

2.2

1.5

0.3

3.2

73.9

70.2

0.2

0.8

0.8

0.2

0.1 0 2 0.2

0.1

1.2

3.4

0.5

4.4

3.9

0.4

6.6

0.6 2 0.2

1.3

5.9

0.2

0.7

0.3 3 0.1

0.6

0.8

0.3

0.1

5.7

0.6

0.1

2.5

0.2

0.1 4 0 0.4

2.5

1.8

0.1 0 2.4

6.2

0.1

1.1

2.1

1.9

0.2

3.3

76.3

73.3

0.1

0.9

0.7

0.2

0.1

0.1

2.2

0.2

0.1

1.3

3.5

0.5

5.8

4.4

0.3

6.8

0.9

2.2

0.2

1.3

6.5

0.4

0.6

0.3

3.4

0.2

0.4 1 0.3

0.1

6.4

0.5 0 2.1

0.1

0.1

3.7 0 0.3

2.2

1.6

0.1

0.1

2.1

6.5 0 1.3 2 1.6

0.2

3.9

80 76.6

0.1

0.8

0.7

0.3 0 0 1.7

0.2

0.1

1.4

4.1

0.5

5.3

4.3

0.2

8.3

1.3

2.6

0.2

1.6

6.2

0.2

0.7

0.3

4.5

0.2

0.5 1 0.4 0 6.3

0.5

0.1

2.7

0.1 0 4.2 0 0.4

2.6

2.1

0.3

0.1

2.1

6.7 0 1.3

2.5 2 0.5

4.3

86.6

82.1

0.2

0.8

0.8

0.4

0.1 0 1.5

0.3

0.1

1.4

3.5

0.5

5.4 4 0.2

7.2

1.1

2.7

0.2

1.2

6.9

0.3

0.7

0.4

3.3

0.2

0.3 1 0.4 0 5.7

0.7 0 2.7

0.1 0 3.5 0 0.3 2 1.9

0.2 0 2.1

7.1 0 1 2.4

1.6

0.4

3.3

80.6

77.4

0.2

0.6

0.7

0.3 0 0 2 0.1

0.1 1 3.2

0.6

5.4

3.8

0.2

6.9 1 2 0.2

1.2 6 0.2

0.9

0.3 3 0.4

0.3 1 0.3

0.1

5.9

0.8 0 2.8

0.1

0.1

3.7 0 0.3

2.2

2.1

0.2

0.1

2.1

6.2 0 0.8

2.1 2 0.6 3 77 74

0.1

0.8

0.8

0.3 0 0 1.5

0.1 0 1.4 4 0.6

6.5

5.1

0.4

6.6

1.1

2.6

0.1

1.2 6 0.3

0.7

0.2

3.5

0.1

0.6

0.9

0.4 0 6.3

0.8 0 3.2

0.1 0 4.1 0 0.4

2.2

2.2

0.2

0.1

2.4 7 0 1.2

2.4 2 0.3 3 84 80.4

0.1 1 0.9

0.2 0 0 2 0.2 0 1.4

3.1

0.5

5.5

4.4

0.3

6.4

0.9

2.2

0.2

0.9

5.8

0.3

0.7

0.2

3.1

0.2

0.4

0.8

0.4 0 5.5

0.8 0 2.9

0.1 0 3.6

0.1

0.3

1.9

2.3

0.3 0 2.1

6.2 0 1.2

2.1 2 0.2

2.9

76.7

73.6

0.1

0.7

0.7

0.2

0.1 0 1.8

0.2 0 1.3

2.8

0.6

6.6

4.7

0.2

6.1

1.3

2.3

0.1

1.3

6.4

0.3

0.8

0.3

3.6

0.2

0.3

0.9

0.3 0 6 0.8

0.1

2.9 0 0.1

3.3 0 0.2

2.2

2.2

0.1

0.1

1.9

6.4 0 0.9

2.3 2 0.2

2.8

78.8

75.2

Tab

le 5

.5.3

Age

Sta

ndar

dize

d In

cide

nce

Rat

e by

Pri

mar

y Si

te a

nd Y

ears

am

ong

Saud

i Mal

es, 1

994-

2011

Lip

Tong

ueM

outh

Sal

ivar

y G

land

sTo

nsil

Oth

er O

roph

aryn

xN

asop

hary

nxH

ypop

hary

nxP

hary

nx U

nspe

cifie

dO

esop

hagu

sS

tom

ach

Sm

all I

ntes

tine

Col

onR

ectu

mA

nus

Live

rG

allb

ladd

er e

tc.

Pan

crea

sN

ose,

Sin

uses

etc

.La

rynx

Trac

hea,

Bro

nchu

s, L

ung

Oth

er T

hora

cic

Org

ans

Bon

eM

elan

oma

of S

kin

Oth

er S

kin

Mes

othe

liom

aK

apos

i Sar

com

aC

onne

ctiv

e,S

oft T

issu

eB

reas

tP

enis

Pro

stat

eTe

stis

Oth

er M

ale

Gen

ital

Kid

ney

Ren

al P

elvi

sU

rete

rB

ladd

erO

ther

Urin

ary

Org

ans

Eye

Bra

in, N

ervo

us S

yste

mTh

yroi

dA

dren

al G

land

Oth

er E

ndoc

rine

Hod

gkin

Dis

ease

Non

-Hod

gkin

Lym

phom

aIm

mun

opro

lifer

ativ

e D

isea

seM

ultip

le M

yelo

ma

Lym

phoi

d Le

ukem

iaM

yelo

id L

euke

mia

Leuk

emia

Uns

peci

fied

Oth

er &

Uns

peci

fied

All

site

s To

tal

All

site

s bu

t C44

Site

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

91

C00

C01

-C02

C03

-C06

C07

-C08

C09

C10

C11

C12

-C13

C14

C15

C16

C17

C18

C19

-C20

C21

C22

C23

-C24

C25

C30

-C31

C32

C33

-C34

C37

-C38

C40

-C41

C43

C44

C45

C46

C47

;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70

-C72

C73

C74

C75

C81

C82

-C85

;C96

C88

C90

C91

C92

-C94

C95

Oth

er

All

Not

C44

ICD

(10t

h)0.

10.

70.

70.

2 0 0 0.9

0.6 0 2.7

2.4

0.3

2.3

1.6

0.2

3.9

1.8

1.1

0.2

0.3

1.9

0.2

0.4

0.3

2.7 0 0 0.9

13.3

0.3

0.2

2.4

2.1

0.1

2.9 0 0.4

1.4 0 0 0.9 0 0.3

1.4

5.5

0.2

0.1

1.4

4.2 0 0.8 1 1.7

0.1

3.5

70.6

67.9

0.1

0.7

1.2

0.2

0.1 0 0.6

0.3

0.1

1.8

2.3

0.4

2.7

1.7

0.1 3 1.3

1.1

0.2

0.1 2 0.2

0.7

0.2

1.7 0 0.1

1.3

13 0.2

0.2

2.2

1.4

0.1 3 0 0.2 1 0 0 1.1 0 0.3

1.5

5.2

0.1 0 1.3

4.2 0 1.2

1.6

1.6

0.1

3.1

66.9

65.1

0.1

0.9

1.1

0.2

0.1 0 1 0.5 0 2.2

2.1

0.3

2.6

1.6 0 3.3

0.8

0.8

0.1

0.2

1.5

0.1

0.7

0.2

2.7 0 0 1

13.2

0.2 0 2.5

1.4

0.3

2.7 0 0.3

1.1 0 0 0.7 0 0.4

1.4

4.7

0.1 0 1 4.1 0 0.7

1.2

1.6 0 2.8

64.4

61.7

0 0.8

0.7

0.1

0.1 0 0.7

0.5 0 1.7

1.7

0.3

2.3

1.9

0.1

2.9 1 0.9

0.1

0.3

1.6

0.1

0.4

0.1

1.8 0 0.3 1

12.5

0.1

0.2

2.2

1.5

0.3

3.1

0.1

0.1

1.3

0.1 0 0.9 0 0.2

1.9

4.9

0.1 0 1.1

3.9 0 0.4

1.1

1.6

0.1

2.8

62.2

60.3

0 0.9 1 0.3 0 0 0.9

0.6 0 1.4

1.9

0.5

2.2

1.7

0.2

3.8

1.6

1.6

0.2

0.2

1.5

0.1

0.6

0.2

2.4 0 0.2

1.1

13.8

0.1 0 2.8 2 0.5

3.1

0.1

0.2

1.4

0.1 0 1.2 0 0.2

1.5

5.8

0.1 0 1.3 5 0 0.7 1 1.5

0.1

4.1

72 69.6

0.1

0.9

1.1

0.2 0 0 0.8

0.4 0 1.4 2 0.2

2.8

2.2 0 2.7

1.7

1.2

0.2

0.3

1.4

0.1

0.5

0.2

2.1

0.1

0.2 1

12.4

0.1

0.1 2 1.6

0.3

2.3

0.1

0.2

1.4

0.1 0 1 0 0.4

1.4

5.6

0.1 0 1.2

4.1 0 0.8

1.3

1.6

0.3

3.3

65.6

63.6

0.1

0.6

0.7

0.2

0.1 0 0.4

0.3

0.1

1.5

1.6

0.2

2.6

1.8

0.1

3.2

1.3

0.9

0.1

0.2

1.5

0.2

0.4

0.1 2 0 0.1

0.8

13.5

0.2 0 1.9

2.5

0.1

2.2

0.1

0.2

0.9

0.1 0 1 0 0.4

1.5

4.8

0.2 0 1.3

4.1 0 0.7

1.7

1.7

0.2

3.1

63.4

61.4

0.1

0.5

0.6

0.2 0 0 0.7

0.3 0 1 1.7

0.3

3.4 2 0.1

2.7

1.4

0.9

0.1 0 1.5

0.1

0.5

0.2

2.5 0 0.1

0.6

12 0.2

0.1 2 2 0.3

2.4

0.1

0.2

1.4 0 0 1.3 0 0.3

1.5

4.7

0.1 0 1.2

4.4 0 0.5

1.3

1.7

0.1 3

62.3

59.8

0.2

0.7

0.7

0.1

0.1

0.1

0.8

0.2

0.1

1.5

1.8

0.2 3 2.3

0.1

2.8

1.1

1.4

0.2

0.2

1.2 0 0.4

0.2

2.2

0.1

0.1

0.6

13.9

0.1

0.1

1.8

2.2

0.3

2.2

0.1

0.2

1.4 0 0 1 0 0.4

1.3

4.8

0.1 0 1.1

4.4 0 0.5

1.3

1.8

0.1

2.7

64.1

61.9

0.1

0.7

0.7

0.2

0.1 0 0.7 0 0 1.2

1.8

0.3

3.4

2.5

0.2

3.3

1.5 1 0 0.1

1.5

0.1

0.5

0.2

2.9

0.2

0.1

0.8

14.6

0.1 0 1.9

2.7

0.4

2.4

0.1

0.1

1.4

0.1 0 1 0 0.3

1.6

6.3

0.2 0 1.6 5 0 0.4

1.2

1.7

0.2

3.8

71.2

68.3

0.2

0.7

0.5

0.3 0 0.1

0.9

0.4

0.1

1.2

1.7

0.3

4.1

2.6

0.1

2.9

1.2

0.9

0.1

0.1

1.6

0.2

0.5

0.2

3.1

0.1

0.1

1.3

16.1

0.2

0.1

1.8 3 0.3

2.4

0.2

0.1

1.8

0.1 0 1 0 0.3

1.7

5.7

0.2 0 1.4

4.8 0 0.6

1.1

1.9

0.2 4

74.6

71.6

0.1

0.5

0.9

0.2 0 0.1

0.7

0.4 0 1.5

1.7

0.3

4.2

3.1

0.2

2.6

1.6

1.2

0.2

0.1

1.9

0.2

0.4

0.2

2.9

0.1

0.2

0.7

18.4 0 0.2

2.1

3.5

0.4 3 0.1

0.2

1.2

0.1

0.1

0.8 0 0.3

1.4

6.2

0.1

0.1

1.3

5.2 0 0.6

1.1

1.6

0.2

3.2

77.8

74.9

0.1

0.6

0.8

0.2 0 0 0.8

0.2 0 1.6

2.7

0.3

5.1

3.2

0.2

3.3

1.7

1.9

0.3

0.2 2 0.2

0.4

0.3 3 0.1

0.4

0.6

18.1

0.1 0 1.5

3.8

0.6

2.9

0.2

0.3

1.5

0.1 0 1 0 0.3

1.7

6.6

0.1

0.1

1.6

5.1 0 0.8

1.3

2.2

0.2 4

84.4

81.4

0.1

0.8 1 0.3 0 0 0.9

0.2 0 1.2

2.5

0.3

4.7

2.9

0.2

2.8

1.9

1.2

0.2

0.2

1.9

0.1

0.3

0.4

2.5

0.1

0.1

0.8

20.5

0.1

0.1

1.8 4 0.7

2.6

0.2

0.2

1.4 0 0 0.7 0 0.3

1.7

6.4

0.1

0.1

1.6

5.1 0 1 1.5

1.6

0.3

3.1

82.6

80.2

0.1

0.6

0.9

0.2

0.1 0 0.8

0.3 0 1.1

1.9

0.3

5.3

3.2

0.1

2.6

1.7

1.5

0.1

0.1

1.8

0.2

0.6

0.2

2.4 0 0.1

0.8

20.3

0.1 0 1.7 4 0.4

3.2

0.1

0.1

1.6 0 0 0.8 0 0.2

1.4 7 0.1 0 1.6

5.6 0 0.6

1.4

1.5

0.4

3.3

82.7

80.3

0.2

0.7

0.7

0.3 0 0 0.7

0.2

0.1

0.9

2.2

0.4

5.9

3.8

0.3 3 1.9

1.8

0.1

0.4

2.1

0.1

0.5

0.1

2.8

0.2

0.1

0.8

23.4

0.1

0.1

1.8

5.4

0.6

3.1

0.1

0.1 2 0.1 0 0.8 0 0.3

1.7

8.1

0.1 0 1.8

5.1 0 0.8

1.6

1.8

0.4

3.1

93.1

90.4

0.1

0.8

0.8

0.2 0 0 0.6

0.3 0 1 2.3

0.2

5.8

3.4

0.2

3.1

1.8

1.6

0.1

0.1

2.1

0.2

0.5

0.2

2.8

0.1

0.1

1.1

24.9

0.1 0 1.5

4.6

0.6 3 0.1

0.1 2 0.1

0.1 1 0 0.3

1.4

7.5

0.2 0 1.6

5.2 0 0.9

1.4

1.8

0.2

3.1

91.2

88.4

0.1

0.9

0.8

0.3 0 0 0.6

0.3 0 1 2.3

0.6

5.7

3.3

0.3

2.9

1.6

1.4 0 0.1

1.9

0.1

0.6

0.2

2.2 0 0.1

0.9

23.4

0.1

0.1

1.7

5.8

0.7

3.1

0.2

0.1

1.7 0 0 1 0 0.2

1.2

8.1 0 0.1

1.7

4.8 0 0.8

1.6

2.2

0.2 3

90.1

88

Tab

le 5

.5.4

Age

Sta

ndar

dize

d In

cide

nce

Rat

e by

Pri

mar

y Si

te a

nd Y

ears

am

ong

Saud

i Fem

ales

, 199

4-20

11

Lip

Tong

ueM

outh

Sal

ivar

y G

land

sTo

nsil

Oth

er O

roph

aryn

xN

asop

hary

nxH

ypop

hary

nxP

hary

nx U

nspe

cifie

dO

esop

hagu

sS

tom

ach

Sm

all I

ntes

tine

Col

onR

ectu

mA

nus

Live

rG

allb

ladd

er e

tc.

Pan

crea

sN

ose,

Sin

uses

etc

.La

rynx

Trac

hea,

Bro

nchu

s, L

ung

Oth

er T

hora

cic

Org

ans

Bon

eM

elan

oma

of S

kin

Oth

er S

kin

Mes

othe

liom

aK

apos

i Sar

com

aC

onne

ctiv

e,S

oft t

issu

eB

reas

tV

ulva

Vag

ina

Cer

vix

Ute

riC

orpu

s U

teri

Ute

rus

Uns

peci

fied

Ova

ryO

ther

Fem

ale

Gen

ital

Pla

cent

aK

idne

yR

enal

Pel

vis

Ure

ter

Bla

dder

Oth

er U

rinar

y O

rgan

sE

yeB

rain

, Ner

vous

Sys

tem

Thyr

oid

Adr

enal

Gla

ndO

ther

End

ocrin

eH

odgk

in D

isea

seN

on-H

odgk

in L

ymph

oma

Imm

unop

rolif

erat

ive

Dis

ease

Mul

tiple

Mye

lom

aLy

mph

oid

Leuk

emia

Mye

loid

Leu

kem

iaLe

ukem

ia U

nspe

cifie

dO

ther

& U

nspe

cifie

d

All

site

s To

tal

All

site

s bu

t C44

Site

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

92

Table 6.1 Number of In Situ Cases among Saudis and Non-Saudis, 2011

SaudisTopographyICD10

Non-Saudis All

Male Female Total

4

18

2

2

2

2

2

1

19

92

20

1

1

2

1

1

1

144

2

2

4

5

1

329

3

4

0

0

1

0

0

0

7

25

8

0

0

1

0

0

0

47

0

0

2

1

0

99

0

3

0

0

0

0

0

0

2

25

8

0

0

1

0

0

0

8

0

0

0

1

0

48

3

1

0

0

1

0

0

0

5

0

0

0

0

0

0

0

0

39

0

0

2

0

0

51

1

14

2

2

1

2

2

1

12

67

12

1

1

1

1

1

1

97

2

2

2

4

1

230

0

5

1

0

0

1

1

0

6

66

12

1

1

1

1

0

0

16

0

0

0

4

1

117

1

9

1

2

1

1

1

1

6

1

0

0

0

0

0

1

1

81

2

2

2

0

0

113

D001

D010, D011, D012

D013

D014

D015

D017, D097

D020

D022

D037, D039, D042, D043, D044, D045, D046 D047, D049

D051, D050, D057, D059

D069, D067

D070

D071

D072

D073

D074

D075

D090

D091

D091

D092

D092

D093

TOTAL

Esophagus

Colorectal

Anus

Small Intestine

Bile Tract

Pancreas

Glottis

Bronchus

Skin

Breast

Cervix

Uteri

Vulva

Vagina

Ovary

Penis

Prostate

Bladder

Kidney

Ureter

Eye

Eye

Thyroid


Table 6.2 Number of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders among Saudis and Non-Saudis, 2011

SaudisMorphologyICD-0-3

Non-Saudis All

Male Female Total

9

12

5

11

3

3

0

1

3

0

27

75

1

2

0

3

1

2

0

0

0

0

2

12

1

0

0

2

0

1

0

0

0

0

0

4

0

3

0

1

1

1

0

0

0

0

2

8

8

10

5

8

2

1

0

1

3

0

25

63

5

4

2

3

1

0

0

1

1

0

7

24

3

6

3

5

1

1

0

0

2

0

18

39

9950

9960

9961

9962

9963

9964

9980

9982

9983

9985

9989

Polycythemia Vera

Chronic Myeloproliferative Disease, NOS

Myelosclerosis with Myeloid Metaplasia

Essential Thrombocythemia

Chronic Neutrophilic Leukemia

Hypereosinophilic Syndrome

Refractory Anemia

Refractory Anemia with Sideroblasts

Refractory Anemia with Excess Blasts

Refractory Cytopenia with Multilineage Dysplasia

Myelodysplastic Syndrome, NOS

Total


93

94

4913 ذكور5956 اناث

657

432

366

343

330

311

208

184

182

178

13.4%

8.8%

7.4%

7.0%

6.7%

6.3%

4.2%

3.7%

3.7%

3.6%

1590

646

537

331

318

312

198

158

157

133

26.7%

10.8%

9.0%

5.6%

5.3%

5.2%

3.3%

2.7%

2.6%

2.0%

‹Èœjäπ]Ê<·Á÷Áœ÷]‡”qÅÁ‚¯÷]<ÎÊ^À€È◊÷]

›Ç÷]<ö^ñÈe]ÌÒÜ÷]Çf”÷]

l^jâÊ2÷]Ç◊¢]

‡”qÅÁ‚<ÎÊ^À€È◊÷]Ìfi^nπ]Ó◊”÷]

ÎÇn÷]ÌÈŒÖÇ÷]<ÏÇ«÷]

‹Èœjäπ]Ê<·Á÷Áœ÷]›Ç÷]<ö^ñÈe]

‹uÜ÷]‡”qÅÁ‚¯÷]<ÎÊ^À€È◊÷]

òÈfπ]Çf”÷]

‡”qÅÁ‚<ÎÊ^À€È◊÷]ÏÇ√π]

∞äfl¢]<¯“<ª<∞ËÅÁ√ä÷]<∞e<^¬ÁÈç<Ün“˘]<ÏÜé√÷]<l^fi^õÜä÷]

∞äfl¢]<¯“<ª<∞ËÅÁ√ä÷]<∞«÷^f÷]<∞e<^¬ÁÈç<Ün“˘]<ÏÜé√÷]<l^fi^õÜä÷]

4548 ذكور5644 اناث

655

386

342

320

310

227

208

182

163

162

14.4%

8.5%

7.5%

7.0%

6.8%

5.0%

4.6%

4.0%

3.6%

3.6%

1589

642

537

318

292

206

194

151

138

133

28.2%

11.4%

9.5%

5.6%

5.2%

3.6%

3.4%

2.7%

2.4%

2.4%

‹Èœjäπ]Ê<·Á÷Áœ÷]‡”qÅÁ‚¯÷]<ÎÊ^À€È◊÷]

ÌÒÜ÷]Çf”÷]

l^jâÊ2÷]›Ç÷]<ö^ñÈe]

Ç◊¢]Ìfi^nπ]Ó◊”÷]ÏÇ√π]

ÎÇn÷]ÌÈŒÖÇ÷]<ÏÇ«÷]

‹Èœjäπ]Ê<·Á÷Áœ÷]‹uÜ÷]

‡”qÅÁ‚¯÷]<ÎÊ^À€È◊÷]›Ç÷]<ö^ñÈe]

òÈfπ]Çf”÷]

‡”qÅÁ‚<ÎÊ^À€È◊÷]ÏÇ√π]

∞äfl¢]<¯“<ª<∞ËÅÁ√ä÷]<Ÿ^Àõ˘]<∞e<^¬ÁÈç<Ün“˘]<ÏÜé√÷]<l^fi^õÜä÷]

363 ذكور312 اناث139

47

37

25

19

17

15

14

10

10

38.3%

12.9%

10.2%

6.9%

5.2%

4.7%

4.1%

3.9%

2.8%

2.8%

125

33

23

21

20

20

19

15

7

4

40.8%

10.8%

7.5%

6.9%

6.5%

6.5%

6.2%

4.9%

2.3%

1.3%

›Ç÷]<ö^ñÈe]‡”qÅÁ‚¯÷]<ÎÊ^À€È◊÷]9í√÷]<á^„¢]Ê<…^⁄Ç÷]

‡”qÅÁ‚<ÎÊ^À€È◊÷]ÏÁ}Ü÷]Ê<Ì⁄^ñ÷]<Ìräfi˘]

›^ø√÷]Ó◊”÷]∞√÷]Çf”÷]

ÌËÜø”÷]<ÏÇ«÷]

›Ç÷]<ö^ñÈe]9í√÷]<á^„¢]Ê<…^⁄Ç÷]

›^ø√÷]ÏÁ}Ü÷]Ê<Ì⁄^ñ÷]<Ìräfi˘]

Ó◊”÷]‡”qÅÁ‚¯÷]<ÎÊ^À€È◊÷]

‡”qÅÁ‚<ÎÊ^À€È◊÷]∞√÷]Çf”÷]

òÈfπ]

95

Arabic Summary of Cancer Statistics in Saudi Arabia for the Year 2011

ÍeÜ√÷]<ì~◊π]›<NLMM<›^√÷<ÌËÅÁ√ä÷]<ÌÈeÜ√÷]<Ì”◊€π]<ª<·^õÜä÷]<l^ÈÒ^íuc

<Ì{{ví÷]<ÏÖ]áÊ<Õ]Ü{{çc<k{{†<p^{{ù˘]<à{{“Ü⁄Ê<Í{{íí~j÷]<ÿ{{íÈ <‘{{◊π]<ÓÀ{{éjä≤<D<›<MUUN<E<{{{‚<MPMN<›^{{¬<ª<›]ÖÊ¯{{÷<ÎÅÁ√{{ä÷]<ÿr{{ä÷]<Û{{éfi_<‡{{⁄ <ÿ“<ª<g{{i^”⁄ <ÅÁ{{qÊ <±] <Ì{{ ^ï˝ê <Ì{{”◊€π] <–{{õ^fl⁄ <ª<≈ÊÜ{{ <Ì{{ä∏<ÿr{{ä÷] <‹{{ñË <JÌ{{È⁄Á”£] <Ì{{Èví÷] <l^{{¬^�œ÷] <‡{{⁄ <Ì“Ö^{{é≤Ê<‡{{⁄˘]<ÔÁ{{Œ<Ê<ÏÇ{{ú<Ì{{Èf�÷]<à{{Ëà√÷]Çf¬<‘{{◊π]<Ì{{flËÇ⁄Ê<ö^{{ËÜ÷ê<Ìv◊{{äπ]<l]Á{{œ÷]Ê<p^{{ù˘]<à{{“Ü⁄Ê<Í{{íí~j÷]<ÿ{{íÈ <‘{{◊π]<l^ÈÀ{{éjä⁄

J{‚MPOQ<›^¬<ª<ÎÅÁ√ä÷]<Íví÷]<ã◊.]<±]<ÿrä÷]<ÿœjfi]Ê<<J<ö^ËÜ÷ê<Í√⁄^¢]<Ç÷^}<‘◊π]<ÓÀéjä⁄<Ê<ö^ËÜ÷ê<Ì{{€øfl⁄<‡{{⁄<Ç{{€j√π]<›^{{øfl÷]<g{{äu<ÿ{{}ÇiÊ<l^{{fi^Èf÷]àÈ⁄ÜiÊ<ƒ{{∂<‹{{jË<o{{Èu<J›<MUUP<›^{{¬<ª<Ü{{Ë^flË<Ü„{{ç<‡{{⁄<l^{{⁄Á◊√π]<ƒ{{∂<ª<‰õ^{{éfi<ÿr{{ä÷]<_Ç{{e<‹{{„f◊õ<Ó{{◊¬<^{{fle<Ì{{◊íÀ⁄<Ì{{ÈÒ^íuc<l^{{⁄Á◊√≤<∞{{nu^f÷]Ê<Ì{{íj~π]<l^{{„¢]<Ç{{ËÊàje<›Á{{œË<ÿr{{ä÷]<·_<^{{€“<JÎÖÊÅ<ÿ”{{ée<ÿ{{◊†Ê<Ì{{Èπ^√÷]<Ì{{ví÷]

V<ÎÅÁ√ä÷]<Íví÷]<ã◊r€◊÷<Í5Ü÷]<ƒŒÁπ]<ª<ÿrä÷]<ÌvÀë<Ó◊¬<î^}<tÉÁ¥<– Ê

http://www.chs.gov.sa/En/HealthRecords/CancerRegistry/Pages/RequestForm.aspx

<∞ËÅÁ√{{â<4∆<<Ê<ASRzP<Ìf{{äfle<∞ËÅÁ√{{âMLTRU<<l˜^£]<ÂÑ‚<∞e<‡⁄<JÌ÷û<<MPNNN<‰¬Á€•<^⁄<›<NLMM<›^¬<ª<Ì◊r{{äπ]<·^õÜ{{ä÷]<l˜û<ÅÇ¬<Í÷^∂c<»◊eJ<AQPzT<Ìfäfle<Ì÷ûQzUQR<<p^fi˝]Ê<<APQzN<Ìfäfle<ÖÁ“É<PzUMO<Ì÷û<<∞ËÅÁ√ä÷]<∞e<‡⁄J<ANOzRÌfäfle<OOQO

MLLzLLLKULzM<^äfl÷]<∞e<<Ê<MLLzLLL<KSTzT<Ÿ^qÜ÷]<∞e<<·^”ä÷]<‡⁄<MLLzLLL<ÿ“<ª<<·^õÜä÷ê<Ìe^ë˛÷<ÎÖ^È√π]<ŸÇ√π]<»◊e<ŸÇ√≤<ö^ËÜ÷]<Ì{{œ�fl⁄<^„È◊i<<ÖÁ{{“Ñ÷]<∞e<·^”{{ä÷]<‡⁄<MLLzLLL<ÿ“<ª<MMOzR<ŸÇ{{√≤<<·^õÜ{{ä÷]<l˜û<pÊÇ{{£<ŸÇ{{√⁄<Ó{{◊¬_<ÌÈŒÜ{{é÷]<Ì{{œ�flπ]<k◊r{{â<·^”{{ä÷]<‡⁄<MLLzLLL<ÿ“<ª<SSzP<ŸÇ√≤<Ì⁄Ü”π]<Ì”⁄<Ìœ�fl⁄<‹{{m<·^”{{ä÷]<‡⁄<MLLzLLL<ÿ“<ª<TSzN<ŸÇ{{√≤<’Á{{fi<Ì{{œ�fl⁄<‹{{m<·^”{{ä÷]<‡{{⁄<MLLzLLL<ÿ“<ª<<MLQzS<ª<MMQzN<ŸÇ√≤<<·^õÜ{{ä÷]<l˜û<pÊÇ£<ŸÇ√⁄<Ó◊¬_<ö^ËÜ÷]<Ìœ�fl⁄<k◊r{{â<^€flÈe<J·^”{{ä÷]<‡⁄<MLLzLLL<ÿ“<ª<<RRzQ<ŸÇ√≤<<‹Èíœ÷]<Ìœ�fl⁄<]4}_Ê<‡⁄<MLLzLLL<ÿ“<ª<UOzM<ŸÇ√≤<Ì⁄Ü”π]<Ì”⁄<Ìœ�fl⁄<‹m<H·^”{{ä÷]<‡⁄<MLLzLLL<ÿ“<ª<<MMLzR<ŸÇ√≤<ÌÈŒÜ{{é÷]<Ìœ�flπ]<^„È◊i<<p^fi˜]<∞e<·^”{{ä÷]<‡⁄<MLLzLLL<ÿ“

J·^”ä÷]<‡⁄<MLLzLLL<ÿ“<ª<<TMzU<ŸÇ√≤<<ÕÁ¢]<Ìœ�fl⁄<]4}_Ê<·^”ä÷]<‡⁄<MLLzLLL<ÿ“<ª<UMzQ<<ŸÇ√≤<’Áfi<Ìœ�fl⁄<‹m<·^”ä÷]

V<∞äfl¢]<¯“<ª<∞ËÅÁ√ä÷]<∞e<^¬ÁÈç<Ün“˘]<ÏÜé√÷]<l^fi^õÜä÷]ÌÈŒÖÇ÷]<ÏÇ«÷]<·^õÜ{{{{â<‰È◊Ë<AMMzL<Ìfäfle<D<Ì÷û<MMUP<E<‹Èœjäπ]Ê<·Á÷Áœ÷]<·^õÜ{{{â<‹m<AMPzT<<Ìfäfle<D<Ì÷ûMRLR<E<±Ê˘]<ÌfiÜπ]<ÎÇn÷]<·^õÜ{{{{â<ÿj¨<‰{{È◊Ë<A<RzP<<Ìf{{äfle<D<Ì{{÷û<RUS<<E<›Ç{{÷]<ö^{{ñÈe]<·^õÜ{{â<‹{{m<A<RzT<Ìf{{äfle<DÌ{{÷û<SPP<<E<‡{{”qÅÁ‚¯÷]<ÎÊ^{{À€◊÷]<·^õÜ{{ä÷]<‹{{m<A<SzP<Ìf{{äfle<D<Ì{{÷û<TLL<<E<<‹m<A<OzM<Ìf{{äfle<D<Ì÷û<<OPM<<E<‡{{”qÅÁ‚<ÎÊ^{{À€◊÷]<·^õÜ{{ä÷]<‰{{È◊Ë<APzN<<Ìf{{äfle<D<Ì{{÷û<<PQN<E<Ì{{ÒÜ÷]<·^õÜ{{â<‰{{È◊Ë<A<PzQ<Ìf{{äfle<D<Ì{{÷û<PTT<<E<Ç{{f”÷]<·^õÜ{{â

JA<NzU<Ìfäfle<D<Ì÷û<<OMT<E<‹uÜ÷]<·^õÜâ<]4}_Ê<A<OzM<Ìfäfle<D<Ì÷û<<OOO<E<Ç◊¢]<·^õÜâ

V<∞äfl¢]<¯“<ª<∞ËÅÁ√ä÷]<∞«÷^f÷]<∞e<^¬ÁÈç<Ün“˘]<ÏÜé√÷]<l^fi^õÜä÷]ÌÈŒÖÇ÷]<ÏÇ{{{{{{{{«÷]<·^õÜâ<‰È◊Ë<AMMzL<Ìfäfle<D<Ì÷û<MMUN<E<‹Èœjäπ]Ê<·Á÷Áœ÷]<·^õÜâ<‹m<A<MPzR<Ìfäfle<D<Ì÷û<MQTU<E<±Ê˘]<ÌfiÜπ]<ÎÇn÷]<·^õÜâ<ÿj¨<‰{{È◊Ë<APzL<<Ìf{{äfle<D<Ì{{÷û<POO<<E<›Ç{{÷]<ö^{{ñÈe]<·^õÜ{{â<‹{{m<A<RzN<Ìf{{äfle<DÌ{{÷û<RSS<<E<‡{{”qÅÁ‚¯÷]<ÎÊ^{{À€◊÷]<·^õÜ{{ä÷]<‹{{m<A<SzO<Ìf{{äfle<D<Ì{{÷û<SUQ<<E<‹uÜ÷]<·^õÜ{{{â<‹m<A<OzM<Ìfäfle<D<Ì÷û<<OON<E<Ç◊¢]<·^õÜ{{{{â<‹m<APzM<<Ìfäfle<D<Ì÷û<<PQL<E<ÌÒÜ÷]<·^õÜ{{{â<‰È◊Ë<A<PzO<Ìfäfle<D<Ì÷û<PSM<<E<Çf”÷]<·^õÜ{{â

JA<NzU<Ìfäfle<D<Ì÷û<<OML<E<l^jâÊ2÷]<·^õÜâ<]4}_Ê<<A<NzU<Ìfäfle<D<Ì÷û<<OMT<E

V<∞äfl¢]<¯“<ª<∞ËÅÁ√ä÷]<Ÿ^Àõ˘]<∞e<^¬ÁÈç<Ün“˘]<ÏÜé√÷]<l^fi^õÜä÷]‡”qÅÁ‚<ÎÊ^À€◊÷]<·^õÜ{{{{â<‹m<A<MLzP<Ìfäfle<D<Ì÷û<<SLE<…^⁄Ç÷]<·^õÜâ<‰È◊Ë<A<OUzM<Ìf{{{{{{äfle<D<Ì÷û<NRP<E<±Ê˘]<ÌfiÜπ]<›Ç÷]<ö^ñÈe]<·^õÜâ<ÿj¨<›^ø√÷]<·^õÜâ<‰È◊Ë<HA<RzM<Ìfäfle<D<Ì÷û<PM<E<Ó◊”÷]<·^õÜâ<‹m<A<RzQ<Ìfäfle<D<Ì÷û<PP<E<‡”qÅÁ{{{{{{{{{‚¯÷]<ÎÊ^À€◊÷]<·^õÜä÷]<‹m<A<UzU<Ìfäfle<D<Ì÷û<RS<E<<Ìr{{äfi˘]<·^õÜ{{â<‰{{È◊Ë<zA<PzO<Ìf{{äfle<D<Ì{{÷û<<NU<E<Ì{{ËÜø”÷]<ÏÇ{{«÷]<·^õÜ{{â<‰{{È◊Ë<HAQzN<<Ìf{{äfle<D<Ì{{÷û<<OQ<E<∞{{√÷]<·^õÜ{{â<‹{{m<<HA<QzU<Ìf{{äfle<D<Ì{{÷û<<PL<<E

JA<MzT<Ìfäfle<D<Ì÷û<<MN<E<<Çf”÷]<·^õÜâ<]4}_Ê<zA<NzQ<Ìfäfle<D<Ì÷û<MS<<E<Ì⁄^ñ÷]

·^õÜä÷]<öÜ≤<Ìe^ë˝]<ŸÇ√⁄<ÜËÜœi٢٠١١

ÌËÅÁ√ä÷]<ÌÈeÜ√÷]<Ì”◊€π]ÎÅÁ√ä÷]<Íví÷]<ã◊.]›]ÖÊ˙÷<ÎÅÁ√ä÷]<ÿrä÷]

August 2015